Benzamide containing compounds for modulating BRG1- or BRM-associated factors
Benzamide compounds targeting the BAF complex inhibit BRG1 and BRM activity, addressing the limitations of current treatments for BAF-related disorders by reducing tumor growth and viral replication.
Patent Information
- Application Number
- CA3166554
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-01-29
- Filing Date
- 2021-01-29
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-01-29
AI Technical Summary
Current treatments for disorders associated with alterations in the BRG1- or BRM-associated factors (BAF) complexes, such as certain cancers and viral infections, are inadequate, particularly in cases where BRG1 or BRM function is altered or deficient.
Development of benzamide-containing compounds that modulate the activity of the BAF complex by inhibiting BRG1 or BRM, thereby reducing their activity and inducing apoptosis in cancer cells or inhibiting viral replication.
The compounds effectively reduce BRG1 and BRM activity in cancer cells, leading to decreased tumor growth and metastasis, and inhibit viral infections by targeting the BAF complex, offering therapeutic benefits for various cancers and viral disorders.
Abstract
Description
Date reçue / Received Benzamide Containing Compounds for Modulating BRG1- or BRM- Associated Factors Background date The invention relates to compounds useful for modulating BRG1- or BRM-associated factors 2025-04-14 (BAF) complexes. In particular, the invention relates to compounds useful for treatment of disorders associated with BAF complex function. Chromatin regulation is essential for gene expression, and ATP-dependent chromatin remodeling is a mechanism by which such gene expression occurs. The human Switch / Sucrose Non-Fermentable (SWI / SNF) chromatin remodeling complex, also known as BAF complex, has two SWI2-like ATPases known as BRG1 (Brahma-related gene-1) and BRM (Brahma). The transcription activator BRG1 is also known as ATP-dependent chromatin remodeler SMARCA4, is encoded by the SMARCA4 gene on chromosome 19. BRG1 is overexpressed in some cancer tumors and is needed for cancer cell proliferation. BRM, also known as probable global transcription activator SNF2L2 and / or ATP-dependent chromatin remodeler SMARCA2, is encoded by the SMARCA2 gene on chromosome 9 and has been shown to be essential for tumor cell growth in cells characterized by loss of BRG1 function mutations. Deactivation of BRG and / or BRM results in downstream effects in cells, including cell cycle arrest and tumor suppression. Summary The present invention features compounds useful for modulating a BAF complex. In some embodiments, the compounds are useful for the treatment of disorders associated with an alteration in a BAF complex, e.g., a disorder associated with an alteration in one or both of the BRG1 and BRM proteins. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating such disorders. In an aspect, the invention features a compound having the structure: [Image disponible dans le document PDF, Image available in the PDF document] Formula I wherein [Image disponible dans le document PDF, Image available in the PDF document] A is m is 0, 1, 2, or 3; n is 1 or 2; o is 0 or 1; X is O, <com:Math><semantics>CH2<annotation encoding="application / x-tex">CH_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR7<annotation encoding="application / x-tex">NR^7< / annotation>< / semantics>< / com:Math>; X' is N, CH, or CR<com:Sup>x< / com:Sup>, wherein R<com:Sup>x< / com:Sup> is a halogen; B is an optionally substituted 6-membered monocyclic heteroarylene or an optionally substituted 9- or 10-membered bicyclic heteroarylene; Date reçue _ L is a covalent bond, optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene, C<com:Sub>2< / com:Sub> alkynylene, optionally substituted Received C₂ alkenylene, optionally substituted C₂-C₃ heteroalkylene, optionally substituted C₃-C₅ cycloalkylene, or optionally substituted 4- to 10-membered heterocyclylene; date Z is optionally substituted 3- to 10-membered cycloalkyl; optionally substituted 6- to 10- membered aryl; optionally substituted 5- to 10-membered heteroaryl; or optionally substituted 5- to 10- 2025-04-14 membered heterocyclyl; R¹ and R<com:Sup>7< / com:Sup> are, independently, hydrogen or optionally substituted C₁-C<com:Sub>6< / com:Sub> alkyl; each R<com:Sup>2< / com:Sup> and R<com:Sup>3< / com:Sup> is independently, hydrogen, optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; or optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl; R<com:Sup>4< / com:Sup> is cyano, fluoro, hydroxy, or -CH<com:Sub>2< / com:Sub>OH; R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups; and R<com:Sup>6< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups, or a pharmaceutically acceptable salt thereof. In some embodiments, R<com:Sup>1< / com:Sup> is hydrogen. In some embodiments, m is 1. In some embodiments, R<com:Sup>3< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>2< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>2< / com:Sup> is optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl (e.g., methyl). In some embodiments, R<com:Sup>2< / com:Sup> is optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl (e.g., -CH<com:Sub>2< / com:Sub>OCH<com:Sub>3< / com:Sub>). [Image disponible dans le document PDF, Image available in the PDF document] S 3166554 In some embodiments, A is In some embodiments, R<com:Sup>6< / com:Sup> is -CHF<com:Sub>2< / com:Sub>. [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments, A is . In some embodiments, R<com:Sup>5< / com:Sup> is methyl or -CHF<com:Sub>2< / com:Sub>. In some embodiments, X is O. In some embodiments, X is CH<com:Sub>2< / com:Sub>. In some embodiments, X is NR<com:Sup>7< / com:Sup>. In some embodiments, X' is N. In some embodiments, X' is CH. In some embodiments, X' is CRx (e.g., Rx is fluoro). In some embodiments, R<com:Sup>7< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>7< / com:Sup> is methyl. In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, R4 is cyano. In some embodiments, R4 is fluoro. In some embodiments, R⁴ is hydroxy. In some embodiments, R⁴ is -CH₂OH. In some embodiments, A is [Image disponible dans le document PDF, Image available in the PDF document] ОΗ [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments, Z is optionally substituted 3- to 10-membered cycloalkyl (e.g., cyclopropyl). In some embodiments, Z is optionally substituted 6- to 10-membered aryl (e.g., phenyl, 3- difluoromethyl-phenyl, 4-dilfluoromethylphenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,5-difluorophenyl, 3-difluoromethylphenyl, 2-methoxy-5-methyl-phenyl, 2-methoxy-4-chloro-phenyl, 3- cyano-phenyl, 3-fluoro-5-methoxy-phenyl, 3-fluoro-5-azitidinyl-phenyl, 3-azetidyl-phenyl, 4-azetidyl-2- methoxy-phenyl, 4-morpholin-4-yl-2-methoxy-phenyl, 4-tert-butyl-2-methoxy-phenyl, 4-azetidyl-phenyl, 2- methoxy-4-oxetan-3-yl-phenyl, 2-azetidin-2-one-1-yl-phenyl, 3-(3-difluoromethyloxetan-3-yl)-phenyl, 3-(3- methoxyoxetan-3-yl)-phenyl, 3-(N-methyl-N-acetamido)-phenyl, 3-cyclopropylphenyl, 3-(N-methylazetidin- 3-yl)-phenyl, 3-(N-methyl-N'-piperazinyl)-phenyl, 3-fluoro-5-azetidyl-phenyl, 3-methyl ester-phenyl, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] ^ 5 , Date reçue / Received date 2025-04-14 [Image disponible dans le document PDF, Image available in the PDF document] - CA 3166554 Date reçue / Received date 2025-04-14 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] pyrrolidinyl). In some embodiments, Z is ፠ ~ محر , or In some embodiments, B is an optionally substituted 6-membered monocyclic heteroarylene. In some embodiments, B has the structure: [Image disponible dans le document PDF, Image available in the PDF document] wherein Ra is hydrogen or fluoro; R<com:Sup>b< / com:Sup> is hydrogen, fluoro, or C₁-C₃ alkyl; and Xa is N or CH. In some embodiments, Ra is hydrogen. In some embodiments, Ra is fluoro. In some embodiments, R<com:Sup>b< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>b< / com:Sup> is fluoro. In some embodiments, C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl (e.g., methyl). In some embodiments, Xa is N. In some embodiments, Xa is CH. In some embodiments, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] B is CH3, or . In some , [Image disponible dans le document PDF, Image available in the PDF document] embodiments, B is In some embodiments, B is an optionally substituted 9- or 10-membered bicyclic heteroarylene. In some embodiments, B has the structure: [Image disponible dans le document PDF, Image available in the PDF document] wherein D is an optionally substituted 5- or 6-membered heteroaryl or optionally substituted 5- or [Image disponible dans le document PDF, Image available in the PDF document] 6-membered heterocyclyl (e.g., Date reçue / Received date In some embodiments, L is optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene, C<com:Sub>2< / com:Sub> alkynylene, optionally substituted C2 alkenylene, optionally substituted C2-C3 heteroalkylene, optionally substituted C3-C5 cycloalkylene, or optionally substituted 4- to 10-membered heterocyclylene. In some embodiments, L is covalent a bond, e.g., the compound of Formula I is a compound of Formula la: [Image disponible dans le document PDF, Image available in the PDF document] 2025-04-14 Formula la or a pharmaceutically acceptable salt thereof, where all variables are as described herein. In some embodiments, L is optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene (e.g., ethylene). In some embodiments, C<com:Sub>2< / com:Sub> alkynylene. In some embodiments, L is optionally substituted C<com:Sub>2< / com:Sub> alkenylene (e.g., , or ). In some embodiments, L is optionally substituted C2-C3 heteroalkylene (e.g. or In some embodiments, L is optionally [Image disponible dans le document PDF, Image available in the PDF document] substituted C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub> cycloalkylene (e.g., In some embodiments, L is optionally substituted 4- to 10-membered heterocyclylene (e.g., CA 3166554 or In some embodiments, the compound is any one of compounds 1-48 in Table 1. Table 1. Compounds of the invention [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments, the compound is any one of compounds 49-84 in Table 2. Table 2. Compounds of the invention [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments, the compound is any one of compounds 85-126 in Table 3. Table 3. Compounds of the invention [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments, the compound is any one of compounds 127-525 in Table 3a. Table 3a. Compounds of the invention [Image disponible dans le document PDF, Image available in the PDF document] CA - [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] In another aspect, the invention features a pharmaceutical composition including any one of the above compounds and a pharmaceutically acceptable excipient. In another aspect, the invention features a method of decreasing the activity of a BAF complex in 5 a cell, the method involving contacting the cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell. CA In another aspect, the invention features a method of treating a BAF complex-related disorder in a subject in need thereof, the method involving administering to the subject an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the BAF complex-related disorder is cancer. In a further aspect, the invention features a method of inhibiting BRM, the method involving contacting a cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell. In another aspect, the invention features a method of inhibiting BRG1, the method involving contacting the cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell. In a further aspect, the invention features a method of inhibiting BRM and BRG1, the method involving contacting the cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell. In another aspect, the invention features a method of treating a disorder related to a BRG1 loss of function mutation in a subject in need thereof, the method involving administering to the subject an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the disorder related to a BRG1 loss of function mutation is cancer. In other embodiments, the subject is determined to have a BRG1 loss of function disorder, for example, is determined to have a BRG1 loss of function cancer (for example, the cancer has been determined to include cancer cells with loss of BRG1 function). In another aspect, the invention features a method of inducing apoptosis in a cell, the method involving contacting the cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell. In a further aspect, the invention features a method of treating cancer in a subject in need thereof, the method including administering to the subject an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments of any of the foregoing methods, the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non- melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin lymphoma, small-cell lung cancer, prostate cancer, embryonal tumor, germ cell tumor, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, Adrenocortical carcinoma, appendiceal cancer, small bowel cancer, or penile cancer. In some embodiments of any of the foregoing methods, the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non- melanoma skin cancer, endometrial cancer, or penile cancer. In some embodiments of any of the foregoing methods, the cancer is a drug resistant cancer or has failed to respond to a prior therapy (e.g., vemurafenib, dacarbazine, a CTLA4 inhibitor, a PD1 inhibitor, interferon therapy, a BRAF inhibitor, a MEK inhibitor, radiotherapy, temozolimide, irinotecan, a CAR-T therapy, herceptin, perjeta, tamoxifen, xeloda, docetaxol, platinum agents such as carboplatin, taxanes such as paclitaxel and docetaxel, ALK inhibitors, MET inihibitors, alimta, abraxane, Adriamycin®, CA gemcitabine, avastin, halaven, neratinib, a PARP inhibitor, ARN810, an mTOR inhibitor, topotecan, gemzar, a VEGFR2 inhibitor, a folate receptor antagonist, demcizumab, fosbretabulin, or a PDL1 inhibitor). In some embodiments of any of the foregoing methods, the cancer has or has been determined to have BRG1 mutations. In some embodiments of any of the foregoing methods, the BRG1 mutations are homozygous. In some embodiments of any of the foregoing methods, the cancer does not have, or has been determined not to have, an epidermal growth factor receptor (EGFR) mutation. In some embodiments of any of the foregoing methods, the cancer does not have, or has been determined not to have, an anaplastic lymphoma kinase (ALK) driver mutation. In some embodiments of any of the foregoing methods, the cancer has, or has been determined to have, a KRAS mutation. In some embodiments of any of the foregoing methods, the BRG1 mutation is in the ATPase catalytic domain of the protein. In some embodiments of any of the foregoing methods, the BRG1 mutation is a deletion at the C-terminus of BRG1. In another aspect, the disclosure provides a method treating a disorder related to BAF (e.g., cancer or viral infections) in a subject in need thereof. This method includes contacting a cell with an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or any of the foregoing pharmaceutical compositions. In some embodiments, the disorder is a viral infection is an infection with a virus of the Retroviridae family such as the lentiviruses (e.g., Human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T cell leukemia virus I (HTLV-I), human T cell leukemia virus II (HTLV-II)), Hepadnaviridae family (e.g., hepatitis B virus (HBV)), Flaviviridae family (e.g., hepatitis C virus (HCV)), Adenoviridae family (e.g., Human Adenovirus), Herpesviridae family (e.g., Human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human herpesvirus 6 (HHV-6), Herpesvitus K*, CMV, varicella-zoster virus), Papillomaviridae family (e.g., Human Papillomavirus (HPV, HPV E1)), Parvoviridae family (e.g., Parvovirus B19), Polyomaviridae family (e.g., JC virus and BK virus), Paramyxoviridae family (e.g., Measles virus), Togaviridae family (e.g., Rubella virus). In some embodiments, the disorder is Coffin Siris, Neurofibromatosis (e.g., NF-1, NF-2, or Schwannomatosis), or Multiple Meningioma. In another aspect, the disclosure provides a method for treating a viral infection in a subject in need thereof. This method includes administering to the subject an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or any of the foregoing pharmaceutical compositions. In some embodiments, the viral infection is an infection with a virus of the Retroviridae family such as the lentiviruses (e.g., Human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T cell leukemia virus I (HTLV-I), human T cell leukemia virus II (HTLV-II)), Hepadnaviridae family (e.g., hepatitis B virus (HBV)), Flaviviridae family (e.g., hepatitis C virus (HCV)), Adenoviridae family (e.g., Human Adenovirus), Herpesviridae family (e.g., Human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), human herpesvirus 6 (HHV-6), Herpesvitus K*, CMV, varicella-zoster virus), Papillomaviridae family (e.g., Human Papillomavirus (HPV, HPV E1)), Parvoviridae family (e.g., Parvovirus B19), Polyomaviridae family (e.g., JC virus and BK virus), Paramyxoviridae family (e.g., Measles virus), or Togaviridae family (e.g., Rubella virus). In another aspect, the invention features a method of treating melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject in need thereof, the CA - method including administering to the subject an effective amount of any of the foregoing compounds or pharmaceutical compositions thereof. In another aspect, the invention features a method of reducing tumor growth of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject in need thereof, the method including administering to the subject an effective amount of any of the foregoing compounds or pharmaceutical compositions thereof. In another aspect, the invention features a method of suppressing metastatic progression of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject, the method including administering an effective amount of any of the foregoing compounds or pharmaceutical compositions thereof. In another aspect, the invention features a method of suppressing metastatic colonization of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject, the method including administering an effective amount of any of the foregoing compounds or pharmaceutical compositions thereof. In another aspect, the invention features a method of reducing the level and / or activity of BRG1 and / or BRM in a melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer cell, the method including contacting the cell with an effective amount of any of the foregoing compounds or pharmaceutical compositions thereof. In some embodiments of any of the above aspects, the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cell is in a subject. In some embodiments of any of the above aspects, the effective amount of the compound reduces the level and / or activity of BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference. In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRG1 by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference. In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRG1 by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the effective amount of the compound reduces the level and / or activity of BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours, or more). In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference for at least 4 days (e.g., 5 days, 6 days, 7 days, 14 days, 28 days, or more). In some embodiments of any of the above aspects, the effective amount of the compound reduces the level and / or activity of BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference. In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRM by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference. In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRM by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%). In some embodiments, the effective amount of the compound reduces the level and / or activity of BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours, or more). In some embodiments, the effective amount of the compound that reduces the level and / or activity of BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference for at least 4 days (e.g., 5 days, 6 days, 7 days, 14 days, 28 days, or more). In some embodiments, the subject has cancer. In some embodiments, the cancer expresses BRG1 and / or BRM protein and / or the cell or subject has been identified as expressing BRG1 and / or BRM. In some embodiments, the cancer expresses BRG1 protein and / or the cell or subject has been identified as expressing BRG1. In some embodiments, the cancer expresses BRM protein and / or the cell or subject has been identified as expressing BRM. In some embodiments, the cancer is melanoma (e.g., uveal melanoma, mucosal melanoma, or cutaneous melanoma). In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is a hematologic cancer, e.g., multiple myeloma, large cell lymphoma, acute T-cell leukemia, acute myeloid leukemia, myelodysplastic syndrome, immunoglobulin A lambda myeloma, diffuse mixed histiocytic and lymphocytic lymphoma, B-cell lymphoma, acute lymphoblastic leukemia (e.g., T-cell acute lymphoblastic leukemia or B-cell acute lymphoblastic leukemia), diffuse large cell lymphoma, or non-Hodgkin's lymphoma. In some embodiments, the cancer is breast cancer (e.g., an ER positive breast cancer, an ER negative breast cancer, triple positive breast cancer, or triple negative breast cancer). In some embodiments, the cancer is a bone cancer (e.g., Ewing's sarcoma). In some embodiments, the cancer is a renal cell carcinoma (e.g., a Microphthalmia Transcription Factor (MITF) family translocation renal cell carcinoma (tRCC)). In some embodiments, the cancer is metastatic (e.g., the cancer has spread to the liver). The metastatic cancer can include cells exhibiting migration and / or invasion of migrating cells and / or include cells exhibiting endothelial recruitment and / or angiogenesis. In other embodiments, the migrating cancer is a cell migration cancer. In still other embodiments, the cell migration cancer is a non-metastatic cell migration cancer. The metastatic cancer can be a cancer spread via seeding the surface of the peritoneal, pleural, pericardial, or subarachnoid spaces. Alternatively, the metastatic cancer can be a cancer spread via the lymphatic system, or a cancer spread hematogenously. In some embodiments, the effective amount of a compound of the invention is an amount effective to inhibit metastatic colonization of the cancer to the liver. In some embodiments the cancer harbors a mutation in GNAQ. In some embodiments the cancer harbors a mutation in GNA11. In some embodiments the cancer harbors a mutation in PLCB4. In some embodiments the cancer harbors a mutation in CYSLTR2. In some embodiments the cancer harbors a mutation in BAP1. In some embodiments the cancer harbors a mutation in SF3B1. In some embodiments the cancer harbors a mutation in EIF1AX. In some embodiments the cancer harbors a TFE3 translocation. In some embodiments the cancer harbors a TFEB translocation. In some embodiments the cancer harbors a MITF translocation. In some embodiments the cancer harbors an С EZH2 mutation. In some embodiments the cancer harbors a SUZ12 mutation. In some embodiments the cancer harbors an EED mutation. In some embodiments of any of the foregoing methods, the method further includes administering to the subject or contacting the cell with an anticancer therapy, e.g., a chemotherapeutic or cytotoxic agent, immunotherapy, surgery, radiotherapy, thermotherapy, or photocoagulation, or a combination thereof. In some embodiments, the anticancer therapy is a chemotherapeutic or cytotoxic agent, e.g., an antimetabolite, antimitotic, antitumor antibiotic, asparagine-specific enzyme, bisphosphonates, antineoplastic, alkylating agent, DNA-Repair enzyme inhibitor, histone deacetylase inhibitor, corticosteroid, demethylating agent, immunomodulatory, janus-associated kinase inhibitor, phosphinositide 3-kinase inhibitor, proteasome inhibitor, or tyrosine kinase inhibitor, or a combination thereof. In some embodiments of any of the foregoing methods, the compound of the invention is used in combination with another anti-cancer therapy used for the treatment of uveal melanoma such as surgery, a MEK inhibitor, and / or a PKC inhibitor, or a combination thereof. For example, in some embodiments, the method further comprises performing surgery prior to, subsequent to, or at the same time as administration of the compound of the invention. In some embodiments, the method further comprises administration of a MEK inhibitor and / or a PKC inhibitor prior to, subsequent to, or at the same time as administration of the compound of the invention. In some embodiments, the anticancer therapy and the compound of the invention are administered within 28 days of each other and each in an amount that together are effective to treat the subject. In some embodiments, the subject or cancer has and / or has been identified as having a BRG1 loss of function mutation. In some embodiments, the subject or cancer has and / or has been identified as having a BRM loss of function mutation. In some embodiments, the cancer is resistant to one or more chemotherapeutic or cytotoxic agents (e.g., the cancer has been determined to be resistant to chemotherapeutic or cytotoxic agents such as by genetic markers, or is likely to be resistant, to chemotherapeutic or cytotoxic agents such as a cancer that has failed to respond to a chemotherapeutic or cytotoxic agent). In some embodiments, the cancer has failed to respond to one or more chemotherapeutic or cytotoxic agents. In some embodiments, the cancer is resistant or has failed to respond to dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor (e.g., ipilimumab), a PD-1 inhibitor (e.g., Nivolumab or pembrolizumab), a PD-L1 inhibitor (e.g., atezolizumab, avelumab, or durvalumab), a mitogen-activated protein kinase (MEK) inhibitor (e.g., selumetinib, binimetinib, or tametinib), and / or a protein kinase C (PKC) inhibitor (e.g., sotrastaurin or IDE196). In some embodiments, the cancer is resistant to or failed to respond to a previously administered therapeutic used for the treatment of uveal melanoma such as a MEK inhibitor or PKC inhibitor. For example, in some embodiments, the cancer is resistant to or failed to respond to a mitogen-activated protein kinase (MEK) inhibitor (e.g., selumetinib, binimetinib, or tametinib), and / or a protein kinase C (PKC) inhibitor (e.g., sotrastaurin or IDE196). CA Chemical Terms The terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting. For any of the following chemical definitions, a number following an atomic symbol indicates that total number of atoms of that element that are present in a particular chemical moiety. As will be understood, other atoms, such as H atoms, or substituent groups, as described herein, may be present, as necessary, to satisfy the valences of the atoms. For example, an unsubstituted C<com:Sub>2< / com:Sub> alkyl group has the formula –CH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>. When used with the groups defined herein, a reference to the number of carbon atoms includes the divalent carbon in acetal and ketal groups but does not include the carbonyl carbon in acyl, ester, carbonate, or carbamate groups. A reference to the number of oxygen, nitrogen, or sulfur atoms in a heteroaryl group only includes those atoms that form a part of a heterocyclic ring. The term "acyl," as used herein, represents a H or an alkyl group that is attached to a parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups include from 1 to 6, from 1 to 11, or from 1 to 21 carbons. The term "alkyl," as used herein, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 6 carbon atoms, or 1 to 3 carbon atoms). An alkylene is a divalent alkyl group. The term "alkenyl," as used herein, alone or in combination with other groups, refers to a straight chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, or 2 carbon atoms). The term "alkylsulfinimide," as used herein, refers to a group of formula -N=S(O)R<com:Sub>2< / com:Sub>, where each R is independently an alkyl. The term "alkynyl," as used herein, alone or in combination with other groups, refers to a straight chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, or 2 carbon atoms). The term "amino," as used herein, represents <com:Math><semantics>−N(RN1)2<annotation encoding="application / x-tex">-N(R^{N1})_2< / annotation>< / semantics>< / com:Math>, wherein each <com:Math><semantics>RN1<annotation encoding="application / x-tex">R^{N1}< / annotation>< / semantics>< / com:Math> is, independently, H, OH, NO<com:Sub>2< / com:Sub>, N(R<com:Sup>N2< / com:Sup>)<com:Sub>2< / com:Sub>, SO<com:Sub>2< / com:Sub>OR<com:Sup>N2< / com:Sup>, SO<com:Sub>2< / com:Sub>R<com:Sup>N2< / com:Sup>, SOR<com:Sup>N2< / com:Sup>, an N-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), wherein each of these recited R<com:Sup>N1< / com:Sup> groups can be optionally substituted; or two R<com:Sup>N1< / com:Sup> combine to form an alkylene or heteroalkylene, and wherein each R<com:Sup>N2< / com:Sup> is, independently, H, alkyl, or aryl. The amino groups of the invention can be an unsubstituted amino (i.e., <com:Math><semantics>−NH2<annotation encoding="application / x-tex">-NH_2< / annotation>< / semantics>< / com:Math>) or a substituted amino (i.e., <com:Math><semantics>−N(RN1)2<annotation encoding="application / x-tex">-N(R^{N1})_2< / annotation>< / semantics>< / com:Math>). The term "aryl," as used herein, refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl. The term "arylalkyl," as used herein, represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl, C<com:Sub>1< / com:Sub>-C<com:Sub>10< / com:Sub> alkyl C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl, or C<com:Sub>1< / com:Sub>-C<com:Sub>20< / com:Sub> alkyl C<com:Sub>6< / com:Sub>-C<com:Sub>10< / com:Sub> aryl), such as, benzyl and phenethyl. In some embodiments, the alkyl and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups. The term "azido," as used herein, represents a –N₃ group. CA - - The term "bridged polycycloalkyl," as used herein, refers to a bridged polycyclic group of 5 to 20 carbons, containing from 1 to 3 bridges. The term "cyano," as used herein, represents a –CN group. The term "carbocyclyl," as used herein, refers to a non-aromatic C<com:Sub>3< / com:Sub>-C<com:Sub>12< / com:Sub> monocyclic, bicyclic, or tricyclic structure in which the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl groups and unsaturated carbocyclyl radicals. The term "cycloalkyl," as used herein, refers to a saturated, non-aromatic, and monovalent mono- or polycarbocyclic radical of 3 to 10, preferably 3 to 6 carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl. The term "halo," as used herein, means a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical. The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. Examples of heteroalkyl groups are an "alkoxy" which, as used herein, refers alkyl-O- (e.g., methoxy and ethoxy). A heteroalkylene is a divalent heteroalkyl group. The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkenyl groups. Examples of heteroalkenyl groups are an "alkenoxy" which, as used herein, refers alkenyl-O-. A heteroalkenylene is a divalent heteroalkenyl group. The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkynyl groups. Examples of heteroalkynyl groups are an "alkynoxy" which, as used herein, refers alkynyl—O—. A heteroalkynylene is a divalent heteroalkynyl group. The term "heteroaryl," as used herein, refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing 1, 2, or 3 ring atoms selected from nitrogen, oxygen, and sulfur, with the remaining ring atoms being carbon. One or two ring carbon atoms of the heteroaryl group may be replaced with a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, imidazolyl, oxaxolyl, and thiazolyl. Heteroarylene is a divalent heteroaryl. The term "heteroarylalkyl," as used herein, represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heteroaryl, C<com:Sub>1< / com:Sub>-C<com:Sub>10< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heteroaryl, or C<com:Sub>1< / com:Sub>-C<com:Sub>20< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heteroaryl). In some embodiments, the alkyl and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups. The term "heterocyclyl," as used herein, refers a mono- or polycyclic radical having 3 to 12 atoms having at least one non-aromatic ring containing 1, 2, 3, or 4 ring atoms selected from N, O and S and no aromatic rings containing any N, O or S ring atoms. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl. Heterocyclylene is a divalent heterocyclyl. CA The term "heterocyclylalkyl," as used herein, represents an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heterocyclyl, C<com:Sub>1< / com:Sub>-C<com:Sub>10< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heterocyclyl, or C<com:Sub>1< / com:Sub>-C<com:Sub>20< / com:Sub> alkyl C<com:Sub>2< / com:Sub>-C<com:Sub>9< / com:Sub> heterocyclyl). In some embodiments, the alkyl and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups. The term "hydroxyalkyl," as used herein, represents alkyl group substituted with an -OH group. The term "hydroxyl," as used herein, represents an -OH group. The term "N-protecting group," as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999). N-protecting groups include, but are not limited to, acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4- bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L, or D, L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p- bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4- 20 dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, <com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>,<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>-dimethyl-3,5- dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups, such as trimethylsilyl. Preferred N-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t- butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz). The term "nitro," as used herein, represents an –NO₂ group. The term "oxo," as used herein, represents an =O group. The term "thiol," as used herein, represents an -SH group. The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups may be substituted or unsubstituted. When substituted, there will generally be 1 to 4 substituents present, unless otherwise specified. Substituents include, for example: alkyl (e.g., unsubstituted and substituted, where the substituents include any group described herein, e.g., aryl, halo, hydroxy), alkynyl (e.g., unsubstituted and substituted, where the substituents include any group described herein, e.g., aryl, halo, hydroxy, or alkoxy), aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH<com:Sub>2< / com:Sub> or mono- or dialkyl amino), alkylsulfinimide, azido, cyano, nitro, oxo, or thiol. In some embodiments (e.g., for the compounds of Formula la), substituents include, for example: alkyl (e.g., unsubstituted and substituted, where the substituents include any group described herein, e.g., CA aryl, halo, hydroxy), aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH<com:Sub>2< / com:Sub> or mono- or dialkyl amino), azido, cyano, nitro, or thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and heterocyclyl groups may also be substituted with alkyl (unsubstituted and substituted such as arylalkyl (e.g., substituted and unsubstituted benzyl)). Compounds of the invention can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbents or eluant). That is, certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and / or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art. "Racemate" or "racemic mixture" means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. "Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon- carbon double bond may be in an E (substituents are on opposite sides of the carbon- carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting material or a final product using various well known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight relative to the other CA stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight optically pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight pure. Percent optical purity is the ratio of the weight of the enantiomer or over the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer or over the weight of all the diastereomers. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole fraction pure. Percent purity by mole fraction is the ratio of the moles of the enantiomer or over the moles of the enantiomer plus the moles of its optical isomer. Similarly, percent purity by moles fraction is the ratio of the moles of the diastereomer or over the moles of the diastereomer plus the moles of its isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound, or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s), or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms. Compounds of the present disclosure also include all of the isotopes of the atoms occurring in the intermediate or final compounds. "Isotopes" refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, such as <com:Sup>2< / com:Sup>H, <com:Sup>3< / com:Sup>H, <com:Sup>11< / com:Sup>C, <com:Sup>13< / com:Sup>C, <com:Sup>14< / com:Sup>C, <com:Sup>13< / com:Sup>N, <com:Sup>15< / com:Sup>N, <com:Sup>15< / com:Sup>O, <com:Sup>17< / com:Sup>O, <com:Sup>18< / com:Sup>O, <com:Sup>32< / com:Sup>P, <com:Sup>33< / com:Sup>P, <com:Sup>35< / com:Sup>S, <com:Sup>18< / com:Sup>F, <com:Sup>36< / com:Sup>Cl, <com:Sup>123< / com:Sup>I and <com:Sup>125< / com:Sup>I. Isotopically-labeled compounds (e.g., those labeled with <com:Sup>3< / com:Sup>H and <com:Sup>14< / com:Sup>C) can be useful in compound or substrate tissue distribution assays. Tritiated (i.e., <com:Sup>3< / com:Sup>H) and carbon-14 (i.e., <com:Sup>14< / com:Sup>C) isotopes can be useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., <com:Sup>2< / com:Sup>H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, one or more hydrogen atoms are replaced by <com:Sup>2< / com:Sup>H or <com:Sup>3< / com:Sup>H, or one or more carbon atoms are replaced by <com:Sup>13< / com:Sup>C- or <com:Sup>14< / com:Sup>C-enriched carbon. Positron emitting isotopes such as <com:Sup>15< / com:Sup>O, <com:Sup>13< / com:Sup>N, <com:Sup>11< / com:Sup>C, and <com:Sup>18< / com:Sup>F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Preparations of isotopically labelled compounds are known to those of skill in the art. For example, CA isotopically labeled compounds can generally be prepared by following procedures analogous to those disclosed for compounds of the present invention described herein, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present disclosure; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. In case of conflict, the present specification, including definitions, will control. Definitions In this application, unless otherwise clear from context, (i) the term "a" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; and (iii) the terms "comprising" and "including" may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps. As used herein, the terms "about" and "approximately" refer to a value that is within 10% above or below the value being described. For example, the term "about 5 nM" indicates a range of from 4.5 to 5.5 nM. As used herein, the term "administration" refers to the administration of a composition (e.g., a compound or a preparation that includes a compound as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intratumoral, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal, and vitreal. As used herein, the term "BAF complex" refers to the BRG1- or HBRM-associated factors complex in a human cell. As used herein, the term "BAF complex-related disorder" refers to a disorder that is caused or affected by the level of activity of a BAF complex. As used herein, the term "BRG1 loss of function mutation" refers to a mutation in BRG1 that leads to the protein having diminished activity (e.g., at least 1% reduction in BRG1 activity, for example 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1 activity). Exemplary BRG1 loss of function mutations include, but are not limited to, a homozygous BRG1 mutation and a deletion at the C-terminus of BRG1. As used herein, the term "BRG1 loss of function disorder" refers to a disorder (e.g., cancer) that exhibits a reduction in BRG1 activity (e.g., at least 1% reduction in BRG1 activity, for example 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1 activity). The term "cancer" refers to a condition caused by the proliferation of malignant neoplastic cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas. As used herein, a "combination therapy" or "administered in combination" means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent and the agents may be co-formulated. In some embodiments, the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. In some embodiments, administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be administered orally. By "determining the level" of a protein or RNA is meant the detection of a protein or an RNA, by methods known in the art, either directly or indirectly. "Directly determining" means performing a process (e.g., performing an assay or test on a sample or "analyzing a sample" as that term is defined herein) to obtain the physical entity or value. "Indirectly determining" refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Methods to measure protein level generally include, but are not limited to, western blotting, immunoblotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF) mass spectrometry, liquid chromatography (LC)-mass spectrometry, microcytometry, microscopy, fluorescence activated cell sorting (FACS), and flow cytometry, as well as assays based on a property of a protein including, but not limited to, enzymatic activity or interaction with other protein partners. Methods to measure RNA levels are known in the art and include, but are not limited to, quantitative polymerase chain reaction (qPCR) and Northern blot analyses. By a "decreased level" or an "increased level" of a protein or RNA is meant a decrease or increase, respectively, in a protein or RNA level, as compared to a reference (e.g., a decrease or an increase by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, or more; a decrease or an increase of more than about 10%, about 15%, about 20%, about 50%, about 75%, about 100%, or about 200%, as compared to a reference; a decrease or an increase by less than about 0.01-fold, about 0.02-fold, about 0.1-fold, about 0.3-fold, about 0.5-fold, about 0.8-fold, or less; or an increase by more than about 1.2-fold, about 1.4-fold, about 1.5-fold, about 1.8-fold, about 2.0- fold, about 3.0-fold, about 3.5-fold, about 4.5-fold, about 5.0-fold, about 10-fold, about 15-fold, about 20- fold, about 30-fold, about 40-fold, about 50-fold, about 100-fold, about 1000-fold, or more). A level of a protein may be expressed in mass / vol (e.g., g / dL, mg / mL, µg / mL, ng / mL) or percentage relative to total protein in a sample. CA By "decreasing the activity of a BAF complex" is meant decreasing the level of an activity related to a BAF complex, or a related downstream effect. A non-limiting example of decreasing an activity of a BAF complex is Sox2 activation. The activity level of a BAF complex may be measured using any method known in the art, e.g., the methods described in Kadoch et al. Cell, 2013, 153, 71-85. As used herein, the term "inhibiting BRM" refers to blocking or reducing the level or activity of the ATPase catalytic binding domain or the bromodomain of the protein. BRM inhibition may be determined using methods known in the art, e.g., a BRM ATPase assay, a Nano DSF assay, or a BRM Luciferase cell assay. As used herein, the term "LXS196," also known as IDE196, refers to the PKC inhibitor having the structure: [Image disponible dans le document PDF, Image available in the PDF document] or a pharmaceutically acceptable salt thereof. The term "pharmaceutical composition," as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient and appropriate for administration to a mammal, for example a human. Typically, a pharmaceutical composition is manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation. A "pharmaceutically acceptable excipient," as used herein, refers to any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of a compound, for example, any compound of Formula I. Pharmaceutically acceptable salts of any of the compounds described herein may include those that are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid. The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparation of the appropriate salts are well-known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. By a "reference" is meant any useful reference used to compare protein or RNA levels. The reference can be any sample, standard, standard curve, or level that is used for comparison purposes. The reference can be a normal reference sample or a reference standard or level. A "reference sample" can be, for example, a control, e.g., a predetermined negative control value such as a "normal control" or a prior sample taken from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (e.g., a cell or tissue) from a subject not having a disease; a sample from a subject that is diagnosed with a disease, but not yet treated with a compound of the invention; a sample from a subject that has been treated by a compound of the invention; or a sample of a purified protein or RNA (e.g., any described herein) at a known normal concentration. By "reference standard or level" is meant a value or number derived from a reference sample. A "normal control value" is a pre-determined value indicative of non-disease state, e.g., a value expected in a healthy control subject. Typically, a normal control value is expressed as a range ("between X and Y"), a high threshold ("no higher than X"), or a low threshold ("no lower than X"). A subject having a measured value within the normal control value for a particular biomarker is typically referred to as "within normal limits" for that biomarker. A normal reference standard or level can be a value or number derived from a normal subject not having a disease or disorder (e.g., cancer); a subject that has been treated with a compound of the invention. In preferred embodiments, the reference sample, standard, or level is matched to the sample subject sample by at least one of the following criteria: age, weight, sex, disease stage, and overall health. A standard curve of levels of a purified protein or RNA, e.g., any described herein, within the normal reference range can also be used as a reference. As used herein, the term "subject" refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition. As used herein, the terms "treat," "treated," or "treating" mean therapeutic treatment or any measures whose object is to slow down (lessen) an undesired physiological condition, disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of CA condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total); an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. Compounds of the invention may also be used to "prophylactically treat" or "prevent" a disorder, for example, in a subject at increased risk of developing the disorder. As used herein, the terms "variant" and "derivative" are used interchangeably and refer to naturally-occurring, synthetic, and semi-synthetic analogues of a compound, peptide, protein, or other substance described herein. A variant or derivative of a compound, peptide, protein, or other substance described herein may retain or improve upon the biological activity of the original material. The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. Brief Description of the Drawings FIG. 1 is a graph illustrating inhibition of cell proliferation of several cancer cell lines by a BRG1 / BRM inhibitor (Compound A). FIG. 2A is a graph illustrating inhibition of cell proliferation of uveal melanoma cell line 92-1 by a BRG1 / BRM inhibitor (Compound A), a MEK inhibitor (Selumetinib), and a PKC inhibitor (LXS196). FIG. 2B is a graph illustrating inhibition of cell proliferation of uveal melanoma cell line MP41 by a BRG1 / BRM inhibitor (Compound A), a MEK inhibitor (Selumetinib), and a PKC inhibitor (LXS196). FIG. 3 is a graph illustrating inhibition of cell proliferation of several cancer cell lines by a BRG1 / BRM inhibitor (Compound B). FIG. 4 is a graph illustrating the area under the curves (AUCs) calculated from dose-response curves for cancer cell lines treated with a BRG1 / BRM inhibitor. FIG. 5 is a graph illustrating inhibition of cell proliferation of uveal melanoma and non-small cell lung cancer cell lines by a BRG1 / BRM inhibitor (Compound B). FIG. 6A is a graph illustrating inhibition of cell proliferation of uveal melanoma cell line 92-1 by a BRG1 / BRM inhibitor (Compound B), a MEK inhibitor (Selumetinib), and a PKC inhibitor (LXS196). FIG. 6B is a graph illustrating inhibition of cell proliferation of uveal melanoma cell line MP41 by a BRG1 / BRM inhibitor (Compound B), a MEK inhibitor (Selumetinib), and a PKC inhibitor (LXS196). FIG. 7A is a graph illustrating inhibition of cell proliferation of parental and PKC-inhibitor refractory uveal melanoma cell lines by a PKC inhibitor (LXS196). FIG. 7B is a graph illustrating inhibition of cell proliferation of parental and PKC-inhibitor refractory uveal melanoma cell lines by a BRG1 / BRM inhibitor (Compound B). FIG. 8A is a graph illustrating inhibition of tumor growth in mice engrafted with uveal melanoma cell lines by a BRG1 / BRM inhibitor (Compound C). FIG. 8B is an illustration of the size of tumors from mice engrafted with uveal melanoma cell lines and dosed with a BRG1 / BRM inhibitor (Compound C). FIG. 8C is a graph illustrating body weight change of mice engrafted with uveal melanoma cell lines and dosed with a BRG1 / BRM inhibitor (Compound C). CA - Date reçue / Received date Detailed Description The present disclosure features compounds useful for the inhibition of BRG1 and / or BRM. These compounds may be used to modulate the activity of a BAF complex, for example, for the treatment of a BAF-related disorder, such as cancer. Exemplary compounds described herein include compounds 2025-04-14 having a structure according to Formula I: [Image disponible dans le document PDF, Image available in the PDF document] Formula I wherein [Image disponible dans le document PDF, Image available in the PDF document] A is m is 0, 1, 2, or 3; n is 1 or 2; o is 0 or 1; X is O, CH<com:Sub>2< / com:Sub>, or NR<com:Sup>7< / com:Sup>; X' is N, CH, or <com:Math><semantics>CRx<annotation encoding="application / x-tex">CR^{x}< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>Rx<annotation encoding="application / x-tex">R^{x}< / annotation>< / semantics>< / com:Math> is a halogen; B is an optionally substituted 6-membered bicyclic heteroarylene or an optionally substituted 9- or 10-membered bicyclic heteroarylene; L is a covalent bond, optionally substituted C₁-C₃ alkylene, C₂ alkynylene, optionally substituted C<com:Sub>2< / com:Sub> alkenylene, optionally substituted C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> heteroalkylene, optionally substituted C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub> cycloalkylene, or optionally substituted 4- to 10-membered heterocyclylene; Z is optionally substituted 3- to 10-membered cycloalkyl; optionally substituted 6- to 10- membered aryl; optionally substituted 5- to 10-membered heteroaryl; or optionally substituted 5- to 10- membered heterocyclyl; R¹ and R² are, independently, hydrogen or optionally substituted C₁-C<com:Sub>6< / com:Sub> alkyl; each R<com:Sup>2< / com:Sup> and R<com:Sup>3< / com:Sup> is independently, hydrogen, optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; or optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl; R⁴ is cyano, fluoro, hydroxy, or -CH<com:Sub>2< / com:Sub>OH; R<com:Sup>5< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups; and R<com:Sup>6< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl optionally substituted with one, two, three, four, five, six, or seven fluoro groups, or a pharmaceutically acceptable salt thereof. Preferably, when B is optionally substituted 6-membered bicyclic heteroarylene, L is a covalent bond, optionally substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene, C<com:Sub>2< / com:Sub> alkynylene, optionally substituted C<com:Sub>2< / com:Sub> alkenylene, optionally substituted C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> heteroalkylene, optionally substituted C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub> cycloalkylene, or optionally substituted 4- to 10-membered heterocyclylene. Also preferably, when B is an optionally substituted 9- or 10-membered bicyclic heteroarylene, L is a covalent bond, e.g., the compound of Formula I is a compound of Formula la: Date reçue / Received [Image disponible dans le document PDF, Image available in the PDF document] date Formula la 2025-04-14 or a pharmaceutically acceptable salt thereof, where all variables are as described herein. In some embodiments, the compound, or pharmaceutically acceptable salt thereof, has the structure of any one of compounds 1-48 in Table 1, compounds 49-84 in Table 2, or compounds 85-126 in Table 3. Other embodiments, as well as exemplary methods for the synthesis of production of these compounds, are described herein. Pharmaceutical Uses The compounds described herein are useful in the methods of the invention and, while not bound by theory, are believed to exert their ability to modulate the level, status, and / or activity of a BAF complex, i.e., by inhibiting the activity of the BRG1 and / or BRM proteins within the BAF complex in a mammal. BAF complex-related disorders include, but are not limited to, BRG1 loss of function mutation-related disorders. An aspect of the present invention relates to methods of treating disorders related to BRG1 loss of function mutations such as cancer (e.g., non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, or penile cancer) in a subject in need thereof. In some embodiments, the compound is administered in an amount and for a time effective to result in one or more (e.g., two or more, three or more, four or more) of: (a) reduced tumor size, (b) reduced rate of tumor growth, (c) increased tumor cell death (d) reduced tumor progression, (e) reduced number of metastases, (f) reduced rate of metastasis, (g) decreased tumor recurrence (h) increased survival of subject, (i) increased progression free survival of subject. Treating cancer can result in a reduction in size or volume of a tumor. For example, after treatment, tumor size is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater) relative to its size prior to treatment. Size of a tumor may be measured by any reproducible means of measurement. For example, the size of a tumor may be measured as a diameter of the tumor. Treating cancer may further result in a decrease in number of tumors. For example, after treatment, tumor number is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater) relative to number prior to treatment. Number of tumors may be measured by any reproducible means of measurement, e.g., the number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification (e.g., 2x, 3x, 4x, 5x, 10x, or 50x). Treating cancer can result in a decrease in number of metastatic nodules in other tissues or organs distant from the primary tumor site. For example, after treatment, the number of metastatic nodules is reduced by 5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment. The number of metastatic nodules may be measured by any reproducible means of measurement. For example, the number of metastatic nodules may be measured by counting metastatic nodules visible to the naked eye or at a specified magnification (e.g., 2x, 10x, or 50x). Treating cancer can result in an increase in average survival time of a population of subjects treated according to the present invention in comparison to a population of untreated subjects. For example, the average survival time is increased by more than 30 days (more than 60 days, 90 days, or 120 days). An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with the compound of the invention. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with a pharmaceutically acceptable salt of the invention. Treating cancer can also result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. For example, the mortality rate is decreased by more than 2% (e.g., more than 5%, 10%, or 25%). A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with a pharmaceutically acceptable salt of the invention. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with a pharmaceutically acceptable salt of the invention. Exemplary cancers that may be treated by the invention include, but are not limited to, non-small cell lung cancer, small-cell lung cancer, colorectal cancer, bladder cancer, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin lymphoma, prostate cancer, embryonal tumor, germ cell tumor, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, Adrenocortical carcinoma, appendiceal cancer, small bowel cancer and penile cancer. Combination Formulations and Uses Thereof The compounds of the invention can be combined with one or more therapeutic agents. In particular, the therapeutic agent can be one that treats or prophylactically treats any cancer described herein. Combination Therapies A compound of the invention can be used alone or in combination with an additional therapeutic agent, e.g., other agents that treat cancer or symptoms associated therewith, or in combination with other types of treatment to treat cancer. In combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone. For example, doses may be determined empirically from drug combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., Neurology 65:S3-S6, 2005). In this case, dosages of the compounds when combined should provide a therapeutic effect. CA In some embodiments, the second therapeutic agent is a chemotherapeutic agent (e.g., a cytotoxic agent or other chemical compound useful in the treatment of cancer). These include alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodopyyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. Also included is 5-fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin, capecitabine, paclitaxel and doxetaxel. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enedigne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem. Intl. Ed Engl. 33:183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo- 5-oxo-L-norleucine, Adriamycin® (doxorubicin, including morpholino-doxorubicin, cyanomorpholino- doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5- FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T- CA 2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., Taxol® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABraxane®, cremophor- free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and Taxotere® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; Gemzar® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; Navelbine® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail to be administered in combination with the first therapeutic agent described herein. Suitable dosing regimens of combination chemotherapies are known in the art and described in, for example, Saltz et al. (1999) Proc ASCO 18:233a and Douillard et al. (2000) Lancet 355:1041-7. In some embodiments, the second therapeutic agent is a therapeutic agent which is a biologic such a cytokine (e.g., interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In some embodiments the biologic is an anti-angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab (Avastin®). In some embodiments the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof) that agonizes a target to stimulate an anti-cancer response or antagonizes an antigen important for cancer. Such agents include Rituxan® (Rituximab); Zenapax™ (Daclizumab); Simulect® (Basiliximab); Synagis® (Palivizumab); Remicade® (Infliximab); Herceptin® (Trastuzumab); Mylotarg™ (Gemtuzumab ozogamicin); Campath® (Alemtuzumab); Zevalin® (Ibritumomab tiuxetan); Humira® (Adalimumab); Xolair® (Omalizumab); Bexxar® (Tositumomab-I-131); Raptiva™ (Efalizumab); Erbitux® (Cetuximab); Avastin® (Bevacizumab); Tysabri® (Natalizumab); Actemra® (Tocilizumab); Vectibix® (Panitumumab); Lucentis® (Ranibizumab); Soliris® (Eculizumab); Cimzia® (Certolizumab pegol); Simponi (Golimumab); Ilaris® (Canakinumab); Stelara® (Ustekinumab); Arzerra® (Ofatumumab); Prolia® (Denosumab); Numax™ (Motavizumab); ABThrax™ (Raxibacumab); Benlysta® (Belimumab); Yervoy® (Ipilimumab); Adcetris® (Brentuximab Vedotin); Perjeta® (Pertuzumab); Kadcyla® (Ado-trastuzumab emtansine); and Gazyva® (Obinutuzumab). Also included are antibody-drug conjugates. The second agent may be a therapeutic agent which is a non-drug treatment. For example, the second therapeutic agent is radiation therapy, cryotherapy, hyperthermia and / or surgical excision of tumor tissue. The second agent may be a checkpoint inhibitor. In one embodiment, the inhibitor of checkpoint is an inhibitory antibody (e.g., a monospecific antibody such as a monoclonal antibody). The antibody may be, e.g., humanized or fully human. In some embodiments, the inhibitor of checkpoint is a fusion protein, e.g., an Fc-receptor fusion protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with the ligand of a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of CTLA-4 (e.g., an anti-CTLA4 antibody such as ipilimumab / Yervoy or tremelimumab). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PD-1 (e.g., nivolumab / Opdivo®; pembrolizumab / Keytruda®; pidilizumab / CT-011). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PDL1 (e.g., MPDL3280A / RG7446; MEDI4736; MSB0010718C; BMS 936559). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or Fc fusion or small molecule inhibitor) of PDL2 (e.g., a PDL2 / lg fusion protein such as AMP 224). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of B7-H3 (e.g., MGA271), B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, B-7 family ligands, or a combination thereof. In any of the combination embodiments described herein, the first and second therapeutic agents are administered simultaneously or sequentially, in either order. The first therapeutic agent may be administered immediately, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17 hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14, 1-21 or 1-30 days before or after the second therapeutic agent. Pharmaceutical Compositions The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to a mammal, preferably, a human, in a biologically compatible form suitable for administration in vivo. Accordingly, in an aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a suitable diluent, carrier, or excipient. The compounds of the invention may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention. In accordance with the methods of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time. A compound of the invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard- or soft-shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers. A compound of the invention may also be administered parenterally. Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003, 20th ed.) and in The United CA States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe. Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant. The aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base. A compound described herein may be administered intratumorally, for example, as an intratumoral injection. Intratumoral injection is injection directly into the tumor vasculature and is specifically contemplated for discrete, solid, accessible tumors. Local, regional, or systemic administration also may be appropriate. A compound described herein may advantageously be contacted by administering an injection or multiple injections to the tumor, spaced for example, at approximately, 1 cm intervals. In the case of surgical intervention, the present invention may be used preoperatively, such as to render an inoperable tumor subject to resection. Continuous administration also may be applied where appropriate, for example, by implanting a catheter into a tumor or into tumor vasculature. The compounds of the invention may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice. Dosages The dosage of the compounds of the invention, and / or compositions comprising a compound of the invention, can vary depending on many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds of the invention may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, satisfactory results may be obtained when the compounds of the invention are administered to a human at a daily dosage of, for example, between 0.05 mg and 3000 mg. Dose ranges include, for example, between 10-1000 mg. Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of a compound, or pharmaceutical composition thereof, administered to a patient may range from 0.1-100 mg / kg. CA Examples Definitions used in the following Schemes and elsewhere herein are: [Image disponible dans le document PDF, Image available in the PDF document] CA [Image disponible dans le document PDF, Image available in the PDF document] 2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., Taxol® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABraxane®, cremophor- free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and Taxotere® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; Gemzar® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; Navelbine® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail to be administered in combination with the first therapeutic agent described herein. Suitable dosing regimens of combination chemotherapies are known in the art and described in, for example, Saltz et al. (1999) Proc ASCO 18:233a and Douillard et al. (2000) Lancet 355:1041-7. In some embodiments, the second therapeutic agent is a therapeutic agent which is a biologic such a cytokine (e.g., interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In some embodiments the biologic is an anti-angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab (Avastin®). In some embodiments the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof) that agonizes a target to stimulate an anti-cancer response or antagonizes an antigen important for cancer. Such agents include Rituxan (Rituximab™); Zenapax (Daclizumab™); Simulect (Basiliximab™); Synagis (Palivizumab™); Remicade (Infliximab™); Herceptin (Trastuzumab™); Mylotarg (Gemtuzumab ozogamicin™); Campath (Alemtuzumab™); Zevalin (Ibritumomab tiuxetan™); Humira (Adalimumab™); Xolair (Omalizumab™); Bexxar (Tositumomab-l-131™); Raptiva (Efalizumab™); Erbitux (Cetuximab™); Avastin (Bevacizumab™); Tysabri (Natalizumab™); Actemra (Tocilizumab™); Vectibix (Panitumumab™); Lucentis (Ranibizumab™); Soliris (Eculizumab™); Cimzia (Certolizumab pego™l); Simponi (Golimumab™); Ilaris (Canakinumab™); Stelara (Ustekinumab™); Arzerra (Ofatumumab™); Prolia (Denosumab™); Numax (Motavizumab™); ABThrax (Raxibacumab™); Benlysta (Belimumab™); Yervoy (Ipilimumab™); Adcetris (Brentuximab Vedotin™); Perjeta (Pertuzumab™); Kadcyla (Ado-trastuzumab emtansine™); and Gazyva (Obinutuzumab™). Also included are antibody-drug conjugates. The second agent may be a therapeutic agent which is a non-drug treatment. For example, the second therapeutic agent is radiation therapy, cryotherapy, hyperthermia and / or surgical excision of tumor tissue. The second agent may be a checkpoint inhibitor. In one embodiment, the inhibitor of checkpoint is an inhibitory antibody (e.g., a monospecific antibody such as a monoclonal antibody). The antibody may be, e.g., humanized or fully human. In some embodiments, the inhibitor of checkpoint is a fusion protein, e.g., an Fc-receptor fusion protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with the ligand of a checkpoint protein. In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of CTLA-4 (e.g., an anti-CTLA4 antibody such as ipilimumab / Yervoy or tremelimumab). In some embodiments, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.99 (d, J = 2.0 Hz, 1H), 7.82-7.79 (m, 1H), 7.56 (d, J = 8.4 Hz, 1H), 4.97 (s, 2H), 3.88 (s, 3H) ppm. Step 3. Methyl 6-bromo-4-oxo-isochromane-3-carboxylate Sodium hydride (39 g, 974 mmol, 60% purity) was added to a mixture of methyl 5-bromo-2- (bromomethyl)benzoate (150 g, 487 mmol) and methyl 2-hydroxyacetate (75 mL, 974 mmol) in DMF (1.5 L) at 0 °C. The mixture was stirred at 25°C for 1hr. The mixture was poured into saturated NH<com:Sub>4< / com:Sub>Cl (aq., 6 L), and then extracted with MTBE (3 L x 2). The combined organic layers were dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure affording the title compound (140 g, crude) as a brown oil, which was used to next step directly. Step 4. 6-Bromoisochroman-4-one A mixture of methyl 6-bromo-4-oxo-isochromane-3-carboxylate (140 g, 487 mmol) in EtOH (500 mL) and HCI (12 M, I L) was stirred at 120°C for 1hr. The reaction mixture was cooled to 25 °C and filtered. The filter cake was saved. The filtrate was diluted with water (2 L) and extracted with MTBE (1.5 L x 2). The combined organic layers were dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure to give brown oil. The brown oil was combined with the filter cake and then triturated with EtOH (200 mL) at 0°C for 0.5 hrs. The solid was collected by filtration, washed with EtOH (50 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2) and dried in vacuo affording the title compound (50 g, 242 mmol) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.17 (d, J = 20 Hz, 1H), 7.69-7.67 (m, 1H), 7.13 (d, J = 8.4 Hz, 1H), 4.85 (s, 2H), 4.37 (s, 2H) ppm. Step 5. 6-Bromo-4-methyl-isochroman-4-ol Methylmagnesium bromide (3 M in THF, 440 mL) was added dropwise to a mixture of 6- bromoisochroman-4-one (100 g, 440 mmol) and CeCl<com:Sub>3< / com:Sub> (54.3 g, 220 mmol, dried in a muffle furnace at 300°C for 3 hrs.) in THF (2 L) at -50 °C. The mixture was warmed to 20°C and stirred for 1 hr. The reaction mixture was poured into water (2 L) and then filtered through diatomite. The diatomite was then washed with EA (2L). The filtrate was separated and the aqueous layer was extracted with EA (1 L <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2). The combined organic layers were washed with brine (2 L), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give a residue. The crude residue was purified by FCC (Eluent: PE:EA = 50:1 to 3:1) affording the title compound (105 g, 432 mmol) as light yellow oil. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.67 (d, J = 2.0 Hz, 1H), 7.38-7.35 (m, 1H), 6.99 (d, J = 8.4 Hz, 1H), 5.35 (s, 1H), 4.71 - 4.58 (m, 2H), 3.68 - 3.59 (m, 1H), 3.58 - 3.50 (m, 1H), 1.38 (s, 3H) ppm. Step 6. 6-Bromo-4-methyl-isochromane-4-carbonitrile TMSCN (102.9 mL, 823 mmol) was added to a solution of 6-bromo-4-methyl-isochroman-4-ol (100 g, 411 mmol) in DCM (2 L) at 0 °C. InBr<com:Sub>3< / com:Sub> (29.2 g, 82.3 mmol) was then added, and the mixture was warmed and stirred at 25 °C for 1 hr. The mixture was poured into water (2 L) and extracted with DCM (1 L x 2). The combined organic layers were washed with brine (1 L), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by FCC (Eluent: PE:EA = 20:1 to 5:1) affording the title compound (55 g, 218 mmol) as a white solid. CA <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.82 (d, J = 2.0 Hz, 1H), 7.55-7.52 (m, 1H), 7.13 (d, J = 8.3 Hz, 1H), 4.83 - 4.68(m, 2H), 4.17 (d, J = 11.5 Hz, 1H), 3.79 (d, J = 11.5 Hz, 1H), 1.65 (s, 3H) ppm. Step 7. (4S)-4-Cyano-4-methyl-isochromane-6-carboxylic acid and (4R)-4-Cyano-4-methyl- isochromane-6-carboxylic acid Palladium acetate (490 mg, 2.18 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (9.05 g, 65.4 mmol) were added to a mixture 6-bromo-4-methyl-isochromane-4-carbonitrile (11 g, 43.6 mmol) and DCPP-2HBF<com:Sub>4< / com:Sub> (2.67 g, 4.36 mmol) in DMSO (110 mL) and H<com:Sub>2< / com:Sub>O (5.5 mL). The mixture was degassed and purged with CO (g) three times, and then the mixture was stirred at 100 °C for 4 hrs under an atmosphere of CO (15 psi). The aqueous layer was then extracted with EA (1 L x 2). The aqueous phase was acidified with HCI (2N) until a pH = 3 was achieved. The aqueous layer was then extracted with EA(1 L <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic phase was washed with brine (1 L), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under vacuum. The crude product was triturated with EA (100 mL) at 20°C for 15 min, then the solid was collected by filtration, washed with EA (50 mL), and dried affording the title compounds (30 g, 138 mmol) as a white solid. The mixture of stereoisomers was purified by SFC separation (column: DAICEL CHIRALPAK AD-H (250mm x 30mm, 5μm); mobile phase: [0.1%NH₃-H₂O MEOH]; B%: 20%-20%, 3.52min; 514minmin). Peak 1 was concentrated under reduced pressure to give an oil. The oil was dissolved in water (200 mL). The mixture was acidified with HCI (2N) to pH = 3 and extracted with EA (100 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic phase washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum affording Intermediate 1 (4.15 g, 19.1 mmol) as an off-white solid. Peak 2 was concentrated under reduced pressure to give an oil. The oil was dissolved in water (200 mL). The mixture was acidified with HCI (2N) to pH = 3 and extracted with EA (100 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic phase washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum affording Intermediate 2 (4.1 g, 18.9 mmol) as an off- white solid. Intermediate 1: Chiral SFC: AD-3_5CM_MEOH(DEA)_5_40_3ML_AT35.M; RT = 0.89 min LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=218.3<annotation encoding="application / x-tex">[M+H]+ = 218.3< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>HNMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.17 (br s, 1H), 8.07 (d, J = 1.6 Hz, 1H), 7.89-7.87 (m, 1H), 7.29 (d, J <com:Math><semantics>=8.0 Hz,1H,4.95−4.79(m,2H),4.19(d,J=11.6 Hz,1H),3.88(d,J=11.6 Hz,1H),1.67(s,3H)ppm.<annotation encoding="application / x-tex">= 8.0 \text{ Hz}, 1\text{H}, 4.95 - 4.79 (m, 2\text{H}), 4.19 (d, J = 11.6 \text{ Hz}, 1\text{H}), 3.88 (d, J = 11.6 \text{ Hz}, 1\text{H}), 1.67 (s, 3\text{H}) ppm.< / annotation>< / semantics>< / com:Math> Intermediate 2: Chiral SFC: AD-3 5CM MEOH(DEA) 5 40 3ML AT35.M; RT = 1.03 min LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=218.3<annotation encoding="application / x-tex">[M+H]+ = 218.3< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.17 (br s, 1H), 8.07 (d, J = 1.6 Hz, 1H), 7.89-7.87 (m, 1H), 7.29 (d, J <com:Math><semantics>=8.0 Hz,1H,4.95−4.79(m,2H),4.19(d,J=11.6 Hz,1H),3.88(d,J=11.6 Hz,1H),1.67(s,3H)ppm.<annotation encoding="application / x-tex">= 8.0 \text{ Hz}, 1\text{H}, 4.95 - 4.79 (m, 2\text{H}), 4.19 (d, J = 11.6 \text{ Hz}, 1\text{H}), 3.88 (d, J = 11.6 \text{ Hz}, 1\text{H}), 1.67 (s, 3\text{H}) ppm.< / annotation>< / semantics>< / com:Math> Intermediates 3 and 4: (4R)-4-Hydroxy-4-methylisochromane-6-carboxylic acid and (4S)-4- Hydroxy-4-methylisochromane-6-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] (4R)-4-Hydroxy-4-methylisochromane-6-carboxylic acid and (4S)-4-Hydroxy-4- methylisochromane-6-carboxylic acid A mixture of 6-bromo-4-methyl-isochroman-4-ol (1.00 g, 4.11 mmol), dccp·2BF4 (252 mg, 0.41 mmol), K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (853 mg, 6.17 mmol), Pd(OAc)<com:Sub>2< / com:Sub> (92.4 mg, 0.41 mmol) and H<com:Sub>2< / com:Sub>O (1.48 mL, 82.3 mmol) in DMSO (10 mL) was degassed and purged with CO (g) three times. The mixture was stirred at 100°C for 14 hrs under a CO atmosphere. The reaction mixture was filtered to remove the black solid and then diluted with water (60 mL) and extracted with EA (60 mL x 2). The oganic layer was discarded and the aqueous phase was adjusted to pH = 6 with aqueous HCl. The aqueous solution was then extracted with EA (100 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layer was washed with brine (200 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure affording a mixture of the title compounds (550 mg, 2.43 mmol) as a light yellow solid. The stereoisomers were separated by chiral SFC (column: DAICEL CHIRALPAK AD (250mm*30mm, 10μm); mobile phase: [0.1%NH<com:Sub>3< / com:Sub>•H<com:Sub>2< / com:Sub>O IPA]; B%: 40%-40%,4.0 min; 60 minmin). The desired fractions were collected and concentrated under reduced pressure. The product was diluted with water, adjusted to pH = 4 with aq. HCI, then extracted with EA (80 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure affording Intermediate 3 (260 mg, 1.18 mmol) as a yellow solid and Intermediate 4 (240 mg, 1.04 mmol) as a yellow solid. Intermediate 3: Chiral SFC: AD-3_5CM_IPA (DEA)_5_40_3ML_AT35.M; RT = 1.537min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M−18+H]+=191.1<annotation encoding="application / x-tex">[M-18+H]+ = 191.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.19 - 12.40 (m, 1H), 8.15 (d, J = 1.6 Hz, 1H), 7.75 - 7.73 (m, 1H), <com:Math><semantics>7.13(d,J=8.0Hz,1H),5.34(s,1H),4.82−4.68(m,2H),3.71−3.65(m,1H),3.61−3.54(m,1H),1.40<annotation encoding="application / x-tex">7.13 (d, J = 8.0 Hz, 1H), 5.34 (s, 1H), 4.82 - 4.68 (m, 2H), 3.71 - 3.65 (m, 1H), 3.61 - 3.54 (m, 1H), 1.40< / annotation>< / semantics>< / com:Math> (s, 3H) ppm. Intermediate 4: Chiral SFC: AD-3_5CM_IPA (DEA)_5_40_3ML_AT35.M; RT = 1.926 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M−17+H]+=191.1<annotation encoding="application / x-tex">[M-17+H]+ = 191.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.86 (br s, 1H), 8.15 (d, J = 1.6 Hz, 1H), 7.75 - 7.73 (m, 1H), 7.13 (d, <com:Math><semantics>J=8.0Hz,1H),5.34(s,1H),4.84−4.67(m,2H),3.73−3.62(m,1H),3.62−3.53(m,1H),1.40(s,3H)<annotation encoding="application / x-tex">J = 8.0 Hz, 1H), 5.34 (s, 1H), 4.84 - 4.67 (m, 2H), 3.73 - 3.62 (m, 1H), 3.62 - 3.53 (m, 1H), 1.40 (s, 3H)< / annotation>< / semantics>< / com:Math> ppm. Intermediates 5 and 6: (S)-4-Cyano-4-methylchroman-6-carboxylic acid and (R)-4-Cyano-4- methylchroman-6-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 6-Bromochromane-4-carbonitrile Potassium tert-butoxide (54.4 g, 484 mmol) was added to a solution of 6-bromochroman-4-one (50 g, 220 mmol) and 1-(isocyanomethylsulfonyl)-4-methyl-benzene (64.5 g, 330 mmol) in DME (2.5 L) and EtOH (100 mL) at 0 °C. The reaction mixture was warmed and stirred at 25°C for 16 hrs. The reaction mixture was poured into water (2 L) and adjusted to pH=6~7 with NH<com:Sub>4< / com:Sub>Cl (56.9 g). The organic solvents were removed in vacuo. The aqueous phase was extracted with EA (1.5 L x 2). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> and concentrated in vacuum. The residue was purified by FCC (Eluent: PE:EA = 20:1). The purified residue was combined with another batch that was run under the same conditions and triturated with MTBE (150 mL). The solid was filtered and concentrated in vacuo affording the title compound (40 g, 151 mmol) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.43 - 7.42 (m, 1H), 7.33 - 7.31 (m, 1H), 6.76 (d, J = 8.8 Hz, 1H), 4.36 - 4.30 (m, 1H), 4.26 - 4.21 (m, 1H), 4.01 - 3.98 (m, 1H), 2.35 - 2.31 (m, 2H) ppm. Step 2. 6-Bromo-4-methyl-chromane-4-carbonitrile Sodium hydride (8.40 g, 210 mmol, 60% purity) was added to a solution of 6-bromochromane-4- carbonitrile (25 g, 105 mmol) in THF (250 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hr, then Mel (32.7 mL, 525 mmol) was added. The reaction mixture was stirred at 25°C for 2 hrs. The reaction mixture was diluted with saturated NH<com:Sub>4< / com:Sub>Cl (aq., 800 mL) and extracted with EA (800 mL x 3). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The crude residue was purified by FCC (Eluent: PE / EA = 1:0 to 5:1) affording the title compound (18 g, 69.2 mmol) as a light yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.69 (d, J = 2.4 Hz, 1H), 7.41 - 7.38 (m, 1H), 6.83 (d, J = 8.8 Hz, 1H), 4.33 - 4.25 (m, 1H), 4.24 - 4.15 (m, 1H), 2.41 - 2.35 (m, 1H), 2.17 - 2.11 (m, 1H), 1.75 (s, 3H) ppm. Step 3. (S)-4-Cyano-4-methylchroman-6-carboxylic acid and (R)-4-Cyano-4- methylchroman-6-carboxylic acid A mixture of 6-bromo-4-methyl-chromane-4-carbonitrile (8.5 g, 33.7 mmol), dccp-2HBF<com:Sub>4< / com:Sub> (2.06 g, 3.37 mmol), K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (6.99 g, 50.6 mmol), Pd(OAc)<com:Sub>2< / com:Sub> (757 mg, 3.37 mmol), and H<com:Sub>2< / com:Sub>O (1.22 mL, 67.4 mmol) in DMSO (85 mL) was degassed and purged with CO (g) three times. The mixture was then stirred at CA 100°C for 14 hrs under a CO (15 psi) atmosphere. The reaction mixture combined with a 2<com:Sup>nd< / com:Sup> batch and filtered to remove the black solid. The filtrate was diluted with water (60 mL) and extracted with EA (60 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2). The organic layer was discarded and the pH of aqueous phase was adjusted to pH=4 with aq. HCl resulting in a precipitate. The mixture was filtered and the white solid was washed with water (40 mL x 2), filtered, and dried in vacuo affording a mixture of the title compounds (12 g, 51.2 mmol) as a white solid. Intermediates 5 and 6 were separated by chiral SFC (column: DAICEL CHIRALPAK AD- H(250mm*30mm,5μm);mobile phase:[0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O MEOH];B%: 30%-30%,4.7 min; 600 min.). The fraction was concentrated under reduced pressure to get Intermediate 5 (5.3 g, 24.3 mmol) as an off- white solid and Intermediate 6 (5.2 g, 23.6 mmol) as an off-white solid. Intermediate 5: Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, RT = 0.958min LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=218.2<annotation encoding="application / x-tex">[M+H]+= 218.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.00 (d, J = 2.0 Hz, 1H), 7.79 - 7.76 (m, 1H), 6.88 (d, J = 8.4 Hz, 1H), 4.37 - 4.22 (m, 2H), 2.45 - 2.39 (m, 1H), 2.22 - 1.75 (m, 1H), 1.76 (s, 3H) ppm. Intermediate 6: Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, RT = 1.294 LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=218.2<annotation encoding="application / x-tex">[M+H]+= 218.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.00 (d, J = 2.0 Hz, 1H), 7.79 - 7.76 (m, 1H), 6.89 (d, J = 8.4 Hz, 1H), 4.37 - 4.23 (m, 2H), 2.50 - 2.41 (m, 1H), 2.22 - 2.18 (m, 1H), 1.76 (s, 3H) ppm. Intermediates 7 and 8: (4R)-4-Fluoro-4-methyl-isochromane-6-carboxylic acid and (4S)-4-Fluoro-4- methyl-isochromane-6-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 6-Bromo-4-fluoro-4-methyl-isochromane DAST (52.2 mL, 395 mmol,) was added dropwise to a mixture of Intermediate 8 (32 g, 132 mmol) in DCM (320 mL) at 0 °C. The mixture was warmed and stirred at 25 °C for 20 min. The mixture was poured into ice water (600 mL) and extracted with DCM (250 mL x 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 30:1) affording the title compound (24.5 g, 99.96 mmol) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M−18+H]+=226.9<annotation encoding="application / x-tex">[M-18+H]+ = 226.9< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.72 (s, 1H), 7.45 - 7.42 (m, 1H), 6.93 (d, J = 8.0 Hz, 1H), 4.84 - 4.74 (m, 1H), 4.73 - 4.64 (m, 1H), 4.06 - 4.00 (m, 1H), 3.86 - 3.78 (m, 1H), 1.76 - 1.64 (m, 3H) ppm. Step 2. (4R)-4-Fluoro-4-methyl-isochromane-6-carboxylic acid and (4S)-4-Fluoro-4-methyl- isochromane-6-carboxylic acid Palladium acetate (687 mg, 3.06 mmol), dccp-2HBF₄ (1.87 g, 3.06 mmol), K₂CO₃ (6.34 g, 45.9 mmol), and H<com:Sub>2< / com:Sub>O (7.50 mL) were added to a solution of 6-bromo-4-fluoro-4-methyl-isochromane (7.5 g, 30.6 mmol) in DMSO (75 mL) at 25 °C. The mixture was purged with CO (g) three times. The mixture was heated and stirred at 100°C for 4 hrs under an atmosphere of CO (15 psi). The reaction mixture was CA poured into H<com:Sub>2< / com:Sub>O (1.2 L) and extracted with EA (400 mL x 2). The aqueous phase was acidified with 1N HCl to pH=5 and extracted with EA (300 mL x 3). The combined organic layers were washed with brine (300 mL x 2), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo affording a mixture of the title compounds (2.6 g, 12.2 mmol) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.42 - 12.67 (m, 1H), 8.13 (s, 1H), 7.92 - 7.88 (m, 1H), 7.29 (d, J = 8.0 Hz, 1H), 4.91 - 4.82 (m, 1H), 4.77 - 4.68 (m, 1H), 4.10 - 4.01 (m, 1H), 3.89 - 3.76 (m, 1H), 1.70 - 1.58 (m, 3H) ppm. Intermediates 7 and 8 were separated by SFC (Column: DAICEL CHIRALPAK IG (250mm*30mm, 10μm); mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O MeOH];B%: 20%-20%, 3.4min; 2300minmin) to give two peaks. Peak 1 was concentrated under reduced pressure to remove 95% MeOH and poured into H<com:Sub>2< / com:Sub>O (500 mL). The mixture was acidified with HCl (1N) to pH=5 and extracted with EA (150 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure to afford Intermediate 7 (1.06 g, 5.04 mmol) as a white solid. Peak 2 was concentrated under reduced pressure and poured into H<com:Sub>2< / com:Sub>O (500 mL). The mixture was acidified with HCl (1N) to pH=5 and extracted with EA (150 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure to afford Intermediate 8 (1.07 g, 5.09 mmol) as a white solid. Intermediate 7: Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, RT = 0.819 min. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 13.08 (br s, 1H), 8.13 (s, 1H), 7.92 - 7.88 (m, 1H), 7.29 (d, J = 8.0 Hz, 1H), 4.90 - 4.81 (m, 1H), 4.78 - 4.68 (m, 1H), 4.05 - 4.01 (m, 1H), 3.87 - 3.78 (m, 1H), 1.72 - 1.58 (m, 3H) ppm. Intermediate 8: Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, RT = 0.903 min. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 13.31 - 12.88 (m, 1H), 8.13 (s, 1H), 7.92 - 7.88 (m, 1H), 7.29 (d, J = 8.0) Hz, 1H), 4.90 - 4.81 (m, 1H), 4.78 - 4.68 (m, 1H), 4.08 - 4.01 (m, 1H), 3.89 - 3.77 (m, 1H), 1.72 - 1.58 (m, 3H) ppm. Intermediates 9 and 10: (R)-1-(tert-Butoxycarbonyl)-4-cyano-4-methyl-1,2,3,4-tetrahydroquinoline- 6-carboxylic acid and (S)-1-(tert-Butoxycarbonyl)-4-cyano-4-methyl-1,2,3,4-tetrahydroquinoline-6- carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] 30 Step 1. tert-Butyl 6-bromo-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate A mixture of 6-bromo-2,3-dihydro-1H-quinolin-4-one (2 g, 8.85 mmol), Boc<com:Sub>2< / com:Sub>O (3.86 g, 17.7 mmol), DMAP (108 mg, 0.88 mmol), and DIEA (3.1 mL, 17.7 mmol) in DCM (20 mL) was stirred at 60°C for 12 hrs. The mixture was concentrated under reduced pressure and then poured into water (5 mL). The aqueous solution was then extracted with EA (5mL x 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The residue was purified by FCC (Eluent: 0 to 12% EA in PE) affording the title compound (1.75 g, 5.37 mmol) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=326.0<annotation encoding="application / x-tex">[M+H]+ = 326.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.89 - 7.88 (m, 1H), 7.75 (d, J = 1.2 Hz, 2H), 4.11 - 4.07 (m, 2H), 2.79 - 2.75 (m, 2H), 1.51 (s, 9H) ppm. Step 2. tert-Butyl 6-bromo-4-cyano-3,4-dihydroquinoline-1(2H)-carboxylate Potassium tert-butoxide (1.38 g, 12.26 mmol) was added to a mixture of tert-Butyl 6-bromo-4- oxo-3,4-dihydroquinoline-1(2H)-carboxylate (2 g, 6.13 mmol) and 1-(isocyanomethylsulfonyl)-4-methyl- benzene (1.80 g, 9.20 mmol) in DME (100 mL) and EtOH (4 mL) at 0 °C. The mixture was stirred at 25 °C for 12 hrs. The reaction mixture was poured into water (5 mL) and extracted with EA (5 mL x 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The residue was purified by FCC (Eluent: 0 to 20% EA in PE) affording the title compound (900 mg, 2.67 mmol) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M−55]+=281.0<annotation encoding="application / x-tex">[M-55]+ = 281.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.67 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 2.4 Hz, 1H), 7.51 - 7.47 (m, 1H), 4.48 - 4.44 (m, 1H), 3.74 - 3.69 (m, 2H), 2.21 - 2.15 (m, 2H), 1.48 (s, 9H) ppm. Step 3. tert-Butyl 6-bromo-4-cyano-4-methyl-3,4-dihydroquinoline-1(2H)-carboxylate Sodium hydride (89 mg, 2.22 mmol, 60% purity) was added slowly to a mixture of tert-butyl 6- bromo-4-cyano-3,4-dihydroquinoline-1(2H)-carboxylate (500 mg, 1.48 mmol) in THF (5 mL) at 0 °C. The mixture was stirred at 0 °C for 0.5 hr, then MeI (0.14 mL, 2.22 mmol) was added. The reaction mixture was warmed to 25°C and stirred for 2 hrs. The reaction mixture was quenched with saturated NH₄Cl (20 mL) and extracted with EA (10 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The resulting oil was purified by FCC (Eluent: 0 to 50% EA in PE) affording the title compound (370 mg, 1.01 mmol) as yellow oil. LCMS (ESI) m / z: [M-55]+=295.0 <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl3) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.66 (d, J = 8.8 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.38 - 7.36 (m, 1H), 3.89 - 3.80 (m, 2H), 2.40 - 2.34 (m, 1H), 2.04 - 2.00 (m, 1H), 1.73 (s, 3H), 1.53 (s, 9H) ppm. Step 4. (R)-1-(tert-Butoxycarbonyl)-4-cyano-4-methyl-1,2,3,4-tetrahydroquinoline-6- carboxylic acid & (S)-1-(tert-Butoxycarbonyl)-4-cyano-4-methyl-1,2,3,4-tetrahydroquinoline-6- carboxylic acid Palladium acetate (11.8 mg, 0.053 mmol) and dccp 2HBF<com:Sub>4< / com:Sub> (64.5 mg, 0.11 mmol) were added to a mixture of tert-butyl 6-bromo-4-cyano-4-methyl-3,4-dihydroquinoline-1(2H)-carboxylate (370 mg, 1.05 mmol) and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (218 mg, 1.58 mmol) in DMSO (3 mL) and H<com:Sub>2< / com:Sub>O (1 mL) at 25 °C. The mixture was degassed and purged with CO (g, 15 psi) three times, and then the mixture was warmed stirred at 100 °C CA under CO (g) for 12 hrs. The reaction mixture was filtered and the filtrate was purified by reversed-phase HPLC affording a mixture of the title compounds (190 mg, 0.60 mmol) as a white solid. The stereoisomers were separated via chiral SFC (DAICEL CHIRALPAK AD(250mm*30mm,10µm); mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O MEOH]; B%: 20%- 20%,1.75min; 75minmin) to afford Intermediate 9 (80 mg, 0.25) mmol) as light yellow solid and Intermediate 10 (90 mg, 0.28 mmol) as light yellow solid. Intermediate 9: LCMS (ESI) m / a: [M-55]+=261.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.96 (d, J = 1.6 Hz, 1H), 7.80 - 7.78 (m, 1H), 7.69 (d, J = 8.8 Hz, 1H), 3.79 - 3.74 (m, 2H), 2.36 - 2.32 (m, 1H), 2.07 - 2.05 (m, 1H), 1.71 (s, 3H), 1.47 (s, 9H) ppm. Chiral SFC: AD-3_5CM_MEOH(DEA)_5_40_3ML_AT35.M, Rt = 0.766 min, ee value = 98.82 %. Intermediate 10: LCMS (ESI) m / a: [M-55]+=261.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.96 (br s, 1H), 7.81 - 7.78 (m, 1H), 7.71 (br d, J = 8.8 Hz, 1H), 3.80 - 3.74 (m, 2H), 2.36 - 2.31 (m, 1H), 2.07 - 2.04 (m, 1H), 1.71 (s, 3H), 1.48 (s, 9H) ppm. Chiral SFC: AD-3_5CM_MEOH(DEA)_5_40_3ML_AT35.M. Rt =0.916 min, ee value =93.82 %. Intermediate 11: tert-Butyl N-[1-(4-bromo-2-pyridyl)-2-methoxy-ethyl]carbamate [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 1-(4-Bromo-2-pyridyl)-2-methoxy-ethanone n-Butyl lithium (2.5 M, 16.9 mL) was added to a solution of 2,4-dibromopyridine (10.0 g, 42.2 mmol) in toluene (400 mL) at -60 °C. The mixture was stirred at -60°C for 1 hr, and then methyl 2- methoxyacetate (7.53 mL, 76.0 mmol) was added to the mixture and the mixture was stirred at -60 °C for 1 hr. The reaction mixture was quenched by addition water (1 L), and then extracted with EA (1 L x 2). The combined organic layers were washed with brine (1 L), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The crude product was purified by FCC (Eluent: PE:EA = 3:1) affording the title compound (5 g, 21.7 mmol) as a brown solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl3) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.45 (d, J = 5.2 Hz, 1H), 8.23 (d, J = 2.0 Hz, 1H), 7.68 – 7.66 (m, 1H), 5.01 (s, 2H), 3.54 (s, 3H) ppm. Step 2. tert-Butyl N-[1-(4-bromo-2-pyridyl)-2-methoxy-ethyl]carbamate Ammonium acetate (13.4 g, 174 mmol) and NaBH₃CN (10.93 g, 174 mmol) were added to a solution of 1-(4-bromo-2-pyridyl)-2-methoxy-ethanone (4 g, 17.4 mmol) in THF (120 mL) at 20 °C. The mixture was stirred at 20 °C for 2 hr. Boc₂O (22.8 g, 104 mmol) and saturated NaHCO₃ (60 mL) were added to the reaction mixture and the mixture was stirred at 20 °C for 2 hrs. The reaction mixture was diluted with water (300 mL) and extracted with EA (300 mL x 2). The combined organic layers were washed with brine (300 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced CA pressure. The crude product was purified by FCC (Eluent: PE:EA = 3:1) and concentrated under reduced pressure to give a white solid. The white solid was then re-purified by RPC. The fractions containing the title compound were collected and concentrated to remove the MeCN. The aqueous layer was basified with sodium carbonate (solid) until <com:Math><semantics>pH=9.0<annotation encoding="application / x-tex">pH = 9.0< / annotation>< / semantics>< / com:Math> was achieved. The aqueous solution was extracted with EA (100 mL x 2). The combined organic layers were dried with anhydrous Na₂SO₄ and concentrated in vacuo affording the title compound (1.5 g, 4.19 mmol) as brown oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [Br81M+H]+ = 333.1. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.41 (d, J = 5.2 Hz, 1H), 7.62 (d, J = 1.2 Hz, 1H), 7.58 – 7.56 (m, 1H), 7.37 (br d, <com:Math><semantics>J=8.8Hz<annotation encoding="application / x-tex">J = 8.8 \, Hz< / annotation>< / semantics>< / com:Math>, 1H), 4.81 - 4.76 (m, 1H), 3.56 - 3.54 (m, 2H), 3.23 (s, 3H), 1.40 - 1.37 (m, 9H) ppm. Intermediates 12 and 13: (S)-4-(Difluoromethyl)-4-fluoroisochroman-6-carboxylic acid and (R)-4- (Difluoromethyl)-4-fluoroisochroman-6-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 6-Bromo-4-(difluoro(phenylsulfonyl)methyl)isochroman-4-ol LiHMDS (1 M, 26.4 mL) was added to a solution of 6-bromoisochroman-4-one (3 g, 13.2 mmol), difluoromethylsulfonylbenzene (2.8 mL, 19.8 mmol) in THF (30 mL) at -78 °C. The mixture was stirred at -78 °C for 2 hr. The reaction mixture was poured into saturated aq. NH₄CI (50 mL) and extracted with EA (50 mL x 2). The organic layer was washed with brine (50 mL) and dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 10:1 to 3:1) affording the title compound (3 g, 6.70 mmol) as yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H2O]+=435.8,437.8<annotation encoding="application / x-tex">[M+H2O]+ = 435.8, 437.8< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.04 (d, J = 7.6 Hz, 2H), 7.90 - 7.89 (m, 1H), 7.85 - 7.76 (m, 1H), 7.71 - 7.62 (m,2H), <com:Math><semantics>7.49−7.47<annotation encoding="application / x-tex">7.49 - 7.47< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.97<annotation encoding="application / x-tex">6.97< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.00<annotation encoding="application / x-tex">5.00< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=12.4<annotation encoding="application / x-tex">J = 12.4< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>4.93−4.73<annotation encoding="application / x-tex">4.93 - 4.73< / annotation>< / semantics>< / com:Math> (m, 2H), 3.93 - 3.88 (m, 1H), 3.83 (s,1H). Step 2. 6-Bromo-4-(difluoromethyl)isochroman-4-ol Magnesium (2.61 g, 107 mmol) was added to a solution of 6-bromo-4- (difluoro(phenylsulfonyl)methyl)isochroman-4-ol (3 g, 7.16 mmol) and NaOAc / HOAc (aq., 8 M, 44.7 mL) in DMF (100 mL). The mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into water CA (50 mL), and then extracted with EA (50 mL x 3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 10:1 to 3:1) affording the title compound (1.5 g, 5.37 mmol) as colorless oil. LCMS (ESI) m / z: <com:Math><semantics>[79BrM−H2O]<annotation encoding="application / x-tex">[79BrM-H_2O]< / annotation>< / semantics>< / com:Math>+ = 260.9. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.83 - 7.60 (m, 1H), 7.51 - 7.33 (m, 1H), 7.11 - 6.93 (m, 1H), 6.25 - 5.88 (m, 1H), 4.92 - 4.70 (m, 2H), 4.26 - 4.17 (m, 1H), 3.87 - 3.66 (m, 1H), 2.75 - 2.58 (m, 1H). Step 3. 6-Bromo-4-(difluoromethyl)-4-fluoroisochroman DAST (1.33 mL, 10.0 mmol) was added to a solution of 6-bromo-4-(difluoromethyl)isochroman-4- ol (1.4 g, 5.02 mmol) in DCM (20 mL) at 0 °C. The mixture was stirred at 0 °C for 2 hr. The reaction mixture was poured into water (50 mL) and extracted with DCM (20 mL x 2). The organic layer was washed with brine (20 mL) and dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 10:1 to 5:1) affording the title compound (900 mg, 2.88 mmol) as colorless oil. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.73 - 7.51 (m, 1H), 7.48 - 7.28 (m, 1H), 7.08 - 6.89 (m, 1H), 6.20 - 5.80 (m, 1H), 4.82 - 4.61 (m, 2H), 4.33 - 4.18 (m, 1H), 4.01 - 3.82 (m, 1H). Step 4. (S)-4-(Difluoromethyl)-4-fluoroisochroman-6-carboxylic acid and (R)-4- (Difluoromethyl)-4-fluoroisochroman-6-carboxylic acid Palladium acetate (34.0 mg, 0.15 mmol), K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (627 mg, 4.54 mmol) and dccp-·2HBF<com:Sub>4< / com:Sub> (185 mg, 0.30 mmol) were added to a solution of 6-bromo-4-(difluoromethyl)-4-fluoroisochroman (850 mg, 3.02 mmol), in H<com:Sub>2< / com:Sub>O (0.11 mL) and DMSO (10 mL). The mixture was stirred at 100 °C for 16 hrs under CO (g, 15 psi). The reaction mixture was poured into water (20 mL) and extracted with EA (20 mL x 2). The organic layer was washed with brine (20 mL), dried over anhydrous Na₂SO₄, and concentrated in vacuo. The crude product was purified by reverse phase column chromatography affording a mixture of the title compounds (450 mg, 1.64 mmol) as colorless oil. The mixture of stereoisomers was purified by SFC separation (column: DAICEL CHIRALPAK IG (250mm*30mm,10μm);mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O MEOH];B%: 20%- 20%,3min;36minmin) to give intermediate 12 (220 mg, 0.89 mmol) as a colorless oil and intermediate 13 (220 mg, 0.89 mmol) as a colorless oil. Intermediate 12: Chiral SFC: Chiralpak IG-3 50×4.6mm I.D., RT = 0.928 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H2O]+=247.2<annotation encoding="application / x-tex">[M+H2O] + = 247.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.36 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 6.38 - 5.96 (m, 1H), 5.01 - 4.76 (m, 2H), 4.40 - 4.35 (m, 1H), 4.18 - 4.01 (m, 1H). Intermediate 13: Chiral SFC: Chiralpak IG-3 50×4.6mm I.D., RT = 1.115 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H2O]+=247.2<annotation encoding="application / x-tex">[M+H2O] + = 247.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.36 (s, 1H), 8.14 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.4 Hz, 1H), 6.38 - 5.96 (m, 1H), 5.01 - 4.76 (m, 2H), 4.40 - 4.35 (m, 1H), 4.18 - 4.01 (m, 1H). C Intermediates 14 and 15: (R)-3-Cyano-3-methyl-2,3-dihydrobenzofuran-5-carboxylic acid & (S)-3- Cyano-3-methyl-2,3-dihydrobenzofuran-5-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] Step 1. Methyl 5-bromo-2,3-dihydrobenzofuran-3-carboxylate Magnesium (9.53 g, 392 mmol) was added to a solution of methyl 5-bromobenzofuran-3- carboxylate (10 g, 39.2 mmol) in MeOH (400 mL). The reaction solution was stirred at 25 °C for 6 hrs. 4N HCI (200 mL) was carefully added to the solution. After complete dissolution of the magnesium metal, the solution was concentrated under reduced pressure to remove MeOH. The resulting mixture was partitioned between EA (200 mL x 3) and water (100 mL). The organic phase was separated, dried over anhydrous MgSO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by reversed phase chromatography and concentrated under reduced pressure to remove MeCN. The aqueous layer was then extracted with EA (50 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layers were washed with brine (50 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure affording the title compound (6 g, 23.3 mmol) as a red oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.41 - 7.40 (m, 1H), 7.25 - 7.16 (m, 1H), 6.62 (d, J = 8.8 Hz, 1H), 4.89 - 4.85 (m, 1H), 4.61 – 4.60 (m, 1H), 4.28 - 4.24 (m, 1H), 3.73 (s, 3H) ppm. Step 2. Methyl 5-bromo-3-methyl-2,3-dihydrobenzofuran-3-carboxylate Sodium hydride (350 mg, 8.75 mmol, 60% purity) was slowly added to a mixture of methyl 5- bromo-2,3-dihydrobenzofuran-3-carboxylate (1.5 g, 5.83 mmol) in THF (15 mL) at 0 °C. The mixture was stirred at 0°C for 0.5 hr, then MeI (0.54 mL, 8.75 mmol) was added drop-wise at 0 °C. The reaction mixture was warmed up to 25 °C and stirred for 2 hrs. The reaction mixture was quenched with saturated aqueous NH<com:Sub>4< / com:Sub>Cl (30 mL) and extracted with EA (10 mL x 3). The combined organic phase was concentrated to afford yellow oil. The oil was purified by FCC (Eluent: 0 to 40% EA / PE) affording the title compound (670 mg, 2.43 mmol) as yellow oil. LCMS (ESI) m / z: [79BrM+H]+=271.0. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.43 (d, J = 2.0 Hz, 1H), 7.29 - 7.27 (m, 1H), 6.71 (d, J = 8.4 Hz, 1H), 5.08 <com:Math><semantics>(d,J=9.2Hz,1H),4.28(d,J=9.2Hz,1H),3.76(s,3H),1.61(s,3H)ppm.<annotation encoding="application / x-tex">(d, J = 9.2 Hz, 1H), 4.28 (d, J = 9.2 Hz, 1H), 3.76 (s, 3H), 1.61 (s, 3H) ppm.< / annotation>< / semantics>< / com:Math> Step 3. 5-Bromo-3-methyl-2,3-dihydrobenzofuran-3-carboxylic acid A mixture of methyl 5-bromo-3-methyl-2,3-dihydrobenzofuran-3-carboxylate (650 mg, 2.40 mmol) and NaOH (240 mg, 5.99 mmol) in MeOH (5 mL) and H₂O (2 mL) was stirred at 25 °C for 1 hour. The CA - reaction mixture was diluted with water (10 mL). HCl (1 M) was added to adjust pH to 4, and then the solution was extracted with EA (10 mL x 3). The combined organic layer was concentrated affording the title compound (600 mg) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.44 (d, J = 2.0 Hz, 1H), 7.34 - 7.31 (m, 1H), 6.80 (d, J = 8.4 Hz, 1H), 4.94 (d, J = 9.2 Hz, 1H), 4.30 (d, J = 9.2 Hz, 1H), 1.53 (s, 3H) ppm. Step 4. 5-Bromo-3-methyl-2,3-dihydrobenzofuran-3-carboxamide Ammonium chloride (1.25 g, 23.3 mmol) was added to a mixture of 5-bromo-3-methyl-2,3- dihydrobenzofuran-3-carboxylic acid (600 mg, 2.33 mmol), DIPEA (2.0 mL, 11.7 mmol), and HATU (1.33 g, 3.50 mmol) in DMF (6 mL) at 25 °C. The mixture was stirred for 12 hrs. The reaction mixture was diluted with water (20 mL) and extracted with EA (10 mL x 3). The combined organic layer was washed with brine (10 mL x 3), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo affording the title compound (580 mg) as a yellow solid. LCMS (ESI) m / z: [79BrM+H]+=257.0. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.60 (d, J = 2.0 Hz, 1H), 7.38 - 7.24 (m, 3H), 6.76 (d, J = 8.4 Hz, 1H), <com:Math><semantics>5.03(d,J=8.8Hz,1H),4.20(d,J=9.2Hz,1H),1.52(s,3H)ppm.<annotation encoding="application / x-tex">5.03 (d, J = 8.8 Hz, 1H), 4.20 (d, J = 9.2 Hz, 1H), 1.52 (s, 3H) ppm.< / annotation>< / semantics>< / com:Math> Step 5. 5-Bromo-3-methyl-2,3-dihydrobenzofuran-3-carbonitrile Triethylamine (0.95 mL, 6.79 mmol) was added to a mixture of 5-bromo-3-methyl-2,3- dihydrobenzofuran-3-carboxamide (580 mg, 2.26 mmol) in DCM (6 mL) at 0 °C. TFAA (0.79 mL, 5.66 mmol) was then added at 0 °C. The mixture was stirred for 10 minutes. The reaction mixture was diluted with water (20 mL) and extracted with DCM (10 mL x 2). The combined organic phase was concentrated to afford yellow oil. The oil was purified by FCC (Eluent: 0 to 20% EA in PE) affording the title compound (500 mg, 1.89 mmol) as yellow oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.80 (d, J = 2.0 Hz, 1H), 7.47 - 7.44 (m, 1H), 6.93 (d, J = 8.8 Hz, 1H), <com:Math><semantics>4.96(d,J=9.4Hz,1H),4.46(d,J=9.6Hz,1H),1.74(s,3H)ppm.<annotation encoding="application / x-tex">4.96 (d, J = 9.4 Hz, 1H), 4.46 (d, J = 9.6 Hz, 1H), 1.74 (s, 3H) ppm.< / annotation>< / semantics>< / com:Math> Step 6. (R)-3-Cyano-3-methyl-2,3-dihydrobenzofuran-5-carboxylic acid and (S)-3-Cyano-3- methyl-2,3-dihydrobenzofuran-5-carboxylic acid Palladium acetate (18.9 mg, 0.084 mmol) and dccp·2HBF<com:Sub>4< / com:Sub> (103 mg, 0.17 mmol) were added to a mixture of 5-bromo-3-methyl-2,3-dihydrobenzofuran-3-carbonitrile (400 mg, 1.68 mmol) and K₂CO₃ (348 mg, 2.52 mmol) in DMSO (3.2 mL) and H₂O (0.8 mL) at 25 °C. The mixture was degassed and purged with CO (g) three times. The mixture was stirred at 100 °C under a CO atmosphere (15 psi) for 12 hrs. The reaction mixture was filtered and the filtrate was purified by reversed-phase HPLC. The desired fractions were concentrated to remove MeCN and lyophilized affording the mixture of the title compounds (210 mg, 1.02 mmol) as a white solid. The stereoisomers were separated by chiral SFC (DAICEL CHIRALPAK IG (250mm*30mm,10μm);mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O MEOH];B%: 20%-20%,3.9min). The eluent was concentrated to afford Intermediate 14 (90 mg, 0.44 mmol) as a red solid and Intermediate 15 (100 mg, 0.49mol) as a light yellow solid. Intermediate 14: Chiral SFC: AD-3_5CM_ETOH(DEA)_5_40_3ML_AT35.M , RT = 0.924 min. LCMS (ESI) m / z: [M+H]+=204.1. CA <com:Sup>1< / com:Sup>HNMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.02 (s, 1H), 7.90 - 7.88 (m, 1H), 6.98 (d, J = 8.4 Hz, 1H), 4.99 (d, J = 9.6 Hz, 1H), <com:Math><semantics>4.52<annotation encoding="application / x-tex">4.52< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>1.75<annotation encoding="application / x-tex">1.75< / annotation>< / semantics>< / com:Math> (s, 3H) ppm. Intermediate 15: Chiral SFC: AD-3_5CM_ETOH(DEA)_5_40_3ML_AT35.M, RT = 1.078 min. LCMS (ESI) m / z: [M+H]+=204. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.02 (d, J = 1.6 Hz, 1H), 7.89 - 7.87 (m, 1H), 6.97 (d, J = 8.4 Hz, 1H), <com:Math><semantics>4.99(d,J=9.6Hz,1H),4.52(d,J=9.2Hz,1H),1.75(s,3H)ppm.<annotation encoding="application / x-tex">4.99 (d, J = 9.6 Hz, 1H), 4.52 (d, J = 9.2 Hz, 1H), 1.75 (s, 3H) ppm.< / annotation>< / semantics>< / com:Math> Intermediate 16: 3-[3-(difluoromethyl)oxetan-3-yl]benzoic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 3-(3-Bromophenyl)oxetane-3-carbaldehyde DMP (1.66 mL, 5.35 mmol) was added to a solution of [3-(3-bromophenyl)oxetan-3-yl]methanol (1 g, 4.11 mmol) in DCM (10 mL) at 0 °C. The mixture was stirred for 1 hr at 25 °C. The mixture was filtered and concentrated. The residue was purified by FCC (Eluent: PE:EA = 100:1 to 1:100) affording the title compound (850 mg, 3.53 mmol) as colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 259.0. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.71 (s, 1H), 7.46 - 7.40 (m, 1H), 7.24 (t, J = 8.0 Hz, 1H), 7.18 (t, J = 2.0) Hz, 1H), <com:Math><semantics>6.99−6.92<annotation encoding="application / x-tex">6.99 - 6.92< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>5.08<annotation encoding="application / x-tex">5.08< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>4.91<annotation encoding="application / x-tex">4.91< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 2H) ppm. Step 2. 3-(3-Bromophenyl)-3-(difluoromethyl)oxetane DAST (1.15 mL, 8.71 mmol) was added to a solution of 3-(3-bromophenyl)oxetane-3- carbaldehyde (700 mg, 2.90 mmol) in DCM (7 mL) at -78 °C. The mixture was warmed and stirred for 1 hr at 0 °C. The mixture was poured into saturated aqueous solution of NaHCO₃ (5 mL). The organic layer was collected and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 100:1 to 1:1) affording the title compound (500 mg, 1.90 mmol) as brown oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.59 - 7.45 (m, 1H), 7.34 - 7.29 (m, 1H), 7.26 (s, 1H), 7.11 -6.94 (m, 1H), 6.43 - 5.96 (m, 1H), 4.99 (s, 4H) ppm. Step 3. 3-[3-(Difluoromethyl)oxetan-3-yl]benzoic acid Palladium acetate (6.40 mg, 0.029 mmol), dccp 2HBF<com:Sub>4< / com:Sub> (34.9 mg, 0.057 mmol), and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (118 mg, 0.86 mmol was added to a solution of 3-(3-bromophenyl)-3-(difluoromethyl)oxetane (150 mg, 0.57 mmol) in DMSO (5 mL) and H₂O (2.5 mL) at 25 °C. The mixture was degassed and purged with CO (g) three times, and then the mixture was stirred at 100 °C for 16 hrs under a CO atmosphere (15 psi). The mixture was extracted with EA (5 ml). The aqueous layer was adjusted pH to 5 - 6 with aqueous HCI (1 M) and extracted with EA (5 ml x 3). The organic layers were combined, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo affording the title compound (120 mg, 0.53 mmol) as colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=229.1<annotation encoding="application / x-tex">[M+H]+ = 229.1< / annotation>< / semantics>< / com:Math>. Intermediate 17: 4-(3-Oxocyclobutyl)picolinonitrile [Image disponible dans le document PDF, Image available in the PDF document] - 1 Step 1: 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile To a solution of 4-bromopyridine-2-carbonitrile (25 g, 136.61 mmol) and 4,4,5,5-tetramethyl-2- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (41.63 g, 163.93 mmol) in dioxane (250 mL) was added KOAc (40.22 g, 409.82 mmol) and Pd(dppf)Cl<com:Sub>2< / com:Sub>.CH<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (3 g, 3.67 mmol). The mixture was stirred at 80 °C for 3 hrs. The reaction mixture was poured into water (1000 mL), the solution was extracted with EA (1000 mL * 2), the combined organic layer was washed with brine (2000 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=10:1-1:1) to give the title compound (24 g, 104.32 mmol, 76.36% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=231.1<annotation encoding="application / x-tex">[M+H]^+ = 231.1< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.79 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 4.4 Hz, 1H), 8.04 (s, 1H), 7.87 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 4.8 Hz, 1H), 1.31 (s, 12H) ppm Step 2: N'-(3-(Benzyloxy)cyclobutylidene)-4-methylbenzenesulfonohydrazide To a solution of 3-benzyloxycyclobutanone (15 g, 85.13 mmol) in MeOH (150 mL) was added 4- methylbenzenesulfonohydrazide (15.85 g, 85.13 mmol). The mixture was stirred at 20 °C for 5 min. The reaction mixture was filtered, the filter cake was washed MeOH (30 mL) and the filtrate dried in vacuo to give the title compound (23 g, 66.78 mmol, 78.45% yield) as a white solid. Step 3: 4-(3-(Benzyloxy)cyclobutyl)picolinonitrile To a solution of N'-(3-(benzyloxy)cyclobutylidene)-4-methylbenzenesulfonohydrazide (23 g, 66.78 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile (23.05 g, 100.17 mmol) in dioxane (450 mL) was added Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (65.27 g, 200.33 mmol). The mixture was refluxed at 130 °C for 48 hr. The reaction mixture was diluted with water (800 mL) and extracted with EA (300 mL * 3). The combined CA organic layers were washed with dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, DCM / EA=1 / 0 to 10 / 1) to give the title compound (3.7 g, 13.29 mmol, 19.90% yield) as yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=265.1<annotation encoding="application / x-tex">[M+H]^+ = 265.1< / annotation>< / semantics>< / com:Math> Step 4: 4-(3-Hydroxycyclobutyl)picolinonitrile To a solution of 4-(3-(benzyloxy)cyclobutyl)picolinonitrile (3.7 g, 14.00 mmol) in DCM (120 mL) and H<com:Sub>2< / com:Sub>O (12 mL) was added DDQ (17.48 g, 76.99 mmol). The mixture was stirred at 30 °C for 16 hrs under N₂. The reaction mixture was poured into sat. NaSO₃ solution (500 mL) and extracted with DCM (500 mL * 3). The combined organic layer was washed with brine (500 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=5:1-0:1) to give the title compound (1.4 g, 8.04 mmol, 57.41% yield) as a yellow oil. Step 5: 4-(3-Oxocyclobutyl)picolinonitrile To a solution of 4-(3-hydroxycyclobutyl)picolinonitrile (1.4 g, 5.44 mmol) in DCM (15 mL) was added Dess-Martin (6.92 g, 16.31 mmol). The mixture was stirred at 30 °C for 2 hrs. The reaction mixture was poured into Na₂SO₃ solution (100 mL) and extracted with EA (100 mL). The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=5:1-0:1) to give the title compound (900 mg, 4.98 mmol, 91.62% yield) as an off-white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=173.1<annotation encoding="application / x-tex">[M+H]^+ = 173.1< / annotation>< / semantics>< / com:Math> Intermediate 18: 2-Methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 2-Methyl-2,6-naphthyridin-1(2H)-one To a mixture of 2,6-naphthyridin-1(2H)-one (200 mg, 1.37 mmol) in DMF (10 mL) was added Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (668.82 mg, 2.05 mmol) and MeI (291.36 mg, 2.05 mmol, 127.79 uL) at 30 °C. The mixture was stirred at 30 °C for 16 hrs. The mixture was poured into H<com:Sub>2< / com:Sub>O (10 mL) and extracted with DCM (10 mL*3). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM / MeOH = 20 / 1, Rf = 0.4) to afford the title compound (160 mg, 946.72 umol, 69.18% yield) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=161.1<annotation encoding="application / x-tex">[M+H]^+ = 161.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.98 (s, 1H), 8.69 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 1H), 8.19 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 1H), 7.20 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 1H), 6.58 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.65 (s, 3H) ppm. CA Step 2: 2-Benzyl-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-2-ium bromide A mixture of 2-methyl-2,6-naphthyridin-1(2H)-one (50 mg, 312.16 umol) in EtOH (0.5 mL) was stirred at 70 °C for 10 min. Then benzyl bromide (720.00 mg, 4.21 mmol, 0.5 mL) was added. The mixture was stirred at 80 °C for 16 hrs. The mixture was treated with MTBE (10 mL) and filtered. The filter cake was dried under reduced pressure to afford the title compound (130 mg, crude) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.87 (s, 1H), 8.98 - 8.97 (m, 1H), 8.68 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.4 Hz, 1H), 7.96 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 1H), 7.59 - 7.42 (m, 5H), 6.96 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.96 (s, 2H), 3.60 (s, 3H) ppm. Step 3: 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one To a mixture of 2-benzyl-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-2-ium bromide (70 mg, 211.35 umol) in MeOH (1 mL) was added NaBH<com:Sub>4< / com:Sub> (39.98 mg, 1.06 mmol) in several portions at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was poured into 1M HCl aqueous solution (5 mL) and basified with sat. NaHCO₃ to pH=8. The mixture was extracted with EA (10 mL *3). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to afford the title compound (35 mg, 137.62 umol, 65.1% yield) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=255.3<annotation encoding="application / x-tex">[M+H]^+ = 255.3< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=7.40−7.28<annotation encoding="application / x-tex">\delta = 7.40 - 7.28< / annotation>< / semantics>< / com:Math> (m, 5H), 7.07 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.84 (d, <com:Math><semantics>J=6.8<annotation encoding="application / x-tex">J = 6.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.69 (s, 2H), 3.52 (s, 3H), 3.39 (s, 2H), 2.79 - 2.64 (m, 4H) ppm. Step 4: 2-Methyl-2,6-naphthyridin-1(2H)-one To a mixture of 6-benzyl-2-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one (35 mg, 137.62 umol) in MeOH (1 mL) was added TFA (31.38 mg, 275.24 umol, 20.38 uL) and Pd / C (20 mg, 10% purity). The mixture was purged with <com:Math><semantics>H2<annotation encoding="application / x-tex">H_2< / annotation>< / semantics>< / com:Math> 3 times and stirred at 30 °C for 16 hrs under <com:Math><semantics>H2<annotation encoding="application / x-tex">H_2< / annotation>< / semantics>< / com:Math> (15 psi). The mixture was filtered and the mother liquor was concentrated under reduced pressure to afford the title compound (30 mg, 107.83 umol, 78.4% yield, TFA salt) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=165.1<annotation encoding="application / x-tex">[M+H]^+ = 165.1< / annotation>< / semantics>< / com:Math>. Intermediate 19: 7-Fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride [Image disponible dans le document PDF, Image available in the PDF document] Step 1: (E)-N-(2,2-Dimethoxyethyl)-1-(3-fluoro-5-methoxyphenyl)methanimine To a solution of 3-fluoro-5-methoxy-benzaldehyde (2 g, 12.98 mmol) in toluene (20 mL) was added 2,2-dimethoxyethanamine (1.50 g, 14.27 mmol, 1.56 mL). The mixture was stirred at 120 °C for 16 hrs. The reaction mixture was concentrated to give the title compound (3 g, crude) as a yellow oil. Step 2: N-(3-Fluoro-5-methoxybenzyl)-2,2-dimethoxyethan-1-amine To a solution of <com:Math><semantics>(E)−N−(2,2−dimethoxyethyl)−1−(3−fluoro−5−methoxyphenyl)methanimine(3g,12.43)<annotation encoding="application / x-tex">(E)-N-(2,2-dimethoxyethyl)-1-(3-fluoro-5-methoxyphenyl) methanimine (3 g, 12.43)< / annotation>< / semantics>< / com:Math> mmol) in MeOH (30 mL) was added NaBH<com:Sub>4< / com:Sub> (564.53 mg, 14.92 mmol) at 0 °C. The mixture was stirred at 30 °C for 30 min. The reaction mixture was poured into water (100 mL) and the mixture was extracted with EA (100 mL*3). The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄, filtered and concentrated to give the title compound (2.2 g, 9.04 mmol, 72.73% yield) as a yellow oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>=6.66 - 6.63 (m, 2H), 6.51 - 6.48 (m, 1H), 4.49 - 4.46 (m, 1H), 3.79 (s, 3H), 3.76 (s, 2H), <com:Math><semantics>3.47−3.37<annotation encoding="application / x-tex">3.47 - 3.37< / annotation>< / semantics>< / com:Math> (m, 6H), <com:Math><semantics>2.73<annotation encoding="application / x-tex">2.73< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.4<annotation encoding="application / x-tex">J = 5.4< / annotation>< / semantics>< / com:Math> Hz, 2H) ppm. Step 3: 7-Fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinolin-4-ol A mixture of N-(3-fluoro-5-methoxybenzyl)-2,2-dimethoxyethan-1-amine (1 g, 4.11 mmol) in HCl (10 mL) was stirred at 40 °C for 12 hrs. The reaction mixture was concentrated to give the title compound (810 mg, crude) as a yellow oil. Step 4: 7-Fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinoline To a solution of 7-fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinolin-4-ol (810 mg, 4.11 mmol) in DCM (8 mL) was added Et₃SiH (1.43 g, 12.32 mmol, 1.97 mL) and TFA (5.39 g, 47.27 mmol, 3.5 mL). The mixture was stirred at 30 °C for 16 hrs. The reaction mixture was concentrated to give the title compound (744 mg, crude) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=182.3<annotation encoding="application / x-tex">[M+H]^+ = 182.3< / annotation>< / semantics>< / com:Math> Step 5: tert-Butyl 7-fluoro-5-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate To a solution of 7-fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinoline (744 mg, 4.11 mmol) in DCM (10 mL) was added Et₃N (2.08 g, 20.53 mmol, 2.86 mL) and Boc₂O (1.08 g, 4.93 mmol, 1.13 mL). The CA mixture was stirred at 30 °C for 2 hrs. The reaction mixture was poured into water (20 mL) and extracted with EA (20 mL*3). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=5:1-1:1) to give the title compound (150 mg, 494.22 umol, 12.04% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=226.2<annotation encoding="application / x-tex">[M+H]^+ = 226.2< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 6.45 - 6.42 (m, 2H), 4.54 - 4.51 (m, 2H), 3.80 (s, 3H), 3.63 – 3.60 (m, 2H), 2.69 – 2.66 (m, 2H), 1.49 (s, 9H) ppm. Step 6: 7-Fluoro-5-methoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride A mixture of tert-butyl 7-fluoro-5-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (150 mg, 533.20 umol) in HCl / dioxane (2 mL) was stirred at 30 °C for 1 hr. The reaction mixture was concentrated and the residue was triturated with MTBE (10 mL) to give the title compound (60 mg, 263.71 umol, 49.46% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=182.1<annotation encoding="application / x-tex">[M+H]^+ = 182.1< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 6.53 - 6.43 (m, 2H), 4.28 (s, 2H), 3.81 (s, 3H), 3.43 (s, 2H), 3.00 (s, 2H) ppm Intermediate 20: 3-Methoxy-3-phenylpyrrolidine hydrochloride [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 20 Step 1: tert-Butyl 3-methoxy-3-phenylpyrrolidine-1-carboxylate To a solution of tert-butyl 3-hydroxy-3-phenylpyrrolidine-1-carboxylate (200 mg, 759.50 umol) in DMF (3 mL) was added NaH (42.53 mg, 1.06 mmol, 60% purity) at 0 °C. The mixture was stirred at 0 °C for 1 hr. MeI (161.70 mg, 1.14 mmol, 70.92 uL) was added to the mixture and stirring at 25 °C continued for 16 hrs. The mixture was poured into water (50 mL) and extracted with EA (30 mL *3). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~60% Ethyl acetate / Petroleum ether gradient @ 60 mL / min) to give the title compound (180 mg, 648.98 umol, 85.45% yield) as a colorless oil. <com:Sup>1< / com:Sup>HNMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=7.43−7.29<annotation encoding="application / x-tex">\delta = 7.43 - 7.29< / annotation>< / semantics>< / com:Math> (m, 5H), 3.97 - 3.78 (m, 1H), 3.64 - 3.45 (m, 3H), 3.02 (d, <com:Math><semantics>J=1.00<annotation encoding="application / x-tex">J = 1.00< / annotation>< / semantics>< / com:Math> 5.6 Hz, 3H), 2.48 - 2.36 (m, 1H), 2.24 - 2.09 (m, 1H), 1.48 (d, <com:Math><semantics>J=4.8<annotation encoding="application / x-tex">J = 4.8< / annotation>< / semantics>< / com:Math> Hz, 9H) ppm. Step 2: 3-Methoxy-3-phenylpyrrolidine hydrochloride To a solution of tert-butyl 3-methoxy-3-phenylpyrrolidine-1-carboxylate (170 mg, 612.93 umol) in MeOH (2 mL) was added HCl / dioxane (4 M, 2 mL). The mixture was stirred at 25 °C for 2 hrs. The reaction was concentrated under reduced pressure to to give the title compound (120 mg, crude, HCl) as a white solid. CA <com:Sup>1< / com:Sup>HNMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.89 (br s, 1H), 9.48 (br s, 1H), 7.47 - 7.34 (m, 4H), 3.80 - 3.67 (m, 1H), 3.40 - 3.14 (m, 3H), 2.92 (s, 3H), 2.63 - 2.53 (m, 1H), 2.24 - 2.10 (m, 1H) ppm. Intermediate 21: 1-(Azetidin-3-yl)-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: tert-Butyl 3-(1H-indol-1-yl)azetidine-1-carboxylate To a solution of indole (500 mg, 4.27 mmol) in DMF (5 mL) was added NaH (256.06 mg, 6.40 mmol, 60% purity) in portions at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hr. tert-Butyl 3- iodoazetidine-1-carboxylate (1.33 g, 4.69 mmol) was then added dropwise. The reaction solution was stirred at 25 °C for 12.5 hrs. The reaction mixture was quenched by saturated aqueous NH<com:Sub>4< / com:Sub>Cl (10 mL), diluted with H₂O (10 mL) and extracted with EA (10 mL*3). The combined organic layers were washed with brine (10 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by reversed phase chromatography (FA condition). The fraction was concentrated under reduced pressure to remove MeCN and extracted with EA (25 mL * 3). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound (520 mg, 1.77 mmol, 41.41 % yield) as a red oil. LCMS (ESI) m / z: [M+H]+=273.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.66 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.39 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.32 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 3.2 Hz, 1H), <com:Math><semantics>7.26−7.22<annotation encoding="application / x-tex">7.26 - 7.22< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>7.19−7.11<annotation encoding="application / x-tex">7.19 - 7.11< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>6.60<annotation encoding="application / x-tex">6.60< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=2.8<annotation encoding="application / x-tex">J = 2.8< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>5.22−5.18<annotation encoding="application / x-tex">5.22 - 5.18< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>4.52−4.48<annotation encoding="application / x-tex">4.52 - 4.48< / annotation>< / semantics>< / com:Math> (m, 2H), 4.36 - 4.32 (m, 2H), 1.50 (s, 9H) Step 2: 1-(Azetidin-3-yl)-1H-indole To a solution of tert-butyl 3-(1H-indol-1-yl)azetidine-1-carboxylate (220 mg, 807.81 umol) in DCM (3 mL) was added TFA (92.11 mg, 807.81 umol, 59.81 uL). The reaction mixture was stirred at 25 °C for 10 hrs. The reaction mixture was then concentrated under reduced pressure and the residue purified by reversed phase chromatography (FA condition). The fraction was concentrated under reduced pressure to remove MeCN and lyophilized to give the title compound (110 mg, 504.01 umol, 62.39 % yield, FA) as a red solid. LCMS (ESI) m / z: [M+H]+=173.1 Intermediate 22: 7-(Difluoromethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride [Image disponible dans le document PDF, Image available in the PDF document] Step 1: tert-Butyl 7-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate To a solution of tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (1 g, 3.20 mmol) in THF (40 mL) at -78 °C under N<com:Sub>2< / com:Sub> was added n-BuLi (2.5 M, 2.56 mL) dropwise. The reaction was stirred at -78 °C for 0.5 hr. DMF (468.25 mg, 6.41 mmol, 492.89 uL) was then added dropwise at -78 °C and stirred at -78 °C for 2.5 hrs. The reaction mixture was quenched with aq. NH₄Cl (60 mL) and extracted with EA (50 mL*3). The combined organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue purified by flash silica gel chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=1 / 0~1 / 1) to give the title compound (280 mg, 1.01 mmol, 31.46% yield) as a colorless oil. LCMS (ESI) m / z: [M+H-56]<com:Sup>+< / com:Sup>= 206.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.95 (s, 1H), 7.76 - 7.68 (m, 2H), 7.39 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 1H), 4.59 (s, 2H), 3.58 - 3.55 (m, 2H), 2.88 - 2.85 (m, 2H), 1.46 - 1.41 (m, 9H) ppm. Step 2: tert-Butyl 7-(difluoromethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate To a solution of tert-butyl 7-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (150 mg, 574.02 umol) in DCM (1.5 mL) was added DAST (157.29 mg, 975.83 umol, 128.93 uL) and EtOH (5.29 mg, 114.80 umol, 6.71 uL). The mixture was stirred at 25 °C for 14 hrs. Additional DAST (92.53 mg, 574.02 umol, 75.84 uL) was added at 0 °C and the mixture stirred at 25 °C for 2 hrs. The reaction mixture was diluted with H<com:Sub>2< / com:Sub>O (20 mL) and extracted with EA (20 mL*3). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=1 / 0 to 1 / 1) to give the title compound (120 mg, 388.11 umol, 67.61% yield) as a colorless oil. LCMS (ESI) m / z: [M+H-56]<com:Sup>+< / com:Sup>= 228.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.40 - 7.34 (m, 2H), 7.32 - 7.28 (m, 1H), 7.12 - 6.82 (m, 1H), 4.54 (s, 2H), 3.57 - 3.52 (m, 2H), 2.83 - 2.80 (m, 2H), 1.43 (s, 9H) ppm. Step 3: 7-(Difluoromethyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride To a solution of tert-butyl 7-(difluoromethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (120 mg, 423.56 umol) in dioxane (1 mL) was added HCl / dioxane (4 M, 756.34 uL). The reaction mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated under reduced pressure to give the title compound (90 mg, 378.26 umol, 89.30% yield) as white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=184.0<annotation encoding="application / x-tex">[M+H]^+ = 184.0< / annotation>< / semantics>< / com:Math>. CA Intermediate 23: 7-Bromo-1,5-naphthyridin-2(1H)-one [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 3-Bromo-1,5-naphthyridine Boric acid (5.72 g, 92.5 mmol), FeSO<com:Sub>4< / com:Sub>·7H<com:Sub>2< / com:Sub>O (2.09 g, 7.51 mmol), and sodium 3- nitrobenzenesulfonate hydrate (28.1 g, 116 mmol) were added to a solution of concentrated H<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> (50 mL) and the mixture was stirred at 30 °C for 0.5 hr. Glycerol (20.3 mL, 272 mmol), 5-bromopyridin-3- amine (10.0 g, 57.8 mmol), and H<com:Sub>2< / com:Sub>O (50 mL) were added to the reaction solution, and the mixture was stirred at 135°C for 18 hrs. The mixture was cooled to 30°C, and the pH was adjusted to pH=14 with NaOH. The aqueous layer was extracted with EA (300 mL x 3), and the combined organic layer was washed with brine (500 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 10:1 to 2:1) affording the title compuond (4.50 g, 19.9) mmol) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [Br79M+H]+ = 209.0 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.98 – 8.97 (m, 2H), 8.58 (d, J 1.6 Hz, 1H), 8.40 - 8.37 (m, 1H), 7.67 – 7.64 (m, 1H). Step 2. 7-Bromo-1,5-naphthyridine 1-oxide m-CPBA (5.24 g, 25.8 mmol, 85% purity) was added to a solution of 3-bromo-1,5-naphthyridine (4.50 g, 21.5 mmol) in DCM (45.0 mL). The mixture was stirred at 30 °C for 16 hr. The mixture was poured into saturated Na<com:Sub>2< / com:Sub>SO<com:Sub>3< / com:Sub> (100 mL) and extracted with DCM (100 mL x 3). The combined organic layer was washed with brine (100 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated. The crude product was triturated with MTBE (50 mL), and the solid was filtered. The solid was collected and dried in vacuo affording the title compound (3.3 g, 14.66 mmol) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 9.23 - 9.22 (m, 1H), 9.03 (d, J = 2.0 Hz, 1H), 8.55 (d, J = 6.4 Hz, 1H), <com:Math><semantics>7.99(d,J=8.8Hz,1H),7.57−7.53(m,1H).<annotation encoding="application / x-tex">7.99 (d, J = 8.8 Hz, 1H), 7.57 - 7.53 (m, 1H).< / annotation>< / semantics>< / com:Math> Step 3. 7-Bromo-1,5-naphthyridin-2(1H)-one Potassium carbonate (6.89 g, 49.86 mmol) in water (25 mL) was added to a solution of 7-bromo- 1,5-naphthyridine 1-oxide (3.30 g, 14.7 mmol) and TosCl (3.35 g, 17.6 mmol) in CHCl₃ (60 mL). The mixture was stirred at 30 °C for 16 hrs. The reaction mixture was filtered, and the filter cake was dried in vacuo affording the title compound (2.5 g, 10.0 mmol) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [Br79M+H]+ = 225.1 <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.21 - 11.78 (m, 1H), 8.54 (d, J = 2.0 Hz, 1H), 7.91 (d, J = 10.4 Hz, 1H), <com:Math><semantics>7.85<annotation encoding="application / x-tex">7.85< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=1.6<annotation encoding="application / x-tex">J = 1.6< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.78−6.74<annotation encoding="application / x-tex">6.78 - 6.74< / annotation>< / semantics>< / com:Math> (m, 1H). CA Intermediate 24: tert-Butyl N-[1-(2-phenyl-1,6-naphthyridin-7-yl)ethyl]carbamate [Image disponible dans le document PDF, Image available in the PDF document] tert-Butyl N-[1-(2-phenyl-1,6-naphthyridin-7-yl)ethyl]carbamate Methylmagnesium bromide (3 M, 1.73 mL) was added to a solution of 2-phenyl-1,6- naphthyridine-7-carbonitrile (300 mg, 1.30 mmol) in THF (6 mL) at 0 °C. The mixture was warmed and stirred at 25°C for 1 hr. The reaction mixture was quenched by addition dry MeOH (3 mL), then NH₄OAc (1 g, 13.0 mmol) and NaBH₃CN (815 mg, 13.0 mmol) were added and the mixture was stirred at 25 °C for 1 hr. Boc<com:Sub>2< / com:Sub>O (1.70 g, 7.78 mmol) was added and the reaction mixture was stirred at 25°C for 16 hrs. The reaction mixture was quenched with water (100 mL) and extracted with EA (100 mL x 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under in vacuo. The crude product was purified by FCC (Eluent: PE:EA = 1:1) affording the title compound (250 mg, 0.68 mmol) as light yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=350.1<annotation encoding="application / x-tex">[M+H]+ = 350.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.34 (s, 1H), 8.63 (d, J = 8.8 Hz, 1H), 8.33 - 8.24 (m, 3H), 7.84 (s, 1H), <com:Math><semantics>7.62−7.53<annotation encoding="application / x-tex">7.62 - 7.53< / annotation>< / semantics>< / com:Math> (m, 4H), <com:Math><semantics>4.87<annotation encoding="application / x-tex">4.87< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>1.47−1.37<annotation encoding="application / x-tex">1.47 - 1.37< / annotation>< / semantics>< / com:Math> (m, 12H) ppm. Intermediates 25 and 26: (3S)-3-(Hydroxymethyl)-3-methyl-indane-5-carboxylic acid and (3R)-3- (Hydroxymethyl)-3-methyl-indane-5-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 6-Bromoindane-1-carbonitrile Potassium tert-butoxide (53.2 g, 474 mmol) was added to a solution of 6-bromoindan-1-one (50 g, 237 mmol) and 1-(isocyanomethylsulfonyl)-4-methyl-benzene (69.4 g, 356 mmol) in DME (2.5 L) and EtOH (100 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 16 hrs. The reaction mixture was poured into water (2 L) and extracted with EA (2 L x 2). The combined organic layer was concentrated in vacuo. The crude product was diluted with EA (500 mL), washed with brine (500 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 20:1). - The desired fractions were collected and concentrated in vacuo. The solid was then triturated with MTBE (100 mL) affording the title compound (29 g, 130 mmol) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CHLOROFORM-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.58 (s, 1H), 7.42 - 7.40 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 4.12 - 4.08 (m, 1H), 3.10 - 3.00 (m, 1H), 2.97 - 2.86 (m, 1H), 2.65 - 2.55 (m, 1H), 2.43 - 2.37 (m, 1H) ppm. Step 2. 6-Bromo-1-methyl-indane-1-carbonitrile Sodium hydride (10.8 g, 270 mmol, 60% purity) was added to a solution of 6-bromoindane-1- carbonitrile (30 g, 135 mmol) in THF (300 mL) at 0 °C. The reaction mixture was warmed and stirred at 10°C for 0.5 hr. CH₃I (42.1 mL, 675.43 mmol) was added at 0 °C. The mixture was warmed and stirred at 25 °C for 2 hrs. The reaction was diluted with NH₄Cl (aq., 800 mL) and extracted with EA (500 mL x 3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure. The crude residue was purified by FCC (Eluent: PE:EA = 1:0 to 5:1) affording the title compound (27 g, 114 mmol) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.70 (d, J = 2.0 Hz, 1H), 7.50 - 7.48 (m, 1H), 7.29 (d, J = 8.0 Hz, 1H), 2.97 - 2.93 (m, 2H), 2.60 - 2.53 (m, 1H), 2.18 (d, J = 12.8 Hz, 1H), 1.64 (s, 3H) ppm. Step 3. 3-Cyano-3-methyl-indane-5-carboxylic acid A mixture of 6-bromo-1-methyl-indane-1-carbonitrile (6.5 g, 27.5 mmol), dccp·2HBF4 (1.69 g, 2.75 mmol), postassium carbonate (5.71 g, 41.3 mmol), Pd(OAc)<com:Sub>2< / com:Sub> (618 mg, 2.75 mmol), and water (0.99 mL) in DMSO (60 mL) was degassed and purged with CO (g) three times. The mixture was stirred at 100°C for 14 hr under a CO (15 psi) atmosphere. The reaction mixture was filtered to remove the black solid, and then diluted with water (60 mL) and extracted with EA (80 mL x 3). The organic layer was discarded and the aqueous phase was adjusted to pH=4 with aq. HCl. The aqueous solution was then extracted with EA (100 mL x 3). The combined organic layers were washed with brine (500 mL x 2) then dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated under reduced pressure affording the title compound (4.5 g, 20.7 mmol) as a brown solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=202.1<annotation encoding="application / x-tex">[M+H]+= 202.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.04 (s, 1H), 7.96 (s, 1H), 7.91 - 7.88 (m, 1H), 7.45 (d, J = 8.0 Hz, 1H), 3.07 - 3.04 (m, 2H), 2.64 - 2.53 (m, 1H), 2.28 - 2.19 (m, 1H), 1.65 (s, 3H) ppm. Step 4. 3-Formyl-3-methyl-indane-5-carboxylic acid DIBAL-H (1 M, 159.03 mL) was added to a solution of 3-cyano-3-methyl-indane-5-carboxylic acid (16 g, 79.5 mmol) in toluene (160 mL) at -70 °C. The mixture was stirred at -70 °C for 2 hrs. The reaction was quenched via the addition of HCI (2 M, 323 mL). The reaction mixture was warmed and stirred at 20°C for 1 h. The mixture was diluted with water (2 L) and extracted with EA (1.5 L x 3). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated affording the title compound (14 g, 58.2 mmol) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=205.1<annotation encoding="application / x-tex">[M+H]+= 205.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.91 (br s, 1H), 9.58 (s, 1H), 7.85 - 7.83 (m, 1H), 7.73 (s, 1H), 7.40 <com:Math><semantics>(d,J=8.0Hz,1H),3.06−2.90(m,2H),2.61−2.54(m,1H),1.98−1.87(m,1H),1.39(s,3H)ppm.<annotation encoding="application / x-tex">(d, J = 8.0 Hz, 1H), 3.06 - 2.90 (m, 2H), 2.61 - 2.54 (m, 1H), 1.98 - 1.87 (m, 1H), 1.39 (s, 3H) ppm.< / annotation>< / semantics>< / com:Math> CA Step 5. (3S)-3-(Hydroxymethyl)-3-methyl-indane-5-carboxylic acid and (3R)-3- (Hydroxymethyl)-3-methyl-indane-5-carboxylic acid Sodium borohydride (2.49 g, 65.8 mmol) was added to a solution of 3-formyl-3-methyl-indane-5- carboxylic acid (14 g, 58.2 mmol) in THF (150 mL) at 0 °C. The mixture was warmed and stirred at 25°C for 3 hrs. The reaction was diluted with water (200 mL) and extracted with EA (80 mL x 2). The organic layer was discarded and the aqueous phase was adjusted to pH=4 with aq. HCl. The aqueous solution was then extracted with EA (300 mL x 3). The organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was washed with DCM (50 mL x 3), filtered, and concentrated to get a white solid. The filtrate was concentrated under reduced pressure and the resulting residue was purified by FCC (Eluent: PE:EA = 1:0 to 1:5). The desired fractions were collected and concentrated under reduced pressure to get off-white solid. The solid was then washed with MTBE (20 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2). This solid was combined with the filtered solid and dried in vacuo affording a mixture of the title compounds (9.5 g, 44.3 mmol) as a white solid. The stereoisomers were separated by chiral SFC (column: DAICEL CHIRALPAK AD-H(250mm*30mm,5μm); mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H2O MEOH]; B%: 40%-40%,5 min; 540 min) affording the pure title compounds. Intermediate 25: (4.0 g, 19.40 mmol, white solid) Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, Rt= 1.575 min, ee%= 100%. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=207.2<annotation encoding="application / x-tex">[M+H]+= 207.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) δ= 7.74 - 7.68 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 3.39 - 3.31 (m, 2H), 2.87 - 2.80 (m, 2H), 2.15 - 2.12 (m, 1H), 1.73 - 1.65 (m, 1H), 1.20 (s, 3H) ppm. Intermediate 26: ((4.3 g, 20.44 mmol, light yellow solid) Chiral SFC: AD-3_5CM_MEOH (DEA)_5_40_3ML_AT35.M, Rt= 1.799 min, ee%= 97.93%. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=207.2<annotation encoding="application / x-tex">[M+H]+= 207.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) δ= 7.73 - 7.64 (m, 2H), 7.16 (d, J = 8.4 Hz, 1H), 3.44 - 3.25 (m, 2H), 2.88 - 2.78 (m, 2H), 2.15 - 2.12 (m, 1H), 1.73 - 1.65 (m, 1H), 1.20 (s, 3H) ppm. Intermediates 27 and 28: (S)-3-cyano-1,3-dimethylindoline-5-carboxylic acid and (R)-3-cyano-1,3- dimethylindoline-5-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. Methyl 3-((4-bromophenyl)(methyl)amino)-3-oxopropanoate TCFH (22.6 g, 80.6 mmol) and NMI (12.5 mL, 161.2 mmol) were added to a mixture of 4-bromo- N-methyl-aniline (10 g, 53.8 mmol) and 3-ethoxy-3-oxo-propanoic acid (8.52 g, 64.5 mmol) in MeCN (150 mL) at 20 °C. The mixture was stirred at 20 °C for 15 hrs. The mixture was concentrated and diluted with water (10 mL). The aqueous solution was then extracted with DCM (15 mL x 3). The combined organic phase was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 5:1 to 3:1) affording the title compound (13 g, 43.3 mmol) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=286.0<annotation encoding="application / x-tex">[M+H]+ = 286.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.56 (d, J=8.4 Hz, 2H), 7.14 (d, J=8.4 Hz, 2H), 4.13 (d, J=7.2 Hz, 2H), 3.29 (s, 3H), 3.21 (s, 2H), 1.29 - 1.15 (m, 3H) ppm. Step 2. Methyl 3-((4-bromophenyl)(methyl)amino)-2-methyl-3-oxopropanoate Potassium carbonate (4.14 g, 30.0 mmol), and MeI (3.7 mL, 59.9 mmol) were added to a mixture of methyl 3-((4-bromophenyl)(methyl)amino)-3-oxopropanoate (6 g, 20.0 mmol) in DMF (60 mL) at 0°C. The reaction mixture was stirred at 20 °C for 15 hrs. The reaction was diluted with water (100 mL) and extracted with EA (60 mL x 3). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 5:1 to 3:1) affording the title compound (4 g, 12.7 mmol) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=300.0<annotation encoding="application / x-tex">[M+H]+ = 300.0< / annotation>< / semantics>< / com:Math>. CA <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.57 (d, J=8.4 Hz, 2H), 7.18 - 7.11 (m, 2H), 4.19 - 4.03 (m, 2H), 3.40 - 3.28 (m, 1H), 3.28 (s, 3H), 1.31 (d, J=7.2 Hz, 3H), 1.27 - 1.21 (m, 3H) ppm. Step 3. Ethyl 5-bromo-1,3-dimethyl-2-oxoindoline-3-carboxylate t-BuOK (2.86 g, 25.5 mmol) and copper(II)acetate monohydrate (5.08 g, 25.5 mmol) were added to a mixture of methyl 3-((4-bromophenyl)(methyl)amino)-2-methyl-3-oxopropanoate (4 g, 12.7 mmol) in DMF (120 mL) at 20 °C. The mixture was stirred at 100°C for 1 hr. The mixture was filtered off, the filtrate was diluted with water (150 mL), and then extracted with EA (50 mL x 3). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 5:1 to 3:1) affording the title compound (2 g, 5.77) mmol) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=312.0<annotation encoding="application / x-tex">[M+H]+ = 312.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.46 - 7.44 (m, 1H), 7.38 (d, J=2.0 Hz, 1H), 6.75 (d, J=8.4 Hz, 1H), 4.23 - 4.09 (m, 2H), 3.26 - 3.19 (m, 3H), 1.66 (s, 3H), 1.21 - 1.16 (m, 3H) ppm. Step 4. Ethyl 5-bromo-1,3-dimethylindoline-3-carboxylate BH<com:Sub>3< / com:Sub>·THF (1 M, 9.61 mL) was added to a solution of ethyl 5-bromo-1,3-dimethyl-2-oxoindoline-3- carboxylate (2 g, 6.41 mmol) in THF (20 mL) at 0 °C. The mixture was stirred at 60°C for 2 hrs. The mixture was slowly quenched with MeOH (30 mL) at 0 °C and then concentrated. The crude product was purified by FCC (Eluent: PE:EA = 10:1 to 3:1) affording the title compound (300 mg, 0.86 mmol) as colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=298.0<annotation encoding="application / x-tex">[M+H]+ = 298.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.34 (d, J=2.0 Hz, 1H), 7.23 - 7.20 (m, 1H), 6.35 (d, J=8.4 Hz, 1H), 4.26 - 4.15 (m, 2H), 3.89 (d, J=9.2 Hz, 1H), 3.19 - 3.12 (m, 1H), 2.78 - 2.72 (m, 3H), 1.54 (s, 3H), 1.33 - 1.25 (m, 3H) ppm. Step 5. 5-Bromo-1,3-dimethylindoline-3-carboxylic acid LiOH·H<com:Sub>2< / com:Sub>O (126.66 mg, 3.02 mmol) was added to a mixture of ethyl 5-bromo-1,3-dimethylindoline- 3-carboxylate (300 mg, 1.01 mmol) in MeOH (3 mL) and water (1 mL) at 20 °C. The mixture was stirred at 20°C for 15 hrs. MeOH was removed under vacuum and the solution was diluted with water (1 mL). The pH was adjusted to 3 with 1N HCl and the solution was extracted with EA (5 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic phase was washed with brine (10 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated to affording the title compound (220 mg, 0.70 mmol) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=270.0<annotation encoding="application / x-tex">[M+H]+ = 270.0< / annotation>< / semantics>< / com:Math>. Step 6. 5-Bromo-1,3-dimethylindoline-3-carboxamide Ammonium chloride (436 mg, 8.14 mmol), HATU (465 mg, 1.22 mmol), and DIPEA (0.56 mL, 4.07 mmol) were added to a mixture of 5-bromo-1,3-dimethylindoline-3-carboxylic acid (220 mg, 0.81 mmol) in DMF (4 mL) at 20 °C. The mixture was stirred for 15 hrs. Water (5 mL) was added and the mixture was extracted with EA (5 mL x 3). The combined organic layer was washed with brine (10 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:1) affording the title compound (210 mg, 0.47 mmol) as colorless oil. CA LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=269.0<annotation encoding="application / x-tex">[M+H]+ = 269.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.29 (br d, J=2.0 Hz, 1H), 7.22 (d, J=2.0 Hz, 1H), 6.44 (d, J=8.4 Hz, 1H), 3.84 (d, J=9.2 Hz, 1H), 3.10 (d, J=9.2 Hz, 1H), 2.76 (s, 3H), 1.57 (s, 3H) ppm. Step 7. 5-Bromo-1,3-dimethylindoline-3-carbonitrile Triethylamine (0.33 mL, 2.34 mmol) was added to a mixture of 5-bromo-1,3-dimethylindoline-3- carboxamide (210 mg, 0.78 mmol) in DCM (3 mL) at 0 °C. TFAA (0.27 mL, 1.95 mmol) was added slowly and the resulting mixture was stirred at 20 °C for 4 hrs. The mixture was diluted with water (5 mL) and extracted with DCM (5 mL x 3). The combined organic phase was washed with saturated NaHCO₃ (aq.), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 10:1 to 5:1) affording the title compound (100 mg, 0.39mol) as colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=251.1<annotation encoding="application / x-tex">[M+H]+ = 251.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.33 (d, J=2.0 Hz), 7.31 - 7.28 (m, 1H), 6.42 (d, J=8.4 Hz, 1H), 3.70 (d, J=9.2 Hz, 1H), 3.32 (d, J=9.2 Hz, 1H), 2.77 (s, 3H), 1.68 (s, 3H) ppm. Step 8. 3-Cyano-1,3-dimethylindoline-5-carboxylic acid Palladium acetate (2.2 mg, 0.010 mol), dccp·2HBF₄ (12.2 mg, 0.020 mmol), and potassium carbonate (41.3 mg, 0.30 mmol) were added to a solution of 5-bromo-1,3-dimethylindoline-3-carbonitrile (50 mg, 0.20 mmol) in DMSO (1 mL) and water (0.007 mL). The mixture was degassed and flushed with CO (g) three times. The mixture was then stirred under a CO atmosphere (15 psi) at 100 °C for 15 hrs. Water (3 mL) was added to the mixture and the mixture was extracted with EA (3 mL x 3). The combined organic phase was washed with brine (5 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The crude product was purified by reversed-phase HPLC. The desired fractions were collected and extracted with DCM (5 mL x 3). The combined organic layer was washed with brine (5 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated affording a mixture of the title compounds (40 mg) as a white solid. The stereoisomers were separated by SFC condition (column: DAICEL CHIRALPAK IC(250mm*30mm,5μm);mobile phase: [0.1%NH<com:Sub>3< / com:Sub>•H<com:Sub>2< / com:Sub>O IPA]; B%: 20%-20%,5 min;85 minmin) affording intermediate 27 (20 mg, 0.09 mmol) as a white solid and Intermediate 28 (15 mg, 0.07 mmol) as a white solid. Intermediate 27: Chiral SFC: IC-3-IPA (DEA)-5-40-3mL-35T.lcm; RT =1.517 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=217.1<annotation encoding="application / x-tex">[M+H]+ = 217.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.39 (br s, 1H), 7.85 - 7.76 (m, 2H), 6.66 (d, J=8.4 Hz, 1H), 3.87 (d, J=10.0 Hz, 1H28 3.44 (d, J=10.0 Hz, 1H), 2.83 (s, 3H), 1.68 (s, 3H) ppm. Intermediate 28: Chiral SFC: IC-3-IPA (DEA)-5-40-3mL-35T.lcm; RT =1.608 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=217.1<annotation encoding="application / x-tex">[M+H]+ = 217.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>HNMR (400MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.39 (br s, 1H), 7.85 - 7.76 (m, 2H), 6.66 (d, J=8.4 Hz, 1H), 3.87 (d, J=10.0 Hz, 1H), 3.44 (d, J=10.0 Hz, 1H), 2.83 (s, 3H), 1.68 (s, 3H) ppm. Intermediates 29 and 30: (R)-5-Cyano-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-3-carboxylic acid and (S)-5-Cyano-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-3-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] r Step 1. 5-Bromo-N-methoxy-N,2-dimethylnicotinamide Oxalyl chloride (12.2 mL, 139 mmol) was added to a solution of 5-bromo-2-methyl-pyridine-3- carboxylic acid (10 g, 46.29 mmol) and DMF (0.036 mL, 0.46 mmol) in DCM (100 mL). The reaction mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated in vacuo and the residue was dissolved in DCM (100 mL). The organic solution was added to a solution of N- methoxymethanamine (6.77 g, 69.4 mmol, HCl salt) and DIEA (40.3 mL, 231 mmol) in DCM (50 mL). The reaction mixture was stirred at 25 °C for 14 hrs. The reaction mixture was poured into water (500 mL) and extracted with DCM (500 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 2). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 1:1) affording the title compound (11.5 g, 44.4 mmol) as yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 259.0. Step 2. 1-(5-Bromo-2-methylpyridin-3-yl)ethenone Methylmagnesium bromide (3 M, 21.2 mL) was added to a solution of 5-bromo-N-methoxy-N,2- dimethylnicotinamide (11 g, 42.4 mmol) in THF (100 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 1 hr. The reaction mixture was poured into saturated aq. NH₄CI (400 mL) and extracted with EA (400 mL x 2). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 5:1) affording the title compound (9 g, 41.5 mmol) as yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 214.0. CA <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.66 (d, J = 2.4 Hz, 1H), 8.06 (d, J = 2.0 Hz, 1H), 2.70 (s, 3H), 2.60 (s, 3H) ppm. Step 3. 2-(5-Bromo-2-methylpyridin-3-yl)propanenitrile tBuOK (9.23 g, 82.2 mmol) was added to a solution of 1-(5-bromo-2-methylpyridin-3-yl)ethenone (8 g, 37.4 mmol) and 1-(isocyanomethylsulfonyl)-4-methylbenzene (11.0 g, 56.1 mmol) in DME (400 mL) and EtOH (16 mL) at 0 °C. The reaction mixture was stirred at 25 °C for 14 hrs. The reaction mixture was poured into saturated aq. NH₄Cl (400 mL). The mixture was concentrated in vacuo to remove DME and EtOH. The aqueous phase was extracted with EA (400 mL x 2). The combined organic layer was dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 5:1) affording the title compound (7 g, 31.1 mmol) as colorless oil. LCMS (ESI)<com:Math><semantics>3m / z<annotation encoding="application / x-tex">3m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 225.1. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.55 (d, J = 2.4 Hz, 1H), 7.89 (d, J = 2.0 Hz, 1H), 4.03 - 3.98 (m, 1H), 2.57 <com:Math><semantics>(s,3H),1.66(d,J=7.2Hz,3H)ppm.<annotation encoding="application / x-tex">(s, 3H), 1.66 (d, J = 7.2 Hz, 3H) ppm.< / annotation>< / semantics>< / com:Math> Step 4. 2-(5-Bromo-2-methylpyridin-3-yl)-3-hydroxy-2-methylpropanenitrile Paraformaldehyde (1.12 g, 37.3 mmol) was added to a solution of 2-(5-bromo-2-methylpyridin-3- yl)propanenitrile (7 g, 31.1 mmol) and NaHCO₃ (261 mg, 3.11 mmol) in DMSO (60 mL). The reaction mixture was stirred at 25 °C for 14 hrs. The reaction mixture was poured into water (400 mL) and extracted with EA (400 mL x 2). The combined organic layer was washed with brine (300 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 1:1) affording the title compound (7.5 g, 29.4 mmol) as white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 255.1. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.54 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 2.0 Hz, 1H), 4.14 - 4.09 (m, 1H), 3.96 - 3.92 (m, 1H), 2.80 (s, 3H), 2.69 - 2.66 (m, 1H), 1.81 (s, 3H) ppm. Step 5. 2-(5-Bromo-2-(bromomethyl)pyridin-3-yl)-3-hydroxy-2-methylpropanenitrile NBS (1.40 g, 7.84 mmol) and AIBN (64.4 mg, 0.39 mmol) were added to a solution of 2-(5- bromo-2-methylpyridin-3-yl)-3-hydroxy-2-methylpropanenitrile (1 g, 3.92 mmol) in MeCN (10 mL). The reaction mixture was stirred at 80°C for 4 hrs. The reaction mixture was concentrated. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 1:1) affording the title compound (0.25 g, 0.76 mmol) as brown solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 335.0. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.71 (d, J = 2.0 Hz, 1H), 7.89 (d, J = 2.0 Hz, 1H), 5.00 - 4.85 (m, 2H), 4.21 - 4.06 (m, 2H), 2.24 - 2.21 (m, 1H), 1.89 (s, 3H) ppm. Step 6. 3-Bromo-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-5-carbonitrile Potassium carbonate (1.61 g, 11.7 mmol) was added to a solution of 2-(5-bromo-2- (bromomethyl)pyridin-3-yl)-3-hydroxy-2-methylpropanenitrile (1.3 g, 3.89 mmol) in DMF (65 mL). The reaction mixture was stirred at 25 °C for 12 hrs. The reaction mixture was poured into water (300 mL) and extracted with EA (300 mL x 2). The combined organic layer was washed with water (300 mL), dried CA over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: PE:EA = 1:0 to 1:1) affording the title compound (350 mg, 1.27 mmol) as white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [79BrM+H]+ = 253.0. <com:Sup>1< / com:Sup>HNMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.59 (d, J = 2.4 Hz, 1H), 7.95 (d, J = 2.4 Hz, 1H), 4.85 - 4.76 (m, 2H), 4.12 - 3.94 (m, 2H), 1.75 (s, 3H) ppm. Step 7. (R)-5-Cyano-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-3-carboxylic acid and (S)-5-Cyano-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-3-carboxylic acid A mixture of 3-bromo-5-methyl-6,8-dihydro-5H-pyrano[3,4-b]pyridine-5-carbonitrile (270 mg, 1.07 mmol), dccp·2HBF<com:Sub>4< / com:Sub> (65.3 mg, 0.11 mmol), Pd(OAc)<com:Sub>2< / com:Sub> (23.9 mg, 0.11 mmol), H<com:Sub>2< / com:Sub>O (0.038 mL), and K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (221 mg, 1.60 mmol) in DMSO (3 mL) was degassed and purged with CO (g) three times. The mixture was stirred at 100°C for 16 hrs under a CO atmosphere (15 psi). The reaction mixture was filtered, poured into water (80 mL), and extracted with EA (30 mL x 2). The EA phase was discarded. The aqueous phase was adjusted to <com:Math><semantics>pH=5<annotation encoding="application / x-tex">pH = 5< / annotation>< / semantics>< / com:Math> with aq. <com:Math><semantics>HCI(1M)<annotation encoding="application / x-tex">HCI (1 M)< / annotation>< / semantics>< / com:Math>. The aqueous phase was extracted with EA (30 mL <com:Math><semantics>×<annotation encoding="application / x-tex">\times< / annotation>< / semantics>< / com:Math> 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo affording a mixture of the title compounds (130 mg, 0.57) mmol) as yellow oil. The stereoisomers were separated by chiral SFC (column: DAICEL CHIRALPAK AD (250mm*30mm,10μm); mobile phase: [0.1% NH<com:Sub>3< / com:Sub>•H<com:Sub>2< / com:Sub>O MEOH]; B%: 30% - 30%, 4.2min; 55minmin) affording Intermediate 29 (55 mg, 0.24 mmol) as a yellow solid and Intermediate 30 (50 mg, 0.22 mmol) as a yellow solid. Intermediate 29: Chiral SFC: AD-3-MeOH(DEA)-5-40-3mL-35T.lcm; RT = 1.055min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=219.0<annotation encoding="application / x-tex">[M+H]+ = 219.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.99 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1H), 4.96 - 4.75 (m, 2H), <com:Math><semantics>4.26(d,J=11.8Hz,1H),3.92(d,J=11.8Hz,1H),1.70(s,3H).<annotation encoding="application / x-tex">4.26 (d, J = 11.8 Hz, 1H), 3.92 (d, J = 11.8 Hz, 1H), 1.70 (s, 3H).< / annotation>< / semantics>< / com:Math> Intermediate 30: Chiral SFC: AD-3-MeOH(DEA)-5-40-3mL-35T.lcm; RT = 1.666 min. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=219.0<annotation encoding="application / x-tex">[M+H]+ = 219.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.99 (d, J = 2.0 Hz, 1H), 8.43 (d, J = 2.0 Hz, 1H), 4.96 - 4.75 (m, 2H), <com:Math><semantics>4.26(d,J=11.8Hz,1H),3.92(d,J=11.8Hz,1H),1.70(s,3H).<annotation encoding="application / x-tex">4.26 (d, J = 11.8 Hz, 1H), 3.92 (d, J = 11.8 Hz, 1H), 1.70 (s, 3H).< / annotation>< / semantics>< / com:Math> Intermediates 31 and 32: (4S)-4-(hydroxymethyl)-4-methyl-isochromane-6-carboxylic acid and (4R)-4-(hydroxymethyl)-4-methyl-isochromane-6-carboxylic acid [Image disponible dans le document PDF, Image available in the PDF document] Step 1. 6-Bromo-4-methyl-isochromane-4-carboxylic acid Potassium hydroxide (aq., 9M, 5.29 mL) was added to a solution of 6-bromo-4-methyl- isochromane-4-carbonitrile (1.2 g, 4.76 mmol) in EtOH (12 mL). The mixture was stirred at 90°C for 5 hrs. The reaction mixture was diluted with H<com:Sub>2< / com:Sub>O (20 mL) and extracted with EA (30 mL x 3). The combined organic layers were discarded and the aqueous phase was adjusted pH = 4 with 1N HCl. The aqueous layer was extracted with EA (30 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo affording the title compound (800 mg, 2.95 mmol) as yellow oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.11 - 12.45 (m, 1H), 7.52 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.75 - 4.62 (m, 2H), 4.16 (d, J = 11.2 Hz, 1H), 3.59 (d, J = 11.2 Hz, 1H), 1.41 (s, 3H). Step 2. (6-Bromo-4-methyl-isochroman-4-yl)methanol 6-bromo-4-methyl-isochromane-4-carboxylic acid (800 mg, 2.95 mmol) was dissolved in BH<com:Sub>3< / com:Sub>·THF (1 M, 8.85) at 0 °C and the resulting mixture was stirred at 25 °C for 2 hrs. The reaction mixture was quenched by addition of 1N HCl (25 mL) at 20 °C and stirred for 30 min. Then the mixture was diluted with water (20 mL) and extracted with EA (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by FCC (Eluent: DCM:MeOH = 100:1 to 10:1) affording the title compound (400 mg, 1.56 mmol) as colorless oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.47 (d, J = 2.0, 1H), 7.33 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), <com:Math><semantics>4.79−4.68<annotation encoding="application / x-tex">4.79 - 4.68< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>4.05<annotation encoding="application / x-tex">4.05< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=11.6<annotation encoding="application / x-tex">J = 11.6< / annotation>< / semantics>< / com:Math> z, 1H), <com:Math><semantics>3.82−3.75<annotation encoding="application / x-tex">3.82 - 3.75< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>3.71−3.63<annotation encoding="application / x-tex">3.71 - 3.63< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>3.53<annotation encoding="application / x-tex">3.53< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=11.6<annotation encoding="application / x-tex">J = 11.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 1.21 (s, 3H). Step 3. 4-(Hydroxymethyl)-4-methyl-isochromane-6-carboxylic acid Water (1 mL), K₂CO₃ (185 mg, 1.34 mmol), Pd(OAc)₂ (20.1 mg, 0.089 mmol), and dccp·2HBF₄ (110 mg, 0.18 mmol) were added to a solution of (6-bromo-4-methyl-isochroman-4-yl)methanol (230 mg, 0.89 mmol) in DMSO (5 mL). The reaction mixture was purged with CO (g) three times and the resulting mixture was stirred at 100 °C for 16 hrs under a CO atmosphere (15 psi). The reaction mixture was diluted with H<com:Sub>2< / com:Sub>O (30 mL) and extracted with EA (50 mL x 3). The combined organic layers were discarded and the aqueous layer was adjusted to pH = 4 with HCl (1 N). The aqueous layer was extracted with EA (30 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered, and concentrated in vacuo affording a mixture of the title compounds (150 mg, 0.62 mmol) as a yellow solid. The stereoisomers were separated by chiral SFC (column:DAICEL CHIRALPAK IG (250mm x 30mm,10μm);mobile phase: [0.1%NH<com:Sub>3< / com:Sub>-H<com:Sub>2< / com:Sub>O IPA];B%: 25%-25%,6.65min;66min). The mobile phase was concentrated under reduced pressure to remove most of the MeOH. Water (40 mL) was added and each desired compound mixture was lyophilized affording Intermediate 31 (44 mg, 0.20) mmol) as an off-white solid and Intermediate 32 (48 mg, 0.21 mmol) as an off-white solid. Intermediate 31: <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.02 - 12.77 (m, 1H), 7.90 (s, 1H), 7.72 (d, J = 1.2 Hz, 1H), 7.14 (d, J <com:Math><semantics>=8.0 Hz,1H,4.88−4.87 (m, 1H),4.74 (d, J=4.0 Hz,2H),3.90 (d, J=11.2 Hz,1H),3.58−3.50 (m, 1H),<annotation encoding="application / x-tex">= 8.0 \text{ Hz}, 1\text{H}, 4.88 - 4.87 \text{ (m, 1H)}, 4.74 \text{ (d, J} = 4.0 \text{ Hz}, 2\text{H)}, 3.90 \text{ (d, J} = 11.2 \text{ Hz}, 1\text{H)}, 3.58 - 3.50 \text{ (m, 1H)},< / annotation>< / semantics>< / com:Math> 3.42 - 3.35 (m, 2H), 1.14 (s,3H). Intermediate 32: <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.02 - 12.77 (m, 1H), 7.90 (s, 1H), 7.72 (d, J = 1.2 Hz, 1H), 7.14 (d, J <com:Math><semantics>=8.0 Hz,1H,4.88−4.87 (m, 1H),4.74 (d, J=4.0 Hz,2H),3.90 (d, J=11.2 Hz,1H),3.58−3.50 (m, 1H),<annotation encoding="application / x-tex">= 8.0 \text{ Hz}, 1\text{H}, 4.88 - 4.87 \text{ (m, 1H)}, 4.74 \text{ (d, J} = 4.0 \text{ Hz}, 2\text{H)}, 3.90 \text{ (d, J} = 11.2 \text{ Hz}, 1\text{H)}, 3.58 - 3.50 \text{ (m, 1H)},< / annotation>< / semantics>< / com:Math> 3.42 - 3.35 (m, 2H), 1.14 (s,3H). Intermediate 33: 2-Methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 2-Methyl-2,6-naphthyridin-1(2H)-one To a mixture of 2,6-naphthyridin-1(2H)-one (200 mg, 1.37 mmol) in DMF (10 mL) was added Cs₂CO₃ (668.82 mg, 2.05 mmol) and MeI (291.36 mg, 2.05 mmol, 127.79 uL) at 30 °C. The mixture was stirred at 30 °C for 16 hrs. The mixture was poured into H<com:Sub>2< / com:Sub>O (10 mL) and extracted with DCM (10 mL*3). The combined organic layers were dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM / MeOH = 20 / 1, Rf = 0.4) to afford the title compound (160 mg, 946.72 umol, 69.18% yield) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=161.1<annotation encoding="application / x-tex">[M+H]^+ = 161.1< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.98 (s, 1H), 8.69 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 1H), 8.19 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 5.2 Hz, 1H), 7.20 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 1H), 6.58 (d, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.65 (s, 3H) ppm. CA Step 2: 2-Benzyl-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-2-ium bromide A mixture of 2-methyl-2,6-naphthyridin-1(2H)-one (50 mg, 312.16 umol) in EtOH (0.5 mL) was stirred at 70 °C for 10 min. Then benzyl bromide (720.00 mg, 4.21 mmol, 0.5 mL) was added. The mixture was stirred at 80 °C for 16 hrs. The mixture was treated with MTBE (10 mL) and filtered. The filter cake was dried under reduced pressure to afford the title compound (130 mg, crude) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.87 (s, 1H), 8.98 - 8.97 (m, 1H), 8.68 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.4 Hz, 1H), 7.96 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 1H), 7.59 - 7.42 (m, 5H), 6.96 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.96 (s, 2H), 3.60 (s, 3H) ppm. Step 3: 6-Benzyl-2-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one To a mixture of 2-benzyl-6-methyl-5-oxo-5,6-dihydro-2,6-naphthyridin-2-ium bromide (70 mg, 211.35 umol) in MeOH (1 mL) was added NaBH<com:Sub>4< / com:Sub> (39.98 mg, 1.06 mmol) in several portions at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was poured into 1M HCl aqueous solution (5 mL) and basified with sat. NaHCO₃ to pH=8. The mixture was extracted with EA (10 mL *3). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure to afford the title compound (35 mg, 137.62 umol, 65.1% yield) as a yellow solid. LCMS (ESI) m / z: <com:Math><semantics>[M+H]+=255.3<annotation encoding="application / x-tex">[M+H]^+ = 255.3< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.40 - 7.28 (m, 5H), 7.07 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.2 Hz, 1H), 5.84 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.8 Hz, 1H), 3.69 (s, 2H), 3.52 (s, 3H), 3.39 (s, 2H), 2.79 - 2.64 (m, 4H) ppm. Step 4: 2-Methyl-2,6-naphthyridin-1(2H)-one To a mixture of 6-benzyl-2-methyl-5,6,7,8-tetrahydro-2,6-naphthyridin-1(2H)-one (35 mg, 137.62) umol) in MeOH (1 mL) was added TFA (31.38 mg, 275.24 umol, 20.38 uL) and Pd / C (20 mg, 10% purity). The mixture was purged with H<com:Sub>2< / com:Sub> 3 times and stirred at 30 °C for 16 hrs under H<com:Sub>2< / com:Sub> (15 psi). The mixture was filtered and the mother liquor was concentrated under reduced pressure to afford the title compound (30 mg, 107.83 umol, 78.4% yield, TFA salt) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=165.1<annotation encoding="application / x-tex">[M+H]^+ = 165.1< / annotation>< / semantics>< / com:Math>. Intermediate 34: 1-Bromo-4-cyclobutyl-2-methoxybenzene [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 1-(4-Bromo-3-methoxyphenyl)cyclobutan-1-ol To a mixture of 1-bromo-4-iodo-2-methoxy-benzene (2.4 g, 7.67 mmol, 5.41 mL) in THF (25 mL) was added i-PrMgCl-LiCl (1.3 M, 6.19 mL) dropwise at -40 °C. The mixture was stirred at -40 °C for 0.5 hr, then cyclobutanone (591.30 mg, 8.44 mmol) was added at -40 °C slowly. The resulting mixture was stirred at 25 °C for 1 hr. The mixture was poured into sat.NH<com:Sub>4< / com:Sub>Cl (200 mL) and extracted with EA (150 mL) * 2). The combined organic layers were washed with brine (250 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=20 / 1 to 1 / 1) to give the title compound (1.9 g, 6.65 mmol, 86.71% yield) as a colorless oil. CA LCMS (ESI) m / z: [M+H]+=211.0. 1H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.52 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 1H), 7.08 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.0 Hz, 1H), 6.98-6.96 (m, 1H),4.14- 4.12 (m, 1H), 3.93 (s, 3H), 2.61 - 2.48 (m, 2H), 2.43 - 2.30 (m, 2H), 2.12 - 1.97 (m, 3H), 1.80 - 1.68 (m, 1H) ppm Step 2: 1-Bromo-4-cyclobutyl-2-methoxybenzene To a mixture of 1-(4-bromo-3-methoxyphenyl)cyclobutan-1-ol (400 mg, 1.56 mmol) in DCM (20 mL) was added Et₃SiH (1.81 g, 15.56 mmol) and TFA (1.77 g, 15.56 mmol) at 0 °C, then the mixture was stirred at 25 °C for 8 hrs. The mixture was diluted with DCM (150 mL), then washed with sat. NaHCO<com:Sub>3< / com:Sub> (100 mL * 2). The organic phase was dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether) to give the title compound (150 mg, 622.09 umol, 39.99% yield) as a colorless oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.44 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 1H), 6.78 - 6.68 (m, 2H), 3.91 (s, 3H), 3.55 - 3.47 (m, 1H), 2.39 - 2.32 (m, 2H), 2.15 - 2.07(m, 2H), 2.06-1.98 (m, 1H), 1.90 - 1.85 (m, 1H) ppm Intermediate 35: 4-Bromo-7-fluoro-1,2-dimethyl-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 4-Bromo-7-fluoro-2-methyl-1H-indole To a mixture of 4-bromo-1-fluoro-2-nitro-benzene (2 g, 9.09 mmol, 1.12 mL) in THF (20 mL) was added bromo(isopropenyl)magnesium (0.5 M, 72.73 mL) dropwisely at - 40 °C under N₂. The mixture was stirred at - 40 °C for 1 hr. The mixture was poured into sat. NH<com:Sub>4< / com:Sub>Cl (100 mL) and extracted with ethyl acetate (50 mL*2). The combined organic phase was washed with brine (50 mL*1), dried with anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate = 20 / 1) to give the title compound (500 mg, 2.19 mmol, 24.12% yield) as a yellow oil. Step 2: 4-Bromo-7-fluoro-1,2-dimethyl-1H-indole To a solution of 4-bromo-7-fluoro-2-methyl-1H-indole (80 mg, 350.78 umol) in THF (1 mL) was added NaH (28.06 mg, 701.57 umol, 60% purity) at 0 °C and stirred at 25 °C for 0.5 hr. Mel (149.37 mg, 1.05 mmol) was then added to the mixture at 0 °C. The mixture was stirred at 25 °C for 2 hrs. The reaction mixture was diluted with sat. NH₄CI (10 mL) and extracted with EA (10 mL*2). The combined organic layers were dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated. The residue was purified by silica gel chromatography (Petroleum ether / Ethyl acetate = 3 / 1) to give the title compound (60 mg, 247.84 umol, 70.65% yield) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.08 - 7.06 (m 1H), 6.71 - 6.66 (m, 1H), 6.30 - 6.29 (m, 1H), 3.87 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 1.2 Hz, 3H), 2.41(s, 3H) ppm. CA Intermediate 36: 4-Bromo-2-ethyl-1-methyl-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 4-Bromo-1-tosyl-1H-indole To a solution of 4-bromo-1H-indole (1 g, 5.10 mmol, 641.03 uL) in DMF (10 mL) was added NaH (244.82 mg, 6.12 mmol, 60% purity) at 0 °C and the mixture was stirred at 0 °C for 1 hr under N<com:Sub>2< / com:Sub> atmosphere. 4-Methylbenzenesulfonyl chloride (1.16 g, 6.08 mmol) was then added and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was poured into NH<com:Sub>4< / com:Sub>CI (30 mL) and extracted with EA (40 mL *3). The combined organic layers were washed with brine (30 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 3 / 1) to give the title compound (1.6 g, 4.02 mmol, 78.73% yield) as an off-white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.99 - 7.93 (m, 2H), 7.89 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.49 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.39 (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 7.29 - 7.27 (m, 1H), 6.77 (d, <com:Math><semantics>J=3.6<annotation encoding="application / x-tex">J = 3.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 2.31 (s, 3H) ppm. Step 2: 4-Bromo-2-ethyl-1-tosyl-1H-indole To a solution of 4-bromo-1-tosyl-1H-indole (1.2 g, 3.43 mmol) in THF (12 mL) was added LDA (2 M, 2.06 mL) at -20 °C under N₂, and the mixture was stirred at -20 °C for 30 min under N₂ atmosphere. Iodoethane (801.58 mg, 5.14 mmol) was then added and the mixture was stirred at 25 °C for 2 hrs. The reaction mixture was diluted with H₂O (30 mL) and extracted with EA (40 mL * 3). The combined organic layers were washed with brine (30 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (220 mg, 581.58 umol, 16.97% yield) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.15 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.63 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 2H), 7.38 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), <com:Math><semantics>7.22 (d, J=8.4 Hz, 2H),7.15−7.10 (m, 1H),6.47 (s, 1H),3.06−3.01 (m, 2H),2.36 (s, 3H),1.39−1.35 (s, 2H)<annotation encoding="application / x-tex">7.22 \text{ (d, } J = 8.4 \text{ Hz, 2H)}, 7.15 - 7.10 \text{ (m, 1H)}, 6.47 \text{ (s, 1H)}, 3.06 - 3.01 \text{ (m, 2H)}, 2.36 \text{ (s, 3H)}, 1.39 - 1.35 \text{ (s, 2H)}< / annotation>< / semantics>< / com:Math> (m, 3H) ppm. Step 3: 4-Bromo-2-ethyl-1H-indole To a solution of 4-bromo-2-ethyl-1-tosyl-1H-indole (220.00 mg, 581.58 umol) in MeOH (60 mL) was added KOH (1.63 g, 29.08 mmol). The mixture was stirred at 70 °C for 16 hrs. The reaction mixture was treated with 2 N HCl (20 mL) and was extracted with EA (30 mL *3). The combined organic layers were washed with brine (30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced CA pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (100 mg, 446.24 umol, 76.73% yield) as a colorless oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, CHLOROFORM-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.09 - 7.95 (m, 1H), 7.24 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 2H), 7.03 - 6.92 (m, 1H), 6.32 (s, 1H), 2.84 - 2.79 (m, 2H), 1.40 - 1.36 (m, 3H) ppm. Step 4: 4-Bromo-2-ethyl-1-methyl-1H-indole To a solution of 4-bromo-2-ethyl-1H-indole (150 mg, 669.35 umol) in DMF (2 mL) was added NaH (40.16 mg, 1.00 mmol, 60 % purity) at 0 °C under N<com:Sub>2< / com:Sub>. The resulting mixture was stirred at 0 °C for 15 min under N₂ atmosphere. Iodomethane (114.01 mg, 803.22 umol) was then added and the resulting mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into NH₄Cl (30 mL) and extracted with EA (40 mL * 3). The combined organic layers were washed with brine ( 30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (150 mg, 629.93 umol, 94.11% yield) as colorless oil. Intermediate 37: 4-Chloro-2-cyclopropyl-1-methyl-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 3-Chloro-2-(cyclopropylethynyl)aniline To a mixture of 3-chloro-2-iodo-aniline (2 g, 7.89 mmol) and ethynylcyclopropane (521.57 mg, 7.89 mmol) in MeCN (40 mL) was added TEA (7.98 g, 78.91 mmol), Pd(PPh<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>Cl<com:Sub>2< / com:Sub> (553.84 mg, 789.06 umol) and CuI (150.28 mg, 789.06 umol). The mixture was degassed and purged with N₂ 3 times and the mixture was stirred at 25 °C for 2 hrs under N<com:Sub>2< / com:Sub> atmosphere. The reaction mixture was diluted with H<com:Sub>2< / com:Sub>O (20 mL) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 5 / 1) to give the title compound (1.3 g, 6.78 mmol, 85.96% yield) as a yellow oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 6.97 - 6.95 (m, 1H), 6.59 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.0 Hz, 2H), 5.50 (s, 2H), 1.63 - 1.61 (m, 1H), 0.95 - 0.86 (m, 2H), 0.83 - 0.76 (m, 2H) ppm. Step 2: 4-Chloro-2-cyclopropyl-1H-indole To a solution of 3-chloro-2-(cyclopropylethynyl)aniline (1 g, 5.22 mmol) in DMF (10 mL) was added CuI (2.98 g, 15.65 mmol). The mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with H<com:Sub>2< / com:Sub>O (20 mL) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (600 mg, 2.71 mmol, 52.01 % yield) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=191.9<annotation encoding="application / x-tex">[M+H]+ = 191.9< / annotation>< / semantics>< / com:Math>. CA <com:Sup>1< / com:Sup>H NMR (400 MHz, CHLOROFORM-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.37 - 7.67 (m, 1H), 7.18 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.11 - 6.98 (m, 2H), 6.25 (s, 1H), 2.03 - 1.87 (m, 1H), 1.08 - 0.95 (m, 2H), 0.89 - 0.72 (m, 2H) ppm. Step 3: 4-Chloro-2-cyclopropyl-1-methyl-1H-indole To a solution of 4-chloro-2-cyclopropyl-1H-indole (180 mg, 939.18 umol) in DMF (2 mL) was added NaH (56.35 mg, 1.41 mmol, 60% purity) at 0 °C under N<com:Sub>2< / com:Sub> and the mixture was stirred at 0 °C for 15 min under N<com:Sub>2< / com:Sub> atmosphere. Iodomethane (199.96 mg, 1.41 mmol) was then added and the mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into NH<com:Sub>4< / com:Sub>CI (30 mL) and extracted with EA (40 mL * 3). The combined organic layers were washed with brine (30 mL*3), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (190 mg, 864.18 umol, 92.01% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=206.0<annotation encoding="application / x-tex">[M+H]+ = 206.0< / annotation>< / semantics>< / com:Math>. Intermediate 38: 4-Bromo-3-(difluoromethyl)-1-(oxetan-3-yl)-1H-pyrazole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 1-(Oxetan-3-yl)-1H-pyrazole-3-carbaldehyde To a mixture of 1H-pyrazole-3-carbaldehyde (10 g, 104.07 mmol) and Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (67.82 g, 208.14 mmol) in DMF (200 mL) was added 3-iodooxetane (28.72 g, 156.11 mmol), then the mixture was stirred at 60 °C for 10 hrs. The reaction mixture was quenched by the addition of water (1000 mL) and the resulting mixture was extracted with EA (400 mL * 3). The combined organic layers were washed with brine (200 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=10 / 1 to 0 / 1) to give the title compound (3.1 g, 20.37 mmol, 19.58% yield) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 10.01 (s, 1H), 7.63 - 7.62 (m, 1H), 6.86 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 5.57 - 5.50 (m, 1H), 5.09 (d, <com:Math><semantics>J=6.4<annotation encoding="application / x-tex">J = 6.4< / annotation>< / semantics>< / com:Math> Hz, 4H) ppm. Step 2: 3-(Difluoromethyl)-1-(oxetan-3-yl)-1H-pyrazole To a mixture of 1-(oxetan-3-yl)-1H-pyrazole-3-carbaldehyde (600 mg, 3.94 mmol) in DCM (12 mL) was added DAST (1.91 g, 11.83 mmol, 1.56 mL) at -50 °C, then the mixture was stirred at 5 °C for 1 hr. The mixture was poured into sat. NaHCO<com:Sub>3< / com:Sub> (100 mL) and extracted with EA (50 mL * 2). The combined organic layers were washed with brine (40 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by reversed phase HPLC (0.1% FA condition). The product fraction was extracted with EA (150 mL * 2) and the combined organic layers were washed with brine (150 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum to give the title compound (170 mg, 898.09 umol, 22.77% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=175.1<annotation encoding="application / x-tex">[M+H]^+ = 175.1< / annotation>< / semantics>< / com:Math> CA Step 3: 4-Bromo-3-(difluoromethyl)-1-(oxetan-3-yl)-1H-pyrazole To a mixture of 3-(difluoromethyl)-1-(oxetan-3-yl)-1H-pyrazole (170 mg, 976.18 umol) in MeCN (4 mL) was added NBS (191.12 mg, 1.07 mmol) and the mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated under vacuum and the residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=20 / 1 to 5 / 1) to give the title compound (200 mg, 735.05 umol, 75.30% yield) as a colorless oil. LCMS (ESI) m / z: <com:Math><semantics>[81BrM+H]+=255.0<annotation encoding="application / x-tex">[^{81}BrM+H]^{+} = 255.0< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) δ= 7.68 (s, 1H), 6.84 - 6.58 (m, 1H), 5.46-5.51 (m, 1H), 5.07 - 4.99 (m, 4H) ppm Intermediate 39: 4-Bromo-3-(2,2-difluoroethyl)-1-(oxetan-3-yl)-1H-pyrazole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 3-(2,2-Difluorovinyl)-1-(oxetan-3-yl)-1H-pyrazole To a mixture of 1-(oxetan-3-yl)-1H-pyrazole-3-carbaldehyde (1 g, 6.57 mmol) and sodium 2- chloro-2,2-difluoroacetate (1.50 g, 9.86 mmol) in DMF (10 mL) was added PPh₃ (2.59 g, 9.86 mmol) under N<com:Sub>2< / com:Sub>, then the mixture was stirred at 100 °C for 2 hrs. The reaction mixture was diluted with water (250 mL) and extracted with EA (150 mL * 2). The combined organic layers were washed with brine (150 mL * 2), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 3 / 1) to give the title compound (700 mg, 3.12 mmol, 47.49% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=187.1<annotation encoding="application / x-tex">[M+H]^+ = 187.1< / annotation>< / semantics>< / com:Math> Step 2: 3-(2,2-Difluoroethyl)-1-(oxetan-3-yl)-1H-pyrazole A mixture of 3-(2,2-difluorovinyl)-1-(oxetan-3-yl)-1H-pyrazole (250 mg, 1.34 mmol) in MeOH (10 mL) and EA (10 mL) was added Pd / C (100 mg, 1.34 mmol, 10% purity) under H<com:Sub>2< / com:Sub> (15 psi), then the mixture was stirred at 25 °C for 2 hrs. The mixture was filtered and the filtrate concentrated under vacuum to give the title compound (230 mg, crude) as colorless oil, used directly in the next step. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=189.1<annotation encoding="application / x-tex">[M+H]^+ = 189.1< / annotation>< / semantics>< / com:Math> Step 3: 4-Bromo-3-(2,2-difluoroethyl)-1-(oxetan-3-yl)-1H-pyrazole A mixture of 3-(2,2-difluoroethyl)-1-(oxetan-3-yl)-1H-pyrazole (210 mg, 1.12 mmol) and NBS (218.49 mg, 1.23 mmol) in MeCN (4 mL) was stirred at 25 °C for 2 hrs. The mixture was concentrated under vacuum and the residue was purified by column chromatography (SiO2, Petroleum ether / Ethyl acetate=20 / 1 to 3 / 1) to give the title compound (150 mg, 544.80 umol, 48.82% yield) as a colorless oil. CA LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [81BrM+H]+ = 269.0 <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 7.61 (s, 1H), 6.280 - 5.97 (m, 1H), 5.40 - 5.36 (m, 1H), 5. 50 - 4.98 (m, 4H), 3.27-3.17 (m, 2H) ppm Intermediate 40: 4-Bromo-3-fluoro-1-methyl-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 4-Bromo-3,3-difluoroindolin-2-one To a solution of 4-bromoindoline-2,3-dione (1 g, 4.42 mmol) in DCM (10 mL) was added DAST (1.78 g, 11.06 mmol) at 0 °C under N<com:Sub>2< / com:Sub>. The mixture was stirred at 25 °C for 16 hrs. The reaction mixture was poured into sat. NaHCO<com:Sub>3< / com:Sub> (30 mL) and extracted with DCM (30 mL * 3). The combined organic layers were washed with brine (30 mL*2), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 3 / 1) to give the title compound (1 g, 4.03 mmol, 91.13% yield) as a brown solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 11.41 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 0.8 Hz, 1H), 7.50 - 7.40 (m, 1H), 7.34 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.1 Hz, 1H), 6.99 (d, <com:Math><semantics>J=7.6<annotation encoding="application / x-tex">J = 7.6< / annotation>< / semantics>< / com:Math> Hz, 1H) ppm. Step 2: 4-Bromo-3-fluoro-1H-indole To a mixture of NaBH₄ (91.52 mg, 2.42 mmol) in THF (2 mL) was added BF₃ Et₂O (343.34 mg, 2.42 mmol) at 0 °C under N₂ and the mixture was stirred at 0 °C for 1 hr. This mixture was added to a solution of 4-bromo-3,3-difluoroindolin-2-one (200 mg, 806.37 umol) in THF (2 mL) at 0 °C under N<com:Sub>2< / com:Sub> and the resulting mixture was stirred at 25 °C for 16 hrs. After 16 hrs, to a solution of NaBH<com:Sub>4< / com:Sub> (152.54 mg, 4.03) mmol) in THF (2 mL) was added BF₃·Et₂O (572.23 mg, 4.03 mmol) at 0 °C and the mixture was stirred at 0 °C for 1 hr. This mixture was then added to the former reaction mixture at 0 °C. The resulting mixture was stirred at 25 °C for another 4 hrs. The reaction mixture was quenched by addition of 2N HCl, diluted with H<com:Sub>2< / com:Sub>O (30 mL) and extracted with EA (40 mL *3). The combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 5 / 1) to give the title compound (100 mg, 420.07 umol, 52.09% yield) as a colorless oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 11.18 (s, 1H), 7.46 - 7.45 (m, 1H), 7.42 - 7.35 (m, 1H), 7.22 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.10 - 7.01 (m, 1H) ppm. Step 3: 4-Bromo-3-fluoro-1-methyl-1H-indole To a solution of 4-bromo-3-fluoro-1H-indole (100 mg, 467.22 umol) in DMF (1 mL) was added NaH (28.03 mg, 700.82 umol, 60% purity) at 0 °C under N<com:Sub>2< / com:Sub>, and the mixture was stirred at 0 °C for 15 min. lodomethane (79.58 mg, 560.66 umol) was then added and the resulting mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into NH₄Cl (30 mL) and extracted with EA (40 mL *3). The combined organic layers were washed with brine (30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum CA ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (60 mg, 263.09 umol, 56.31% yield) as a colorless oil. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.56 - 7.44 (m, 2H), 7.25 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 7.6 Hz, 1H), 7.16 - 7.06 (m, 1H), 3.74 (s, 3H) ppm. Intermediate 41: 4-Bromo-2-(difluoromethyl)-1-methyl-1H-indole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: (4-Bromo-1H-indol-2-yl)methanol To a solution of 4-bromo-1H-indole-2-carboxylic acid (2 g, 8.33 mmol) in THF (20 mL) was added LiAlH<com:Sub>4< / com:Sub> (948.65 mg, 24.99 mmol) at 0 °C under N<com:Sub>2< / com:Sub>. The mixture was stirred at 25 °C for 4 hrs. The reaction mixture was quenched by addition of H₂O, the mixture was adjusted to pH=2 with HCI (2 N) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (60 mL*2), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, DCM / MeOH=100:1-10:1) to give the title compound (1 g, 4.24 mmol, 50.86% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=235.0<annotation encoding="application / x-tex">[M+H]+ = 235.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 11.40 (s, 1H), 7.34 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.16 - 7.15 (m, 1H), 6.98 - 6.94 (m, 1H), 6.25 (d, <com:Math><semantics>J=1.2<annotation encoding="application / x-tex">J = 1.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.34 - 5.31 (m, 1H), 4.61 (d, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 2H) ppm. Step 2: 4-Bromo-1H-indole-2-carbaldehyde To a solution of (4-bromo-1H-indol-2-yl)methanol (300 mg, 1.33 mmol) in DCM (3 mL) was added Dess-Martin (675.42 mg, 1.59 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into sat. NaHCO₃ (30mL) and extracted with DCM (30 mL * 3). The combined organic layers were washed with brine (30 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound (297 mg, crude) as a brown solid, which was used directly in the next step. Step 3: 4-Bromo-2-(difluoromethyl)-1H-indole To a solution of 4-bromo-1H-indole-2-carbaldehyde (290 mg, 1.29 mmol) in DCM (3 mL) was added DAST (625.90 mg, 3.88 mmol) at 0 °C. The mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into sat. NaHCO<com:Sub>3< / com:Sub> (30mL) and extracted with DCM (30 mL * 3). The combined organic layers were washed with brine (30 mL*2), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 3 / 1) to give the title compound (110 mg, 408.13 umol, 31.53% yield) as a brown solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 8.56 (s, 1H), 7.40 - 7.35 (m, 2H), 7.20 - 7.12 (m, 1H), 7.05 - 6.68 (m, 2H) ppm. CA Step 4: 4-Bromo-2-(difluoromethyl)-1-methyl-1H-indole To a solution of 4-bromo-2-(difluoromethyl)-1H-indole (110 mg, 447.06 umol) in DMF (1 mL) was added NaH (26.82 mg, 670.59 umol, 60% purity) at 0 °C. The mixture was degassed and purged with N<com:Sub>2< / com:Sub> for 3 times and stirred at 0 °C for 15 min under N₂ atmosphere. lodomethane (69.80 mg, 491.77 umol) was then added and the resulting mixture was stirred at 25 °C for 2 hrs. The reaction mixture was poured into NH<com:Sub>4< / com:Sub>Cl (30 mL) and extracted with EA (40 mL * 3). The combined organic layers were washed with brine (30 mL*3), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 10 / 1) to give the title compound (110 mg, 422.95 umol, 94.61% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=261.9<annotation encoding="application / x-tex">[M+H]+ = 261.9< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d6) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.63 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.54 - 7.20 (m, 4H), 6.80 (s, 1H), 3.86 (s, 3H) ppm. Intermediate 42: 4-Bromo-1-(2,2-difluorocyclopropyl)-3-methoxy-1H-pyrazole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 3-Methoxy-1-vinyl-1H-pyrazole A mixture of 3-methoxy-1H-pyrazole (500 mg, 5.10 mmol), potassium trifluoro(vinyl)borate (1.02 g, 7.65 mmol), Cu(OAc)<com:Sub>2< / com:Sub> (1.02 g, 5.61 mmol), Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (1.19 g, 11.21 mmol) and 2,2'-bipyridyl (875.60 mg, 5.61 mmol) in DCE (10 mL) was degassed and purged with O<com:Sub>2< / com:Sub> for 3 times. The mixture was stirred at 70 °C for 16 hrs under O<com:Sub>2< / com:Sub> atmosphere. The mixture was poured into water (100 mL) and extracted with EA (50 mL*3). The combined organic layers were washed with brine (30 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 25 g SepaFlash® Silica Flash Column, Eluent of 0~20% EA / Petroleum ether gradient @50 mL / min) to give the title compound (400 mg, 3.22 mmol, 63.22% yield) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [M+H]<com:Sup>+< / com:Sup> = 125.0 <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.33 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 6.94 - 6.72 (m, 1H), 5.78 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), <com:Math><semantics>5.44−5.32<annotation encoding="application / x-tex">5.44 - 5.32< / annotation>< / semantics>< / com:Math> (m, 1H), <com:Math><semantics>4.67<annotation encoding="application / x-tex">4.67< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>3.93<annotation encoding="application / x-tex">3.93< / annotation>< / semantics>< / com:Math> (s, 3H) ppm. Step 2: 1-(2,2-Difluorocyclopropyl)-3-methoxy-1H-pyrazole To a mixture of 3-methoxy-1-vinyl-1H-pyrazole (400 mg, 3.22 mmol) in THF (5 mL) was added Nal (169.04 mg, 1.13 mmol). TMSCF<com:Sub>3< / com:Sub> (1.60 g, 11.28 mmol) was then added slowly at 80 °C under N<com:Sub>2< / com:Sub>. The reaction was stirred at 80 °C for 30 min. The solvent was removed under vacuum and the residue purified by flash silica gel chromatography (ISCO®; 25 g SepaFlash® Silica Flash Column, Eluent of 0~20% EA / Petroleum ether gradient @ 50 mL / min) to give the title compound (200 mg, 1.15 mmol, 35.64% yield) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [ <com:Math><semantics>M+H<annotation encoding="application / x-tex">M+H< / annotation>< / semantics>< / com:Math>]<com:Sup>+< / com:Sup> = 175.0 CA <com:Sup>1< / com:Sup>HNMR (400 MHz, CDCl<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.32 - 7.13 (m, 1H), 5.62 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 3.91 - 3.83 (m, 1H), 3.81 (s, 3H), 2.08 - 1.99 (m, 1H), 1.97 - 1.88 (m, 1H) ppm. Step 3: 4-Bromo-1-(2,2-difluorocyclopropyl)-3-methoxy-1H-pyrazole To a mixture of 1-(2,2-difluorocyclopropyl)-3-methoxy-1H-pyrazole (100 mg, 574.22 umol) in MeCN (5 mL) was added NBS (112.42 mg, 631.65 umol). The reaction was stirred at 25 °C for 2 hrs. The solvent was removed under vacuum and the residue purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~20% EA / Petroleum ether gradient @ 50mL / min) to give the title compound (120 mg, 474.23 umol, 82.59% yield) as a yellow oil. LCMS (ESI) m / z: <com:Math><semantics>[79BrM+H]+=253.0<annotation encoding="application / x-tex">[^{79}BrM+H]^{+} = 253.0< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCl<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.34 (s, 1H), 3.95 (s, 3H), 3.94 - 3.88 (m, 1H), 2.15 - 1.97 (m, 2H) ppm. Intermediate 43: 1-(4-Bromo-3-methoxyphenyl)azetidine [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 1-(4-Bromo-3-methoxyphenyl)azetidine To a mixture of 1-bromo-4-iodo-2-methoxy-benzene (500 mg, 1.60 mmol) and azetidine (91.35) mg, 1.60 mmol) in toluene (5 mL) was added Pd₂(dba)₃ (146.52 mg, 160.00 umol), Xantphos (185.16 mg, 320.00 umol) and Cs<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (1.56 g, 4.80 mmol) under N<com:Sub>2< / com:Sub>. The mixture was stirred at 80 °C for 16 hrs. The reaction mixture was added slowly into water (50 mL) and extracted with EA (50 mL*2). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, PE / EA=10:1-1:1) to give the title compound (150 mg, 619.55 umol, 38.72% yield) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z=[M+H]+=242.0<annotation encoding="application / x-tex">m / z = [M+H]^+ = 242.0< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.25 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 6.06 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 5.93-5.90 (m, 1H), 3.81 - 3.78 (m, 7H), 2.32-2.24 (m, 2H) ppm. Intermediate 44: 1-Bromo-4-(tert-butyl)-2-methoxybenzene [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 44 Step 1: 2-Bromo-5-(tert-butyl)phenol To a solution of 3-tert-butylphenol (5 g, 33.29 mmol) in DCM (50 mL) was added a solution of Br<com:Sub>2< / com:Sub> (5.59 g, 34.95 mmol, 1.80 mL) in DCM (25 mL) over 30 mins at 0 °C. The mixture was poured into sat. Na<com:Sub>2< / com:Sub>SO<com:Sub>3< / com:Sub> (200 mL) and extracted with DCM (100 mL * 2). The combined organic layers were dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum to give the title compound (8 g, crude) as a colorless oil. C. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 9.98 (s, 1H), 7.35 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.77- 6.74 (m, 1H), 1.22 (s, 9H) ppm. Step 2: 1-Bromo-4-(tert-butyl)-2-methoxybenzene To a solution of 2-bromo-5-(tert-butyl)phenol (1 g, 4.36 mmol) in THF (5 mL) was added t-BuOK (494.66 mg, 4.41mmol) followed by MeI (631.90 mg, 4.45 mmol). The mixture was stirred at 70 °C for 3 hrs. The mixture was poured into water (100 mL) and extracted with EA (100 mL * 2). The combined organic layers were washed with brine (100 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=1 / 0 to 10 / 1) to give the title compound (750 mg, 3.08 mmol, 70.67% yield) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.45 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 7.07 - 7.04 (m, 1H), 6.91-6.88 (m, 1H), 3.85 (s, 3H), 1.28 (s, 9H) ppm Intermediate 45: 4-Bromo-3-(difluoromethoxy)-1-(oxetan-3-yl)-1H-pyrazole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 1-(3-Hydroxy-1H-pyrazol-1-yl)ethan-1-one To a solution of 1H-pyrazol-3-ol (3 g, 35.68 mmol) in pyridine (15 mL) was added a solution of Ac<com:Sub>2< / com:Sub>O (3.82 g, 37.47 mmol, 3.51 mL) in pyridine (6 mL) at 95 °C over 30 min, then the mixture was stirred at 95°C for 3.5 hrs. The reaction mixture was concentrated under reduced pressure and the residue was triturated in MeOH (20 mL) to give the title compound (3.8 g, 30.13 mmol, 84.45% yield) as a yellow solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 10.97 (s, 1H), 8.12 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 3.6 Hz, 1H), 6.00 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.8 Hz, 1H), 2.47 (s, 3H) ppm. Step 2: 3-(Difluoromethoxy)-1H-pyrazole To a mixture of 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one (1000 mg, 7.93 mmol) and sodium 2- chloro-2,2-difluoroacetate (1.45 g, 9.52 mmol) in DMF (10 mL) was added K₂CO₃ (3.29 g, 23.79 mmol). The mixture was stirred at 80 °C for 10 hrs. The mixture was poured into sat. NH₄CI (150 mL) and extracted with EA (100 mL * 3). The combined organic layers were washed with brine (150 mL * 2), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1) to give the title compound (270 mg, 2.01 mmol, 25.39% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=135.1<annotation encoding="application / x-tex">[M+H]^+ = 135.1< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 12.49 (s, 1H), 7.69 (s, 1H), 7.41 - 7.04 (m, 1H), 5.97-5.96 (m, 1H) ppm. Step 3: 3-(Difluoromethoxy)-1-(oxetan-3-yl)-1H-pyrazole CA To a mixture of 3-(difluoromethoxy)-1H-pyrazole (270 mg, 2.01 mmol), 3-iodooxetane (555.70 mg, 3.02 mmol) in DMF (5 mL) was added Cs₂CO₃ (1.31 g, 4.03 mmol). The mixture was stirred at 60 °C for 8 hrs. The mixture was poured into water (50 mL) and extracted with EA (50 mL * 2). The combined organic layers were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=50 / 1 to 3 / 1) to give the title compound (270 mg, 1.18 mmol, 58.53% yield) as a colorless oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=427.1<annotation encoding="application / x-tex">[M+H]^+ = 427.1< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 7.41 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 7.07 - 6.70 (m, 1H), 5.93 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.4 Hz, 1H), 5.34 - 5.27 (m, 1H), 5.08 - 4.97 (m, 4H) ppm. Step 4: 4-Bromo-3-(difluoromethoxy)-1-(oxetan-3-yl)-1H-pyrazole To a mixture of 3-(difluoromethoxy)-1-(oxetan-3-yl)-1H-pyrazole (270 mg, 1.42 mmol) in MeCN (5 mL) was added NBS (278.00 mg, 1.56 mmol), then the mixture was stirred at 25°C for 2 hrs. The mixture was concentrated under vacuum and the residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=10 / 1 to 1 / 1) to give the title compound (300 mg, 1.05 mmol, 73.82% yield) as a white solid. LCMS (ESI) m / z: <com:Math><semantics>[79BrM+H]+=269.0<annotation encoding="application / x-tex">[^{79}BrM+H]^{+} = 269.0< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math>= 7.49 (s, 1H), 7.16 - 6.80 (m, 1H), 5.29 - 5.26 (m, 1H), 5.00 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 6.0 Hz, 4H) ppm. Intermediate 46: Pyrazolo[1,5-a]pyridin-2-yl trifluoromethanesulfonate [Image disponible dans le document PDF, Image available in the PDF document] Step 1 Intermediate 46 Step 1: Pyrazolo[1,5-a]pyridin-2-yl trifluoromethanesulfonate To a solution of pyrazolo[1,5-a]pyridin-2-ol (200 mg, 1.49 mmol) in DMF (1 mL) and THF (1 mL) was added NaH (65.60 mg, 1.64 mmol, 60% purity) at 0 °C under N<com:Sub>2< / com:Sub>, then 1,1,1-trifluoro-N-phenyl-N- (trifluoromethylsulfonyl)methanesulfonamide (639.21 mg, 1.79 mmol) was added to the reaction mixture at 0 °C. The resulting mixture was stirred at 0 °C for 1 hr under N<com:Sub>2< / com:Sub>. The reaction mixture was quenched by addition of water (20 mL) and then extracted with EA (20 mL * 3). The combined organic layers were washed with brine (50 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, PE / EA=5:1) to give the title compound (300 mg, 1.06 mmol, 71.05% yield) as a light yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=267.1<annotation encoding="application / x-tex">[M+H]^+ = 267.1< / annotation>< / semantics>< / com:Math> Intermediate 47: 3-(4-Bromo-3-methoxyphenyl)oxetane CA [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 3-(4-Bromo-3-methoxyphenyl)oxetane To a mixture of 1-bromo-4-iodo-2-methoxy-benzene (500 mg, 1.60 mmol) and 3-iodooxetane (352.75 mg, 1.92 mmol) in DMA (4 mL) was added nickel(II) chloride ethylene glycol dimethyl ether complex (35.11 mg, 159.78 umol), pyridine-2-carboxamidine hydrochloride (25.18 mg, 159.78 umol), TFA (18.22 mg, 159.78 umol, 11.83 uL), Zn (208.96mg, 3.20 mmol) and NaI (119.75 mg, 798.90 umol) in one portion at 25 °C under N<com:Sub>2< / com:Sub>. The mixture was stirred at 60 °C for 12 hrs. The solids were removed by filtration and the filtrate concentrated under vacuum. The residue was purified by reversed phase column (0.1 % FA). The product fraction was concentrated to remove MeCN and the aqueous phase was extracted with ethyl acetate (20 mL*2). The combined organic phase was washed with brine (20 mL), dried with anhydrous Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum to give the title compound (200 mg, 668.21 umol, 41.82% yield) as yellow oil. LCMS (ESI) m / z: [M+H]<com:Sup>+< / com:Sup> =242.8, 244.9. Intermediate 48: 1-(8-Bromo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)ethan-1-one [Image disponible dans le document PDF, Image available in the PDF document] Step 1: N-(3-Bromo-2-hydroxyphenyl)acetamide To a solution of 2-amino-6-bromo-phenol (1 g, 5.32 mmol) in DCM (10 mL) was added Ac₂O (651.56 mg, 6.38 mmol, 597.76 uL) and TEA (1.61 g, 15.96 mmol, 2.22 mL) at 0°C under N₂. The mixture was heated to 25°C and stirred for 1 hr. Water was added (10 mL) and the mixture extracted by dichloromethane (50 mL * 3). The combined organic phase was washed with brine (50 mL * 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate=100 / 1 to 3 / 1) to give the title compound (300 mg, 1.11 mmol, 20.84% yield) as a light brown solid. LCMS (ESI) m / z: <com:Math><semantics>[79BrM+H]+=229.9<annotation encoding="application / x-tex">[^{79}BrM+H]^+ = 229.9< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>HNMR (400 MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.96 (br s, 1H), 7.90 (s, 1H), 7.59 - 7.53 (m, 1H), 7.32 - 7.28 (m, 1H), 6.80 - 6.72 (m, 1H), 2.24 (s, 3H). Step 2: 1-(8-Bromo-2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)ethan-1-one To a solution of N-(3-bromo-2-hydroxyphenyl)acetamide (100 mg, 434.67 umol) in DMF (2 mL) was added K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (180.22 mg, 1.30 mmol) and 1,2-dibromoethane (163.32 mg, 869.35 umol, 65.59 uL) under N<com:Sub>2< / com:Sub>. The mixture was heated to 80°C and stirred for 12 hrs. The mixture was poured into water (5 mL) and extracted with ethyl acetate (10 mL * 3). The combined organic phase was washed with brine CA (10 mL * 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep-TLC (SiO<com:Sub>2< / com:Sub>, PE / EA=1:1) to give the title compound (100 mg, 351.43 umol, 26.95% yield) as a white solid. LCMS (ESI) m / z: <com:Math><semantics>[79BrM+H]+=255.9<annotation encoding="application / x-tex">[^{79}BrM+H]^{+} = 255.9< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>HNMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ=7.77−7.67<annotation encoding="application / x-tex">\delta = 7.77 - 7.67< / annotation>< / semantics>< / com:Math> (m, 1H), 7.33 (d, J = 7.9 Hz, 1H), 6.82 (t, J = 8.0 Hz, 1H), <com:Math><semantics>4.40−4.33<annotation encoding="application / x-tex">4.40 - 4.33< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>3.89<annotation encoding="application / x-tex">3.89< / annotation>< / semantics>< / com:Math> (t, <com:Math><semantics>J=4.5<annotation encoding="application / x-tex">J = 4.5< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>3.09<annotation encoding="application / x-tex">3.09< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>2.25<annotation encoding="application / x-tex">2.25< / annotation>< / semantics>< / com:Math> (s, 3H) Intermediate 49: 7-Bromo-5-fluoro-2-methylisoquinolin-1(2H)-one [Image disponible dans le document PDF, Image available in the PDF document] Intermediate 49 Step 1: 3-Bromo-N-(2,2-dimethoxyethyl)-5-fluorobenzamide To a solution of 3-bromo-5-fluoro-benzoic acid (5 g, 22.83 mmol), 2,2-dimethoxyethanamine (2.40 g, 22.83 mmol, 2.49 mL) in DCM (50 mL) was added EDCI (8.75 g, 45.66 mmol), HOBt (6.17 g, 45.66 mmol) and DIEA (7.38 g, 57.08 mmol). The mixture was stirred at 25 °C for 1 hr. The mixture was poured into water (100 mL) and extracted with DCM (30 mL*3). The combined organic layer was dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by column chormatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate = 10:1) to give the title compound (6.1 g, 19.93) mmol, 87.28% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H−OMe]+=275.9<annotation encoding="application / x-tex">[M+H-OMe]^+ = 275.9< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, MeOD-d4) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.84 (s, 1H), 7.58 - 7.53 (m, 2H), 4.57 - 4.53 (m, 1H), 3.48 (d, J = 5.6) Hz, 2H), 3.40 (s, 6H) ppm. Step 2: 7-Bromo-5-fluoroisoquinolin-1(2H)-one and 5-bromo-7-fluoroisoquinolin-1(2H)-one A solution of 3-bromo-N-(2,2-dimethoxyethyl)-5-fluorobenzamide (5.6 g, 18.29 mmol) in H<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub> (34 mL) was stirred at 100 °C for 3 hrs. The mixture poured into water and the resulting solid was collected by filtration and dried to give a mixture of the title compounds (3.5 g, 14.46 mmol, 79.05% yield) as a white solid. Step 3: 7-Bromo-5-fluoro-2-methylisoquinolin-1(2H)-one and 5-bromo-7-fluoro-2- methylisoquinolin-1(2H)-one CA To a solution of 7-bromo-5-fluoroisoquinolin-1(2H)-one and 5-bromo-7-fluoroisoquinolin-1(2H)- one (1.5 g, 6.20 mmol) in THF (15 mL) was added KHMDS (1 M, 7.44 mL) at 0 °C. The mixture was stirred for 0.5 hr and then iodomethane (3.52 g, 24.79 mmol) was added. The mixture was stirred for 1 hr at 25 °C before pouring into water (5 mL) and extracting with EA (10 mL*3). The organic layer was concentrated, and the residue was purified by column chromatography (SiO<com:Sub>2< / com:Sub>, Petroleum ether / Ethyl acetate = 1:1, Rf = 0.3) to give a mixture of the title compounds (750 mg, 2.93 mmol, 47.26% yield) as a yellow solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=256.1<annotation encoding="application / x-tex">[M+H]^+ = 256.1< / annotation>< / semantics>< / com:Math>. Step 4: 7-Bromo-5-fluoro-2-methylisoquinolin-1(2H)-one The mixture of 7-bromo-5-fluoro-2-methylisoquinolin-1(2H)-one and 5-bromo-7-fluoro-2- methylisoquinolin-1(2H)-one (750 mg, 2.93 mmol) was purified by SFC separation: {method column: DAICEL CHIRALPAK AD (250mm*30mm,10um);mobile phase: [0.1% NH<com:Sub>3< / com:Sub>H<com:Sub>2< / com:Sub>O MEOH]; B%: 40%- 40%,4.25;105min.} to give the title compound (270 mg, 1.05 mmol, 35.95% yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=256.2<annotation encoding="application / x-tex">[M+H]^+ = 256.2< / annotation>< / semantics>< / com:Math>. <com:Sup>1< / com:Sup>H NMR (400 MHz, MeOD-d4) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.22 (s, 1H), 7.67 - 7.63 (m, 1H), 7.47 (d, J = 7.6 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 3.61 (s, 3H) ppm. Intermediate 50: 6-Bromo-7-methoxy-1-methyl-1H-indazole [Image disponible dans le document PDF, Image available in the PDF document] Step 1: 2-Bromo-3-(dimethoxymethyl)phenol To a solution of 2-bromo-3-hydroxybenzaldehyde (2 g, 9.95 mmol) and trimethoxymethane (5.28 g, 49.75 mmol, 5.45 mL) in MeOH (30 mL) was added TsOH (171.33 mg, 994.94 umol). The mixture was stirred at 100 °C for 16 hrs. The solvent was removed under vacuum and the residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~60% EA / Petroleum ether gradient @100 mL / min) to give the title compound (1.6 g, 6.48 mmol, 65.08% yield) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: <com:Math><semantics>[M+H]+=214.9<annotation encoding="application / x-tex">[M+H]^+ = 214.9< / annotation>< / semantics>< / com:Math> <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 7.29 - 7.24 (m, 1H), 7.23 - 7.18 (m, 1H), 7.07 - 7.02 (m, 1H), 5.79 (s, 1H), 5.53 (s, 1H), 3.40 (s, 6H) ppm. CA Step 2: 2,4-Dibromo-3-hydroxybenzaldehyde To a solution of 2-bromo-3-(dimethoxymethyl)phenol (1.4 g, 5.67 mmol) in CHCl₃ (7 mL) was added a solution of Br₂ (1.18 g, 7.37 mmol, 379.72 uL) in CHCl₃ (7 mL) at 0 °C. The reaction was stirred at 25 °C for 16 hrs. The reaction was quenched by aq. Na<com:Sub>2< / com:Sub>S<com:Sub>2< / com:Sub>O<com:Sub>3< / com:Sub> (80 mL) and extracted with EA (50 mL*3). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 25 g SepaFlash® Silica Flash Column, Eluent of 0~60% EA / Petroleum ether gradient @ 100 mL / min) to give the title compound (1.3 g, 4.64 mmol, 81.97 % yield) as a white solid. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [Br M+H]<com:Sup>+< / com:Sup> = 280.8. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 10.44 (s, 1H), 10.17 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 0.8 Hz, 1H), 7.83 - 7.65 (m, 1H), 7.27 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.4Hz,1H)ppm.<annotation encoding="application / x-tex">= 8.4 Hz, 1H) ppm.< / annotation>< / semantics>< / com:Math> Step 3: 2,4-Dibromo-3-methoxybenzaldehyde To a solution of 2,4-dibromo-3-hydroxybenzaldehyde (1.3 g, 4.64 mmol) and K₂CO₃ (1.28 g, 9.29 mmol) in DMF (15 mL) was added MeI (988.80 mg, 6.97 mmol, 433.69 uL). The mixture was stirred at 25 °C for 2 hrs, then poured into water (60 mL) and extracted with EA (30 mL*3). The combined organic layers were washed with brine (30 mL), dried over Na<com:Sub>2< / com:Sub>SO<com:Sub>4< / com:Sub>, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~60% EA / Petroleum ether gradient @ 60 mL / min) to give the title compound (1.2 g, crude) as a white solid. <com:Sup>1< / com:Sup>H NMR (400 MHz, DMSO-d<com:Sub>6< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 10.17 (s, 1H), 7.89 - 7.82 (m, 1H), 7.53 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 8.4 Hz, 1H), 3.85 (s, 3H) ppm. Step 4: (E)-1-(2,4-Dibromo-3-methoxybenzylidene)-2-methylhydrazine To a solution of 2,4-dibromo-3-methoxybenzaldehyde (500 mg, 1.70 mmol) and methylhydrazine (391.84 mg, 3.40 mmol, 447.82 uL) in EtOH (5 mL) was stirred at 25 °C for 16 hrs. The mixture was poured into water (80 mL) and extracted with EA (30 mL*3). The combined organic layer were washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~50% EA / Petroleum ether gradient @ 60 mL / min) to give the title compound (250 mg, 776.41 umol, 45.64% yield) as a yellow oil. LCMS (ESI) <com:Math><semantics>m / z<annotation encoding="application / x-tex">m / z< / annotation>< / semantics>< / com:Math>: [Br M+H]<com:Sup>+< / com:Sup> = 322.8. <com:Sup>1< / com:Sup>H NMR (400 MHz, CDCI<com:Sub>3< / com:Sub>-d) <com:Math><semantics>δ<anno...
Claims
CLAIMS 1. A compound having the structure: [Image disponible dans le document PDF, Image available in the PDF document] Formula I wherein [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] A is ; wherein when A is , one or both carbon atoms inside the brackets is bonded to hydrogen atoms, deuterium atoms, or a combination thereof; m is 0, 1, 2, or 3; n is 1 or 2; o is 0 or 1; X is O, <com:Math><semantics>CH2<annotation encoding="application / x-tex">CH_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR7<annotation encoding="application / x-tex">NR^7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>X′<annotation encoding="application / x-tex">X'< / annotation>< / semantics>< / com:Math> is N, CH, or <com:Math><semantics>CRX<annotation encoding="application / x-tex">CR^X< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>RX<annotation encoding="application / x-tex">R^X< / annotation>< / semantics>< / com:Math> is a halogen; B is an unsubstituted or substituted 6-membered monocyclic heteroarylene or an unsubstituted or substituted 9- or 10-membered bicyclic heteroarylene; L is a covalent bond, unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene, C<com:Sub>2< / com:Sub> alkynylene, unsubstituted or substituted C<com:Sub>2< / com:Sub> alkenylene, unsubstituted or substituted C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> heteroalkylene, unsubstituted or substituted C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub> cycloalkylene, or unsubstituted or substituted 4- to 10-membered heterocyclylene; Z is unsubstituted or substituted 3- to 10-membered cycloalkyl; unsubstituted or substituted 6- to 10-membered aryl; unsubstituted or substituted 5- to 10-membered heteroaryl; or unsubstituted or substituted 5- to 10-membered heterocyclyl; R<com:Sup>1< / com:Sup> and R<com:Sup>7< / com:Sup> are, independently, hydrogen or unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; each R<com:Sup>2< / com:Sup> and R<com:Sup>3< / com:Sup> is independently, hydrogen, unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; or unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl; R<com:Sup>4< / com:Sup> is cyano, fluoro, hydroxy, or -CH<com:Sub>2< / com:Sub>OH; R<com:Sup>5< / com:Sup> is C₁-C₃ alkyl, unsubstituted or substituted with one, two, three, four, five, six, or seven fluoro groups; and R<com:Sup>6< / com:Sup> is C₁-C₃ alkyl, unsubstituted or substituted with one, two, three, four, five, six, or seven fluoro groups, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R<com:Sup>1< / com:Sup> is hydrogen.
3. The compound of claim 1 or 2, wherein m is 1.
4. The compound of any one of claims 1 to 3, wherein R<com:Sup>3< / com:Sup> is hydrogen.
5. The compound of any one of claims 1 to 4, wherein R<com:Sup>2< / com:Sup> is hydrogen.
6. The compound of any one of claims 1 to 4, wherein R<com:Sup>2< / com:Sup> is unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl.
7. The compound of claim 6, wherein R<com:Sup>2< / com:Sup> is methyl.
8. The compound of any one of claims 1 to 4, wherein R<com:Sup>2< / com:Sup> is unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> heteroalkyl.
9. The compound of claim 8, wherein R<com:Sup>2< / com:Sup> is -CH<com:Sub>2< / com:Sub>OCH<com:Sub>3< / com:Sub>. [Image disponible dans le document PDF, Image available in the PDF document] 10. The compound of any one of claims 1 to 9, wherein A is 11. The compound of claim 10, wherein R<com:Sup>6< / com:Sup> is -CHF<com:Sub>2< / com:Sub>. [Image disponible dans le document PDF, Image available in the PDF document] 12. The compound of any one of claims 1 to 9, wherein A is 13. The compound of claim 12, wherein R<com:Sup>5< / com:Sup> is methyl or -CHF<com:Sub>2< / com:Sub>.
14. The compound of claim 12 or 13, wherein X is O.
15. The compound of claim 12 or 13, wherein X is CH<com:Sub>2< / com:Sub>.
16. The compound of claim 12 or 13, wherein X is NR<com:Sup>7< / com:Sup>.
17. The compound of claim 16, wherein R<com:Sup>7< / com:Sup> is hydrogen.
18. The compound of claim 16, wherein R<com:Sup>7< / com:Sup> is methyl.
19. The compound of any one of claims 12 to 18, wherein o is 0.
20. The compound of any one of claims 12 to 18, wherein o is 1.
21. The compound of any one of claims 12 to 20, wherein n is 1.
22. The compound of any one of claims 12 to 20, wherein n is 2.
23. The compound of any one of claims 12 to 22, wherein R<com:Sup>4< / com:Sup> is cyano.
24. The compound of any one of claims 12 to 22, wherein R<com:Sup>4< / com:Sup> is fluoro.
25. The compound of any one of claims 12 to 22, wherein R<com:Sup>4< / com:Sup> is hydroxy.
26. The compound of any one of claims 12 to 22, wherein R<com:Sup>4< / com:Sup> is -CH<com:Sub>2< / com:Sub>OH. <com:Math><semantics>NC<annotation encoding="application / x-tex">NC< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CH3<annotation encoding="application / x-tex">CH_3< / annotation>< / semantics>< / com:Math> CH<com:Sub>3< / com:Sub> 27. The compound of claim 12, wherein A is [Image disponible dans le document PDF, Image available in the PDF document] 28. The compound of any one of claims 1 to 27, wherein Z is unsubstituted or substituted 3- to 10-membered cycloalkyl.
29. The compound of claim 28, wherein Z is cyclopropyl.
30. The compound of any one of claims 1 to 27, wherein Z is unsubstituted or substituted 6- to 10-membered aryl.
31. The compound of claim 30, wherein Z is phenyl, 3-difluoromethyl-phenyl, 4- dilfluoromethylphenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,5-difluorophenyl, 3- difluoromethylphenyl, 2-methoxy-5-methyl-phenyl, 2-methoxy-4-chloro-phenyl, 3-cyano-phenyl, 3-fluoro- 5-methoxy-phenyl, 3-fluoro-5-azitidinyl-phenyl, 3-azetidyl-phenyl, 4-azetidyl-2-methoxy-phenyl, 4- morpholin-4-yl-2-methoxy-phenyl, 4-tert-butyl-2-methoxy-phenyl, 4-azetidyl-phenyl, 2-methoxy-4-oxetan- 3-yl-phenyl, 2-azetidin-2-one-1-yl-phenyl, 3-(3-difluoromethyloxetan-3-yl)-phenyl, 3-(3-methoxyoxetan-3-yl)-phenyl, 3-(3-methoxyoxetan-3-yl)-phenyl, 3-(3-methoxyoxetan-3-yl)-phenyl, 3-(3-methoxyoxetan-3-yl)-phenyl, 3-(3-me yl)-phenyl, 3-(N-methyl-N-acetamido)-phenyl, 3-cyclopropylphenyl, 3-(N-methylazetidin-3-yl)-phenyl, 3-(N- methyl-N'-piperazinyl)-phenyl, 3-fluoro-5-azetidyl-phenyl, 3-methyl ester-phenyl, [Image disponible dans le document PDF, Image available in the PDF document] .
32. The compound of any one of claims 1 to 27, wherein Z is unsubstituted or substituted 5- to 10-membered heteroaryl.
33. The compound of any one of claims 1 to 27, wherein Z is <com:Math><semantics>(NN)<annotation encoding="application / x-tex">\binom{N}{N}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>(NN)<annotation encoding="application / x-tex">\binom{N}{N}< / annotation>< / semantics>< / com:Math> [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] . . [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] N−Ń<com:Br / >N−Ń 25 N , 25 34. The compound of claim 32, wherein Z is <com:Math><semantics>N−CH3<annotation encoding="application / x-tex">N-CH_3< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>N−CH3<annotation encoding="application / x-tex">N-CH_3< / annotation>< / semantics>< / com:Math>.
35. The compound of any one of claims 1 to 27, wherein Z is unsubstituted or substituted 5- to 10-membered heterocyclyl. S 22 N OCH3 36. The compound of claim 35, wherein Z is , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 37. The compound of claim 35, wherein Z is 38. The compound of any one of claims 1 to 37, wherein B is an unsubstituted or substituted 6- membered monocyclic heteroarylene.
39. The compound of claim 38, wherein B has the structure: [Image disponible dans le document PDF, Image available in the PDF document] wherein Ra is hydrogen or fluoro; R<com:Sup>b< / com:Sup> is hydrogen, fluoro, or C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkyl; and Xa is N or CH.
40. The compound of claim 39, wherein R<com:Sup>a< / com:Sup> is hydrogen.
41. The compound of claim 39, wherein Ra is fluoro.
42. The compound of any one of claims 39 to 41, wherein Rb is hydrogen.
43. The compound of any one of claims 39 to 41, wherein R<com:Sup>b< / com:Sup> is fluoro.
44. The compound of any one of claims 39 to 41, wherein R<com:Sup>b< / com:Sup> is C₁-C₃ alkyl.
45. The compound of claim 44, wherein R<com:Sup>b< / com:Sup> is methyl.
46. The compound of any one of claims 39 to 45, wherein X<com:Sup>a< / com:Sup> is N.
47. The compound of any one of claims 39 to 45, wherein X<com:Sup>a< / com:Sup> is CH. [Image disponible dans le document PDF, Image available in the PDF document] 48. The compound of claim 39, wherein B is [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] 49. The compound of claim 48, wherein B is 50. The compound of any one of claims 1 to 37, wherein B is an unsubstituted or substituted 9- or 10-membered bicyclic heteroarylene.
51. The compound of claim 50, wherein B has the structure: [Image disponible dans le document PDF, Image available in the PDF document] wherein D is an unsubstituted or substituted 5- or 6-membered heteroaryl or unsubstituted or substituted 5- or 6-membered heterocyclyl. [Image disponible dans le document PDF, Image available in the PDF document] 52. The compound of claim 50, wherein B is [Image disponible dans le document PDF, Image available in the PDF document] _ 53. The compound of any one of claims 1 to 52, wherein the compound of Formula I is a compound of Formula la [Image disponible dans le document PDF, Image available in the PDF document] , Formula la or a pharmaceutically acceptable salt thereof.
54. The compound of any one of claims 1 to 52, wherein L is unsubstituted or substituted C<com:Sub>1< / com:Sub>-C<com:Sub>3< / com:Sub> alkylene.
55. The compound of claim 54, wherein L is ethylene.
56. The compound of any one of claims 1 to 52, wherein L is C<com:Sub>2< / com:Sub> alkynylene.
57. The compound of any one of claims 1 to 52, wherein L is unsubstituted or substituted C<com:Sub>2< / com:Sub> alkenylene. [Image disponible dans le document PDF, Image available in the PDF document] 58. The compound of claim 57, wherein L is [Image disponible dans le document PDF, Image available in the PDF document] 59. The compound of any one of claims 1 to 52, wherein L is unsubstituted or substituted C<com:Sub>2< / com:Sub>-C<com:Sub>3< / com:Sub> heteroalkylene. [Image disponible dans le document PDF, Image available in the PDF document] 60. The compound of claim 59, wherein L is 61. The compound of any one of claims 1 to 52, wherein L is unsubstituted or substituted C<com:Sub>3< / com:Sub>-C<com:Sub>5< / com:Sub> cycloalkylene. [Image disponible dans le document PDF, Image available in the PDF document] 62. The compound of claim 61, wherein L is 63. The compound of any one of claims 1 to 52, wherein L is unsubstituted or substituted 4- to 10-membered heterocyclylene. [Image disponible dans le document PDF, Image available in the PDF document] 64. The compound of claim 63, wherein L is [Image disponible dans le document PDF, Image available in the PDF document] 65. The compound of claim 1, wherein the compound is represented by any one of the formulae listed below: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] - 66. A pharmaceutical composition comprising a compound of any one of claims 1 to 65 and a pharmaceutically acceptable excipient.
67. An ex vivo method of decreasing the activity of a BRG1- or BRM-associated factors (BAF) complex in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66.
68. The method of claim 67, wherein the BAF complex is in a cancer cell.
69. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for treating a BAF complex-related disorder in a subject in need thereof.
70. The use of claim 69, wherein the BAF complex-related disorder is cancer or a viral infection.
71. An ex vivo method of inhibiting BRM, the method comprising contacting a cell with an effective amount of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66.
72. The method of claim 71, wherein the cell is a cancer cell.
73. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for treating a disorder related to a BRG1 loss of function mutation in a subject in need thereof.
74. The use of claim 73, wherein the disorder related to a BRG1 loss of function mutation is cancer.
75. An ex vivo method of inducing apoptosis in a cell, the method comprising contacting the cell with an effective amount of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66.
76. The method of claim 75, wherein the cell is a cancer cell.
77. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for treating cancer in a subject in need thereof.
78. The use of claim 77, wherein the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin lymphoma, small-cell lung cancer, prostate cancer, embryonal tumor, germ cell tumor, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumor, uterine sarcoma, gastrointestinal stromal tumor, CNS cancer, thymic tumor, Adrenocortical carcinoma, appendiceal cancer, small bowel cancer, or penile cancer.
79. The use of claim 78, wherein the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, soft tissue sarcoma, or penile cancer.
80. The use of claim 79, wherein the cancer is non-small cell lung cancer.
81. The use of claim 79, wherein the cancer is soft tissue sarcoma.
82. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for treating a viral infection in a subject in need thereof.
83. The use of claim 82, wherein the viral infection is an infection with a virus of the Retroviridae family, Hepadnaviridae family, Flaviviridae family, Adenoviridae family, Herpesviridae family, Papillomaviridae family, Parvoviridae family, Polyomaviridae family, Paramyxoviridae family, or Togaviridae family.
84. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for treating melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject in need thereof.
85. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for reducing tumor growth of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject in need thereof.
86. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for suppressing metastatic progression of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject.
87. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for suppressing metastatic colonization of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or a hematologic cancer in a subject.
88. Use of a compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 in the manufacture of a medicament for reducing the level and / or activity of BRG1 and / or BRM in a melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer cell.
89. The use of claim 88, wherein the cell is in a subject.
90. The use of any one of claims 84 to 89, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is metastatic.
91. The use of any one of claims 84 to 87, wherein the use further comprises use of an anticancer therapy.
92. The use of claim 91, wherein the anticancer therapy is a chemotherapeutic or cytotoxic agent, immunotherapy, surgery, radiotherapy, thermotherapy, or photocoagulation, or a combination thereof.
93. The use of claim 92, wherein the anticancer therapy is surgery.
94. The use of claim 92, wherein the anticancer therapy is a chemotherapeutic or cytotoxic agent.
95. The use of claim 94, wherein the chemotherapeutic or cytotoxic agent is an antimetabolite, antimitotic, antitumor antibiotic, asparagine-specific enzyme, bisphosphonates, antineoplastic, alkylating agent, DNA-Repair enzyme inhibitor, histone deacetylase inhibitor, corticosteroid, demethylating agent, immunomodulatory, janus-associated kinase inhibitor, phosphinositide 3-kinase inhibitor, proteasome inhibitor, or tyrosine kinase inhibitor, or a combination thereof.
96. The use of claim 94 or 95, wherein the one or more chemotherapeutic or cytotoxic agent is dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a mitogen-activated protein kinase inhibitor, and / or a protein kinase C inhibitor.
97. The use of any one of claims 91 to 96, wherein the anticancer therapy and the compound of any one of claims 1 to 65 or a pharmaceutical composition of claim 66 are for administration within 28 days of each other and each in an amount that together are effective to treat the subject.
98. The use of any one of claims 84 to 97, wherein the subject or cancer has and / or has been identified as having a BRG1 loss of function mutation.
99. The use of any one of claims 84 to 87, wherein the subject or cancer has and / or has been identified as having a BRM loss of function mutation.
100. The use of any one of claims 84 to 99, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer has failed to respond to or progressed after administration of one or more chemotherapeutic or cytotoxic agents.
101. The use of any one of claims 84 to 100, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is resistant to, or predicted to be resistant to one or more chemotherapeutic agents.
102. The use of claim 100, wherein the one or more chemotherapeutic or cytotoxic agents is dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a mitogen-activated protein kinase inhibitor, and / or a protein kinase C inhibitor.
103. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is melanoma.
104. The use of claim 103, wherein the melanoma is uveal melanoma.
105. The use of claim 103, wherein the melanoma is mucosal melanoma.
106. The use of claim 103, wherein the melanoma is cutaneous melanoma.
107. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is a hematologic cancer.
108. The use of claim 107, wherein the hematologic cancer is multiple myeloma, large cell lymphoma, acute T-cell leukemia, acute myeloid leukemia, myelodysplastic syndrome, immunoglobulin A lambda myeloma, diffuse mixed histiocytic and lymphocytic lymphoma, B-cell lymphoma, acute lymphoblastic leukemia, diffuse large cell lymphoma, or non-Hodgkin's lymphoma.
109. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is prostate cancer.
110. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is breast cancer.
111. The use of claim 110, wherein the breast cancer is an ER positive breast cancer, an ER negative breast cancer, triple positive breast cancer, or triple negative breast cancer.
112. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is bone cancer.
113. The use of claim 112, wherein the bone cancer is Ewing's sarcoma.
114. The use of any one of claims 84 to 102, wherein the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematologic cancer is renal cell carcinoma.
115. The use of claim 114, wherein the renal cell carcinoma is Microphthalmia Transcription Factor (MITF) family translocation renal cell carcinoma.
